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PREFACE  
 
A new voice in science; this title obviously refers to the voice of the 
patient that is heard in decision-making concerning biomedical science 
increasingly. But it is not only the patient that can be subscribed a new 
voice in a scientific field. In some way, this thesis itself reflects a new voice 
as well. Almost twenty years ago I entered the scientific world as a 
biochemical research technician. But now I have raised my voice within 
the field of Science and Technology Studies. This change has much to do 
with the motto of this book. 
“The choices you make, not the chances you take, determine our 
destiny.” This anonymous quote was the subscript of a beautiful poster 
that decorated the wall behind my computer during the years this study 
was undertaken. On the picture is a small boat on the shore. It is still safely 
tied but ready to go. Shall it sail out? But what lies ahead? A robust rock-
work rises from the smooth surface of the sea. And on the horizon, the 
vague contours of an unknown landscape become visible. This image to 
some extent represents the last 10 years of my professional life, which was 
characterized by important but not always easy choices.  
Until 1995 I was working as a research technician within the 
biotechnological and biomedical fields. I loved my work and my colleagues 
and lived in a nice house near Rotterdam. Still I knew I needed to change 
course and to face a new challenge. I decided to resign from my 
professional life, to move to Amsterdam and to go to ‘school’ again. That 
was my first and most radical choice. I left my safe, comfortable life 
behind in order to meet a new but uncertain future. In the following three 
years I studied (bio)chemistry. The second crucial choice was taken during 
my study: I broadened the focus of my study from pure chemistry towards 
policy and management of science. In addition, I started to study 
philosophy as well. After finalizing my MSc, I faced a new choice: would I 
accept a job in the field of science policy or would I apply for a PhD 
position in the field of Science and Technology Studies? As you will guess, 
I choose the latter. This choice implied not only a career in science, but 
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also some more years of financial scarcity and uncertainty about a future 
position and income. Still, I never regretted the choices I made. Firstly, I 
found my way in a scientific field of which I feel it suits me very well. It 
enables me to combine my experiences and interest in biomedical science 
with my new interest in philosophy. Secondly, my new career in 
Amsterdam brought me also a new private life: in this city I met and 
married my dear husband and gave birth to two beautiful, lovely boys, to 
whom I dedicate this book. 
Besides to my personal life, I believe the motto refers to the 
subject of this thesis as well. In the course of this study, I found out that 
involving patients in decision-making on biomedical research is all but self-
evident. It is also a conscious choice; a choice for leaving familiar and 
stabilized decision-making routes and practices, while searching for new 
ways of decision-making that involves patients as partners.  
When I started this study in 1998, patient participation in decision-
making on biomedical research was a new and uncommon subject; it 
required a lot of flexibility and pioneering. I usually faced scepticism on 
the desirability and feasibility of such participation, among both 
researchers and patients. Even when individuals became enthusiastic about 
the potential of patient participation in decision-making on biomedical 
research, their organizational base was not prepared to invest in its 
implementation. Only in the last phase of my study, when I already 
acquiesced in the idea of writing a more theoretical and descriptive 
dissertation, did the opportunity arise to bring patient participation into 
practice. The Netherlands Asthma Foundation was interested and 
prepared to invest in a social experiment that entailed the practical 
application of patient participation in research agenda setting. This social 
experiment could have covered a thesis itself; it entails many starting 
points for further research and analysis. All the same, I hope this thesis will 
inspire people to experiment with and implement patient participation in 
decision-making on (biomedical) research. 
 
Amsterdam, September 2005 
 
 1 
1 
INTRODUCTION 
 
 
Once considered esoteric and reserved for a small elite of qualified 
academics, science is increasingly regarded as a societal endeavour which 
demands a more democratic, participative approach (e.g. Chopyak and 
Levesque, 2002b; Fuller, 2000; Nowotny et al., 2001). Today’s empowered 
public is less willing to accept the self-proclaimed autonomy of science and 
increasingly demands evidence of its legitimacy and accountability. In 
order to forestall social resistance and to ensure public support, new and 
controversial scientific developments, in biotechnology and genomics for 
example, have become the topic of consensus conferences and public 
debates (e.g. Andersen and Jaeger, 1999; Barns et al., 2000; Guston, 1999; 
Joss and Durant, 1995; Rowe and Frewer, 2000). At the same time, the 
growing complexity of society and its problems, resulting – among others 
– from advancing trends of globalization and scientification, requires new 
methods of knowledge production. Scientists increasingly aim to capitalize 
on societal needs and changes in contexts of application, for example by 
integrating knowledge from different (scientific and societal) sources in a 
transdisciplinary way (e.g. Chopyak and Levesque, 2002a; Cornwall and 
Jewkes, 1995; Gibbons et al., 1994; Johnson et al., 2003; Kasemir, Jaeger et 
al., 2003; Pretty, 1995; Thompson Klein et al., 2001; Van Asselt and 
Rijkens-Klomp, 2002) 
Regarding the growing need for participation, it is imperative to 
consider precisely which actors should be involved in science-related 
decision-making. Collins and Evans (2002) have addressed this issue 
explicitly in their discussion paper “The Third Wave of Science Studies: 
Studies of Expertise and Experience”. They identify a political and a 
technical dimension within such decision-making processes, stating that 
political legitimacy requires the involvement of all stakeholders (those who 
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have an interest in, or are affected by, the decision), while technical quality 
requires that relevant experts participate. These ‘relevant experts’ can be 
people with academic certifications as well as uncertified persons who have 
obtained experience-based expertise. Relevant non-certified experts may 
be potential end-users or beneficiaries of research outcomes, people who 
might be directly or indirectly affected by the research, people who have 
obtained certain contextual or experiential knowledge, or even the public 
at large. Their relevance is determined by the content and context of each 
particular decision-making process and what potential contribution they 
can make. Their experience-based expertise may relate to societal needs, 
norms and values, risk perceptions, interests, the relevance of certain 
research topics or questions, the desirability and appropriateness of 
solutions, additional explanations or solutions, etc. This knowledge is often 
referred to as lay knowledge, local knowledge, or indigenous knowledge 
(e.g. Agrawal, 1995; Lopez Cerezo and Gonzalez Garcia, 1996; Pinton, 
2003; Popay and Williams, 1996; Wynne, 1996). 
This dissertation focuses on one specific case of stakeholder 
participation in science-related decision-making, namely patient 
participation in decision-making on biomedical research. Biomedical 
research is one discipline within the broad domain of health research, 
which comprises all medical, social, and environmental research focusing 
on health and health care issues. It covers the invention and development 
of (bio)medical technologies, and thus can be considered the scientific 
foundation of Western medicine. Patients constitute one of the end-user 
groups of biomedical research, as beneficiaries of the generated knowledge 
and technologies within this research.1 Since end-users (or user 
configurations2) strongly determine the design, dissemination, and use of 
technologies (cf. Oudshoorn and Pinch, 2003), patients can be considered 
important stakeholders of biomedical research. In addition, patients obtain a 
specific type of knowledge based on their daily experience of their disease. 
Several scholars have argued that patients’ knowledge and experience can 
complement that of professionals in decision-making processes (Entwistle 
et al., 1998; Goodare and Smith, 1995; Nordin, 2000; Popay and Williams, 
1996; Telford et al., 2002). This knowledge might also be valuable in the 
context of biomedical knowledge production, which makes patients 
potentially relevant (non-certified) experts within the biomedical field. Both 
patients’ roles of relevant stakeholders and potential relevant experts 
                                                 
1  ‘public downstream users’ in the categorization of Lyall et al. (2004). 
2  as ‘co-constructed’ with technologies (Oudshoorn and Pinch, 2003) 
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found arguments in favour of their’3 active involvement in decision-
making on biomedical research. As has been argued by Collins and Evans 
(2002), involving relevant stakeholders and experts in decision-making may 
enhance the political legitimacy and the ‘technical’ quality of this decision-
making respectively.  
Despite these arguments, a significant lack of academic literature 
on patient participation in biomedical research suggests that patients are 
largely uninvolved in decision-making regarding biomedical research 
agendas. This is in contradiction to the growing reference to patient 
participation in decision-making processes regarding other types of health 
research, such as health services research (e.g. Matsunaga et al., 1996; Ong 
and Hooper, 2003; Phillips and Grams, 2003), health technologies research 
(e.g. Oliver et al., 2001; Reuzel, 2004), research on public health and 
prevention (e.g. Bonham and Nathan, 2002; De Koning and Martin, 1996; 
Israel et al., 1998; Parker et al., 1998), and clinical studies (e.g. Epstein, 
1996; Hanley et al., 2001; Kelson, 1999; Koops and Lindley, 2002). 
Likewise, other scientific fields that aim to address societal problems or 
needs, such as agricultural research, sustainability research, environmental 
research, and developmental studies (e.g. Broerse and Bunders, 2000; 
Johnson et al., 2003; Kasemir, Jäger et al., 2003; Pretty, 1995; Scholz et al., 
2000) increasingly rely on societal actors to enrich decision-making with 
broader perspectives. Since biomedical research aims to contribute to the 
fundamental health, and therefore quality, of people’s lives, and since it 
demands enormous international financial investment, one would expect 
that decision-making on this research would involve societal actors as well. 
Therefore, the apparent lack of patient participation in biomedical research 
decision-making is surprising and calls for closer scrutiny.  
But is it true that patients rarely participate in decision-making on 
biomedical research, or is this phenomenon just poorly documented? And 
if it is true, what are the causes of this limited involvement? Do patients 
themselves abstain from participation? Do biomedical researchers prevent 
patient participation? Are other obstacles constraining patient participation 
                                                 
3  In many studies on patient participation in health research, scholars use the term 
‘consumers’, referring to all (potential) users of health care and their representatives 
(e.g. Hanley et al., 2001; Herxheimer and Goodare, 1999; Kelson, 1999; Koops and 
Lindley, 2002; Telford et al., 2002). However, within the framework of biomedical 
research, it is the actual patients (in particular chronically or long-term ill patients), and 
not health care consumers in general, who may be relevant experts, since they have 
built up (bodily) experience with their diseases.  
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in the decision-making processes?  Can these obstacles be overcome? In 
this dissertation I address these questions by examining the current role of 
patients in biomedical research decision-making, investigating any 
obstacles to the enhancement of this role and by searching for a possible 
strategy to overcome these obstacles. The presumption that patients, as 
stakeholders and potential experts, should participate in such decision-
making is taken as a normative starting point. 
In the next section of this chapter I describe the current situation 
of decision-making regarding biomedical research agendas, followed by an 
initial analysis of the role played by patients in this decision-making. The 
third section focuses on the concept of patient participation and elaborates 
on the different degrees of participation and the various objectives as 
reflected by the arguments for patient participation in biomedical research 
decision-making. The fourth section then describes the main research 
question and the research design of this study while the last section 
describes the outline of the book. 
 
1.1 Biomedical research and its decision-making network 
 
Biomedical research is a relatively new, fast-growing, and promising 
scientific research field that brings together fundamental and applied 
aspects of biology and medicine with the ultimate aim to contribute to the 
understanding and improvement of human (or animal) health, for example 
by searching for causes and working mechanisms of, or therapies for, 
pathological disorders. Sub-disciplines are, among others, pathology, 
immunology, human genetics, cell biology, microbiology, and 
neurosciences.4  
Biomedical research can be considered as providing initial stages 
within overall biomedical innovation processes (Gelijns, 1991; Omta, 
1995). Whereas basic biomedical research traditionally focuses on 
understanding physiological processes within the human body, applied 
biomedical research strives for the invention of new therapies, diagnostics, 
                                                 
4  Contrary to definitions of biomedical research (implicitly) used by other scholars (e.g. 
Bondeson et al., 1982; Epstein, 2003; 2004; Nederbragt, 2000; Resnik, 2003) clinical 
trials are excluded from the definition used in this book. Clinical trials entail the testing 
rather than the invention and development of new technologies and thus can be 
considered a different stage within biomedical innovation processes (see also note 4). 
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etc. In contemporary biomedical science the majority of basic research has 
shifted towards ‘strategic research’, which combines scientific excellence 
with societal relevance, for example by searching for pathogenic 
mechanisms or causes of diseases (Rip, 2004). Further stages within the 
biomedical innovation process include technology development, clinical 
testing, production and diffusion (Gelijns, 1991; Nederbragt, 2000; Omta, 
1995)5.  
 The biomedical research field expanded considerably in the second 
half of the twentieth century. Developments within cell biology, molecular 
biology, and molecular genetics have strongly influenced medical thinking 
and acting6, providing new insights in issues of health and illness and 
inspiring the development of innovative diagnostic and therapeutic tools. 
Moreover, diseases which are as of yet incurable, such as cystic fibrosis, 
Parkinson’s, and cancer, might find treatment in the near future. For 
example, the Human Genome Project has caused an exponential growth in 
knowledge of the structure and function of human genes, which may lead 
to new possibilities for diagnosis, treatment and prevention of many 
diseases. The main barriers for the further implementation and diffusion 
of genetic technologies will be issues of societal adoption and regulation 
(Löhnberg et al., 1999). 
In future, new and unforeseen problems may provide additional 
impulses for developments or changes within the biomedical research 
field. For example, the vast expansion of the Acquired Immune Deficiency 
Syndrome (AIDS) in the 80s, demanded new forms of national and 
international cooperation between researchers, physicians, and politicians, 
which has stimulated a more rapid diffusion of knowledge and methods 
and heightened discussions on national deficits in biomedical research. 
Obviously, these developments will also influence the way in which other 
diseases are investigated and handled (Löhnberg et al., 1999). 
                                                 
5  This description requires an additional comment. As has been generally accepted, 
relations between basic science, applied science, and technological development are 
complex and interactive rather than unidirectional (e.g. Dits and Berkhout, 1999; Kline 
and Rosenberg, 1986; Leydesdorff, 2000; Williams and Edge, 1996). However, since 
means and goals of, as well as possible stakes and roles of patients within, the different 
types of research differ, within the framework of this book for pragmatic reasons basic 
biomedical research, applied biomedical research, and clinical testing of biomedical 
technologies are (artificially) distinguished as different but interdependent stages of 
biomedical innovation processes (cf. Nordin, 1999; Omta, 1995).  
6  Within this framework one sometimes refers to the ‘biomedicalization’ of medicine 
(e.g. Clarke et al., 2003). 
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1.1.1 The biomedical research decision-making network 
Within the framework of the study described in this book, it is important 
to find out who decides what research is to be conducted and what factors 
lay at the heart of these decisions. The various sub-disciplines of 
biomedical research are primarily conducted within laboratories and can be 
considered ‘esoteric’ disciplines that require the highly specialist expertise 
and skills of ‘core-scientists’7. These scientists play a decisive role in 
determining research topics, questions, project planning and design, etc., 
and thus in the production of biomedical knowledge (e.g. Omta, 1995; 
Weissmann, 1982). However, scholars in the field of science and 
technology studies have shown that scientific knowledge (and thus 
biomedical knowledge) is not only the result of actions of, and interactions 
between, (core-) scientists. A variety of interactions with ‘external’ actors, 
such as the government, funding agencies, industry, etc., also strongly 
influence decision-making regarding science (e.g. Barnes, 1977; Bloor, 
1976; Cozzens and Woodhouse, 1995). All these different stakeholders 
represent different social and political interests in biomedical research as 
well as different institutional contexts and cultures (cf. Elzinga and 
Jamison, 1995). Below, I describe the most important stakeholders 
involved in biomedical research decision-making processes in more detail. 
The research community 
As has been remarked above, a stakeholder group that plays a central role 
in decision-making on biomedical research topics, questions, design, etc., is 
the biomedical research community. This decision-making is strongly 
influenced by both internal and external factors (Schaffner, 1982). Internal 
scientific motives, such as scientific and technological feasibility and the 
adherence to scientific rules, determine individual research agendas 
(Weissmann, 1982). A range of external factors, such as personal interests 
and curiosities, scientific acknowledgement and prestige, political and 
financial support, societal needs and expectations, and social norms and 
values, play a very important role in decision-making on biomedical 
research agendas, as has been shown by several scholars in science studies, 
e.g. Marx Wartofsky (1982), Bruno Latour and Steve Woolgar (Latour, 
                                                 
7  The term ‘core-scientists’ is borrowed from Harry Collins (1988; Collins and Evans, 
2002) and refers to the group of scientists that is deeply involved in experimentation or 
theorization and thus contributes to the development of a certain scientific field. 
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1987; Latour and Woolgar, 1979), Karin Knorr Cetina (1981), and Joske 
Bunders (1994).  
Besides the researchers themselves, their institutional contexts – 
biomedical research establishments such as universities, public and private 
research institutes, and industrial laboratories, as well as various inter-
institutional and international research partnerships – play an important 
role in the steering of biomedical research. They provide a range of 
research facilities and decide on their own lines of research and research 
priorities. The influence of various institutional contexts on biomedical 
research varies per country. For example, while in the Netherlands a major 
part of biomedical research is conducted within academic laboratories, in 
the United Kingdom pharmacological firms and public research institutes 
play a much larger role (Cabello et al., 1999). 
The government 
A second stakeholder group consists of the national and international 
governments with their agencies, committees, councils, advisory bodies, 
etc. For these stakeholders, biomedical research is chiefly of interest for its 
potential social and economic uses. They decide on biomedical research 
legislation, administration, organization, and coordination.  
In addition, federal funding agencies, such as the National 
Institutes of Health (NIH) in the United States, the Medical Research 
Council (MRC) in the United Kingdom, and the Netherlands Organisation 
for Health Research and Development (ZonMw) in the Netherlands, fund 
a large part of biomedical research. This governmental funding is especially 
important to guarantee that social health care needs are addressed and to 
stimulate the progress of biomedical science, since neither industry nor 
disease-specific charities fund basic biomedical science (Resnik, 2001). The 
funding agencies base the formulation of research priorities and 
programmes and the appraisal of individual research projects on both 
scientific (internal) and societal (external) criteria, such as the scientific 
quality of the researchers involved, the potential contribution to 
biomedical science, the burden of the disease addressed, possible 
institutional support, etc. (Blume and Catshoek, 2001; Cabello et al., 1999; 
Resnik, 2003; Van Hoëvell-van Dapperen, 1998). Officials involved in this 
decision-making are mainly biomedical experts, medical specialists, and 
government representatives. They are structurally advised by governmental 
councils or advisory committees and often seek additional advice from 
other sources, such as scientists, professional associations, patients’ 
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organizations, industry, etc. (Resnik, 2001; Van Hoëvell-van Dapperen, 
1998).  
The industry 
The pharmaceutical and biotechnological industry constitutes a third type 
of stakeholder in biomedical research and of growing importance. 
Companies spend large sums of money on biomedical research which aims 
to develop new drugs, medical devices, or biologics. Although many 
pharmaceutical companies still run their own biomedical research 
programme, they increasingly outsource strategic research to academic or 
private laboratories or research institutes (Meyer-Krahmer and Schmoch, 
1998; Tijssen, 2004). The allocation of their money is mainly based on 
economic factors, such as market potential, liability costs, the scope of 
intellectual property protection, etc. (Hogg, 1999; Resnik, 2003).  
The charities 
Another group of stakeholders that is involved through funding consists 
of the private research funding agencies, such as the many disease-specific 
charities or foundations. They are created by patients’ organizations, 
biomedical research communities, or medical professionals, to stimulate 
biomedical research on a specific disease or group of diseases. They usually 
raise their own (relatively small amount of) money to fund biomedical 
research projects. Main conditions for funding usually are the scientific 
quality of the project proposal and a correspondence with the formulated 
priorities and programmes (Blume and Catshoek, 2001; Cabello et al., 
1999). Decision-making on funding is usually delegated to scientific 
advisory councils that consist of biomedical experts and medical specialists 
(Hogg, 1999; Van Hoëvell-van Dapperen, 1998). 
The medical professionals 
A stakeholder group that represents a different interest in biomedical 
research and influences decision-making in an indirect way is the 
community of medical professionals. Medical professionals can be 
considered as one of the user groups of biomedical research results. Over 
time biomedical developments have strongly influenced medical thinking. 
Within this framework, many medical professionals collaborate and 
communicate intensively with biomedical researchers, or may even 
themselves be researchers. Depending on the extent to which they 
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combine these roles they exercise varying degrees of influence on 
biomedical research agendas. 
The patient community 
Patients and their organizations form a group of stakeholders that is of 
particular interest in this dissertation. Although they are very involved in 
biomedical research as one of the end-user and target groups, they seem to 
be hardly involved in biomedical research decision-making processes. In 
the next section I will elaborate on the role of patients and patients’ 
organizations in biomedical research decision-making in particular. 
The public 
Finally, the public at large can be considered a stakeholder of biomedical 
research, since it involves taxpayers who contribute indirectly to the 
governmental funding of basic academic biomedical research as well as 
constitute the potential supporters of charity funds. As the latter, members 
of the public can be said to influence decision-making on biomedical 
research agendas in a rather passive way. Their decision-making power is 
restricted to the choice of charity fund. Once they have donated their 
money, they leave it to the organization to spend it as it deems wise. 
In addition, social pressure or interest groups, such as animal 
protection societies, may lobby or campaign effectively for either the 
stimulation or the suppression of certain types of biomedical research. 
Their influence is indirect, but may occasionally be substantial.  
Over the last ten years or so biomedical research policy making 
increasingly involves the public in order to canalize social concerns and 
enlarge public trust in biomedical policy. Governmental organizations 
organize consensus conferences or public debates, such as the national 
debate concerning bioethics of embryo research in the United States 
(Kelly, 2003), the public consultation on developments in the biosciences 
in the United Kingdom (Irwin, 2001), and several consensus conferences 
on cloning (Van Est and Van Dijk, 2000).8 In addition, some countries 
involve the general public in decision-making on biomedical research 
through special public advisory councils, such as the Consumer Liaison 
Group in the United Kingdom that aims to ensure the MRC is aware of, 
                                                 
8  However, most consensus conferences on biomedical issues concern the diffusion and 
application of biomedical technologies, such as xenotransplantation, genetic therapies, 
etc. instead of biomedical research itself (e.g. Barns et al., 2000; CunninghamBurley et 
al., 2001; Dietrich and Schibeci, 2003; Einsiedel, 2002).  
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and able to respond to, consumer interests and concerns regarding 
research, and the Council of Public Representatives in the United States 
that advises the NIH on funding priorities; or via membership in decision-
making councils, such as the NIH councils (Hagan, 2001; Resnik, 2001). 
Nevertheless, in spite of these forms of public involvement, in practice 
final decision-making on research funding is strictly determined by peer 
ratings of proposals (Cozzens and Woodhouse, 1995). 
The network 
The totality of actors and factors that determine biomedical research 
agendas can be considered a ‘social network’9, consisting of societal actors 
that are linked to each other by more or less stabilized relationships and 
interactions based on mutual exchange and dependency. Each actor plays 
its own role and has its own degree of involvement within the network 
(Elzen et al., 1996; Wellman, 1983). Kenneth Schaffner (1982: 141-142) 
describes this network as follows:  
“What is decided to be desirable new knowledge in the biomedical 
sciences arises from a partially designed, partially serendipitous 
interplay among many of the groups and actors represented as nodes in 
the net, and involves conceivable alternatives, desired options, possible 
actions and outcomes, and judgements of feasibility and likelihood, as 
construed by many different parties”.  
Within biomedical decision-making networks, the various funding 
systems have a very dominating influence on the steering of biomedical 
research (Cozzens and Woodhouse, 1995). However, the importance of 
                                                 
9  In this dissertation, the concept of ‘network’ can be compared to the concepts of 
‘socio-technical network’ and ‘techno-economic network’ as used by Elzen et al. (1996) 
and Callon et al. (1991) respectively. It should not be mixed up with the concept of 
‘actor-network’ from the ‘Actor-Network Theory’, since only human actors and their 
mutual relations are considered. In fact, the biomedical research field consists of many 
different but strongly overlapping decision-making networks. In these networks finally 
emerging ‘artefacts’ are – instead of certain technologies as in socio-technical or 
techno-economic networks – individual biomedical research projects or programmes 
that are executed. Actors involved often take part in multiple networks, following 
general patterns of interaction. Since this study aims to analyze these general patterns 
within decision-making on biomedical research, it focuses on a kind of overall 
decision-making network that underlies all project or programme centred networks. 
Instead of individual persons, organizations, etc., the nodes of this network consist of 
clusters of actors (communities, types of organizations, etc.).  
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various funding sources differs per country. For example, in the United 
Kingdom, charities play a dominant role in funding biomedical research, 
whereas in the United States the NIH is by far the major source of funding 
for biomedical research. In the Netherlands, a large part of biomedical 
research is funded by general university funds and not bound to 
predetermined priorities or programmes (Cabello et al., 1999; Resnik, 
2003; Van Hoëvell-van Dapperen, 1998). 
As a result of differences in the structures of decision-making 
networks, the dynamics of steering varies per country as well. For example, 
while in the UK there is a lot of hierarchical steering by the charities and 
the MRC, in the Netherlands the influence of, and interaction between, the 
many intermediary organizations (advisory bodies and funding agencies) 
causes mutual adjustment rather than hierarchical steering (Cabello et al., 
1999; Van Hoëvell-van Dapperen, 1998). 
1.1.2 The role of patients in decision-making on biomedical 
research 
Patients, although very involved in the biomedical research field as 
stakeholders, seem to be only marginally involved in biomedical research 
decision-making. Nevertheless, the fact that little has been published about 
the actual participation of patients in decision-making regarding 
biomedical research does not mean that patients and in particular patients’ 
organizations do not occasionally strongly influence this decision-making. 
Some well-known examples concern the successful lobbying of patients’ 
organizations for the stimulation of certain types of biomedical research at 
national policy levels (e.g. Kent, 2002; Parthasarathy, 2003; Rosengarten, 
2004).10 However, this patient activism does not entail the structural 
involvement of patients in formal research decision-making processes. 
Patients are only occasionally more structurally involved in research policy 
advisory structures, such as the Advisory Council on Health Research 
(RGO) in the Netherlands, which advises ZonMw on research funding 
                                                 
10   Since patients are part of the public at large, they also may take part in public 
participation exercises within national biomedical research policy making. However 
public participation usually is inspired by political arguments mainly and does no right 
to the specific status of patients as stakeholders (beneficiaries) and experts. In addition 
it can be questioned how many patients are actually involved in those exercises. At 
most it can be considered a very limited and therefore not an adequate example of 
patient participation in decision-making on biomedical research. 
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programmes or priorities, and the European Platform for Patients’ 
Organizations, Science and Industry that aims to influence European 
policy on health and health research matters.11 Still, in those cases patients’ 
actual influence on decision-making is hard to assess and may be 
questioned. 
More direct examples of patients influencing biomedical research 
agendas concern patients’ organizations that raise their own (small) 
research funds and formulate and implement their own biomedical 
research programmes (e.g. Blume and Catshoek, 2001; Kent, 2002; 
Rabeharisoa and Callon, 2002; Rangnekar and Duckenfield, 2002). A 
rather well-studied example is the case of the German Retinitis Pigmentosa 
(RP) patients’ society Pro Retina, which was quite successful in stimulating 
and influencing biomedical research practices in Germany. It had 
formulated and implemented its own research priorities, intervened in the 
scientific community, lobbied for public funding, and initiated innovative 
research projects (see box 1.1). However, since the implementation of the 
initial RP research program, decision-making about research funding has 
been delegated to the scientific advisory board, which consists of scientists 
only. This board bases its decisions on standard criteria of biomedical 
research and usually does not allocate funds to non-conventional ideas or 
projects.  
 
 
Box 1.1  The case of Pro Retina* 
 
Pro Retina is the German patients’ society for Retinitis Pigmentosa (RP), which 
can be described as any of several hereditary degenerative diseases of the eye that 
usually leads to total blindness. The main aims of Pro Retina are to support 
research on RP with respect to diagnosis and therapy, exchange information and 
experiences among RP patients, inform the public about RP and its social 
consequences, and exert influence on public and private persons, organizations, 
and institutions.  
Soon after its establishment in 1977, Pro Retina discovered that in Germany 
no systematic biomedical research was being conducted on the cause of the 
disease and possible therapies. Therefore, it decided to encourage the scientific 
community and to stimulate systematic research on RP. For this purpose Pro 
Retina published a report on the international state of affairs in RP research, 
installed a research referee that was to form a bridge between patient and 
research communities, established a RP research foundation trust at the German 
Science Foundation, and established a scientific advisory board (mainly 
                                                 
11  see http://www.rgo.nl and http://www.epposi.org 
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concerned with the prioritization and commissioning of research projects on 
RP). 
In addition, Pro Retina organizes national and international conferences on 
RP. The first conference organized by Pro Retina took place in 1984. During this 
conference, characterized by many interactions both between researchers from 
different disciplines and between researchers and patients, Pro Retina played a 
central role in the prioritization of RP research. Patient priorities that were 
expressed included research on the biochemical and genetic causes of retinal 
degeneration, research on the efficacy of current and future treatments of RP, 
the improvement of everyday visual conditions for RP patients, and the 
improvement of conditions for effective genetic counselling. Based on these 
priorities, the scientific advisory board established an integrated RP research 
programme.  
The growing implementation of RP research programmes has been possible 
because of Pro Retina's successful lobby for public funding. As a result in 
Germany there now is a flourishing RP research community with international 
prestige. Apart from prioritizing and funding research, Pro Retina is also 
interested in directing actual research projects to meet the needs and 
requirements of RP patients, for example by inviting specific researchers to 
congresses and seminars, or by financing part of their work. One of the recent 
research priorities of Pro Retina is molecular genetics.  
Pro Retina adopts a flexible attitude toward new and unconventional ideas 
that might not be accepted by the established research community but might give 
rise to promising innovations in the fight against RP. In order to give these ideas 
a chance, Pro Retina occasionally provides funding without consulting its 
scientific advisory board first.  
 
*  A more detailed description of this case has been published before by Flinterman et al. 
(2001). It is based on Von Gizycki (1987), Bunders (1994), Pro Retina (1999), and 
personal communication with H. Gusseck, research contact person at Pro Retina, on 
February 7, 2001. 
 
 
Similar to Pro Retina, most patients’ organizations that financially 
support biomedical research have established scientific advisory 
committees in order to deal with the formulation of research programmes 
and the appraisal of research projects (e.g. Blume and Catshoek, 2001; 
Flinterman et al., 2001; Hogg, 1999; Rabeharisoa and Callon, 2004; 
Rangnekar and Duckenfield, 2002). In addition, many patients’ 
organizations have professionals on their administration board. As a 
consequence the involvement of patients’ organizations in funding 
biomedical research does not necessarily imply the actual involvement and 
influence of patients (as both stakeholders and experts) on biomedical 
research agendas.  
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In the literature, only very few cases have been described 
concerning patients’ organizations that actually involve patients in 
decision-making on research programmes or priorities in a structural way. 
Maybe the two most well-known examples are the Alzheimer’s Society in 
the UK (Alzheimer's Society, 2002; 2004; Kent, 2002) and the French 
Muscular Dystrophy Association, which has been extensively studied and 
described by Rabeharisoa and Callon (2002; 2004). Within the Alzheimer’s 
Society in the UK, the programme ‘Quality Research on Dementia’ is an 
active partnership between carers, people with dementia, and the research 
community. The heart of Quality Research in Dementia is the QRD 
Advisory network: a network of 150 carers, former carers, and people with 
dementia who play a full role in determining the strategy for research, 
providing comments and prioritization of grant applications, selecting 
applications for funding, monitoring on-going projects being funded by 
the Society, and dissemination of research results.12 Each year they decide 
on research priorities for the programme, which have to be actively 
pursued by research applicants (Alzheimer's Society, 2002).  
The French Muscular Dystrophy Association (AFM) is a patients’ 
organization focussing on neuromuscular diseases. Since its creation in 
1958 it has become one of the main funding institutions of molecular-
biological research in France. Diseases that were once orphan, now are 
surrounded by influential research communities. But unlike most other 
patients’ organizations, the AFM did not delegate research decision-
making to scientists once the diseases were recognized and investigated. 
From the outset, patients and their families have maintained full control 
over both the association and the orientation of research. The AFM 
combines the mobilization of research communities around 
neuromuscular diseases with the active participation of patients and their 
families in the orientation of biological and clinical research and the 
production of knowledge on these diseases (see box 1.2).  
At the level of individual projects, patients’ roles are usually 
restricted to supplying research material and being the ultimate target 
group of research outcomes. Examples of patients that influence individual 
research topics or questions often remain anecdotic (e.g. Chalmers, 1995). 
 
 
 
                                                 
12  see http://www.qrd.alzheimers.org.uk/consumers.htm (accessed at December, 4, 
2004) 
INTRODUCTION 
15 
Box 1.2  The case of the French Muscular Dystrophy Association* 
 
The French Muscular Dystrophy Association (AFM – “Association Française 
contre les Myopathies”) is a grassroots organization for patients with 
neuromuscular diseases and their parents, which was founded in 1958 as the 
successor of a number of small-scale support groups. Since at that time only little 
knowledge on the various and rare diseases was available, members of the AFM 
started to produce knowledge themselves by making films, photographs, and 
testimonies about the characteristics and progression of the diseases.  
Today, the AFM has become one of the main funding institutions of 
molecular-biological research in France. One of the most important impulses of 
its growth was the launching of the ‘Telethon’ in 1987, a very successful annual 
TV-fundraising campaign that raises large amounts of money used to support 
and influence research. In its support of research the AFM has devoted itself 
principally to biomedical (including genetic and ‘post gene’) research.  
The AFM has itself defined research as a process that should start with the 
needs of the patients, and eventually return to them by proposing a solution. In 
order to ensure that research meets the demands and expectations of patients, 
the AFM administrators acknowledged the need for intensive interaction 
between researchers and patients. Therefore the AFM has increased the number 
of meetings, discussions, and forms of cooperation between patients, scientists, 
and clinicians. At the same time the association has conceived various political 
and organizational devices to ensure that, in all this interaction and cooperation, 
roles and responsibilities are not confused; the power of decision must remain in 
the patients’ hands.  
Besides an interdisciplinary scientific council that advises on research 
funding, the AFM has established a strategic council of a small number of 
experts with diverse competences, who can be consulted on all kind of issues. In 
regular contact with these experts the association forms an opinion on the most 
promising routes towards treatment, which serves as a basis for strategic 
decisions. In spite of the pressure of certain members of the scientific council to 
bring the research more in line with their own professional interests, the AFM 
board has consistently refused to relinquish any of its strategic power.  
An example of this strategic power was the launching of the Genethon 
laboratory in 1991 (comprising a large research project that aimed to locate and 
identify the genes responsible for neuromuscular diseases) and soon after, the 
AFM’s engagement in therapeutic research. Although the launching of the 
Genethon was not acclaimed by the majority of scientists within the scientific 
council, it has gained an international reputation after providing the first physical 
maps of the human genome in 1993.  
 
*  The description of this case is based on Rabeharisoa & Callon (2002; 2004) and Blume 
& Catshoek (2001). 
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1.2 The concept of patient participation 
 
Thus far, the concept of patient participation has not yet been problematized. 
However, in the framework of this study it is essential to define patient 
participation further and to elaborate arguments for patient participation in 
decision-making on biomedical research.  
As stated above, patients are stakeholders and potentially relevant 
(non-certified) experts within the framework of biomedical research. 
Therefore patient participation in decision-making on biomedical research 
can be considered a form of stakeholder participation. Many definitions 
have been formulated for stakeholder participation, differing in the 
interpretation of the terms ‘stakeholder’ (individual or group; having a 
clear stake or being affected; etc.) and ‘participation’ (passive sharing of 
information or active power sharing; direct or delegated; etc.). In this 
dissertation, I use a broad definition of stakeholder participation, namely 
‘any initiative that aims to involve stakeholders in decision-making on a 
plan, policy, or problem-solving process beyond that of voting in elections’ 
(adjusted from Smith, 1984). Thereby a stakeholder is anyone (individual 
or group) who has a stake or interest in the issue or decision under 
discussion.  
In this study, patient participation in biomedical research decision-
making is therefore defined as any initiative that aims to involve patients in 
that decision-making process. Patient participation could in principle occur 
at several levels of decision-making on, and at several stages within, 
biomedical research processes. For example, at a policy making level, 
patients might participate in the making of decisions concerning themes, 
rules, programmes, priorities, strategies, etc., while at the level of individual 
research projects, patients might be involved in decisions on specific 
research topics or questions. Although patients might not be in the 
position to participate directly in decision-making at the stages of design, 
execution, or result analysis of individual biomedical research projects, 
they could probably contribute to decisions concerning biomedical research 
agendas, whether these are individual, institutional, or national. 
Patient participation initiatives could be described and mutually 
distinguished along two dimensions. The first dimension concerns the 
degree of participation (degree of influence or power sharing) that is to be 
achieved. Stakeholder participation methods described in literature include 
forms of communication or information, stakeholder consultation, 
stakeholder membership in advisory or decision-making structures, 
INTRODUCTION 
17 
deliberative approaches, etc., all reflecting different degrees of stakeholder 
input and influence (e.g. Oliver et al., 2004; Rowe and Frewer, 2000; Van 
Asselt and Rijkens-Klomp, 2002). 
The second dimension concerns the objectives which are reflected by 
the underlying rationales for participation and that implicitly or explicitly 
inspire and shape participation initiatives. Objectives of participation can 
vary from the enhancement of the legitimacy of decision-making 
processes, to the realization of more sophisticated outcomes or the 
achievement of a higher societal acceptation of the outcome. In the 
following subsections these two dimensions of patient participation in 
biomedical research will be studied in more detail. 
1.2.1 Degrees of participation 
The term ‘participation’ can be related to terms like ‘involvement’ and 
‘communication’. Participation and communication both can be 
considered two forms of the broader concept of involvement13. The term 
‘communication’ refers to a more passive involvement and is often 
associated with the so-called ‘deficit model’ (Durant et al., 1992; Ziman, 
1991). This model assumes that the stakeholder involved lacks sufficient 
knowledge or capacities to be able to participate adequately in decision-
making processes. Many stakeholder communication methods aim to 
develop stakeholders’ understanding of issues concerned, and to align their 
visions with the visions of experts, in order to gain a higher acceptance of 
policies or decisions (Rowe and Frewer, 2000). By contrast the term 
‘participation’ is generally considered to refer to a more active involvement 
in decision-making processes. Participation methods often start from the 
assumption that the stakeholder involved has useful knowledge or 
perspectives that can contribute to policy or decision-making (e.g. Fiorino, 
1990; Nordin, 2000; Van Asselt and Rijkens-Klomp, 2002; Wright, 1976). 
In order to utilize the knowledge from stakeholders in an optimal 
way, stakeholders need to be directly involved in decision-making 
processes. Also Collins and Evans (2002: 262) argue that expert-
stakeholder participation in decision-making requires a direct, non-
delegated involvement; not by survey but by action. That applies in 
particular to experience-based experts, whose contributory expertise is 
                                                 
13  In the literature the term ‘patient participation’ is often used synonymously with terms 
like ‘patient involvement’ or ‘consumer involvement’ (see also note 1). I however 
consider participation as one of the many forms of involvement. 
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partly implicit. In addition, the decision-making process should ensure that 
stakeholders’ knowledge is actually integrated in the outcome. At the same 
time (genuine or effective) participation is often associated with values 
such as fairness, competence, equality, mutual respect, and mutual learning 
(e.g. Abelson et al., 2003; Jacobson and Storey, 2004; Webler and Renn, 
1995; Webler and Tuler, 2000). In doing so reference is usually made to 
Jürgen Habermas’s ‘theory of communicative action’ that involves action 
based on consensus among all interested and affected parties in 
collaborative decision-making processes, achieved by free and rational 
discourse (Habermas, 1975; 1984; 1987).  
However, evaluation studies have shown that not all participation 
methodologies bring about direct, influential, and fair public or 
stakeholder participation to the same extent (e.g. Abelson et al., 2003; 
Fiorino, 1990; Guston, 1999; Pratchett, 1999; Rowe and Frewer, 2000). 
Different methodologies reflect different degrees of participation, 
comprising different degrees of influence or power sharing.  
In order to be able to distinguish different degrees of patient 
participation, Sherry Arnstein’s ‘Ladder of citizen participation’ is used as a 
framework (1969). Arnstein defines participation as “the redistribution of 
power that enables the have-not citizens, presently excluded from the 
political and economic processes, to be deliberately included in the future” 
(p. 351). Her ‘ladder’ consists of eight rungs that stand for eight levels of 
citizen participation in local policy making (see figure 1.1). These levels 
reflect different degrees of power distribution, ranging from ‘manipulation’ 
to ‘citizen control’. The three lowest rungs of the ladder (manipulation, 
therapy, and information) reflect levels of communication14 rather than 
participation, leaving all decision-making power to traditional policy 
makers and denying citizens any influence on the outcome. Therefore 
these levels are left out of the further analysis. The five highest degrees of 
participation all reflect some input of citizens, albeit with different 
influence on decision-making. In table 1.1 these five degrees are translated 
into terms of patient participation in biomedical research.  
 
                                                 
14  Arnstein regards ‘information’ as a form of tokenism rather than as non-participation. 
However, since information comprises a one-way communication, usually taking place 
late in decision-making processes, it hardly provides any room for stakeholders to 
influence the decision-making. Therefore I have left out this level of participation from 
further analysis as well. 
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The two levels of consultation and placation reflect low degrees of 
participation and are often conducted with the aim of legitimization or 
satisfaction (‘tokenism’). Consultation takes place when patients are 
consulted for their perspectives by means of a survey or (group) interview. 
Placation concerns the partaking of patients in formal advisory or 
decision-making committees or boards. In both cases patients are allowed 
to express their views and feel that they are being heard but any actual 
influence on outcomes is not guaranteed. Professionals (scientific experts 
or policy makers) ultimately decide if patients’ inputs are included in actual 
decision-making. Therefore, these levels cannot be considered genuine or 
effective participation.  
Following Arnstein, partnership consequently can be considered the 
minimal level of genuine patient participation, reflecting actual power 
sharing in fair decision-making processes that incorporate negotiation and 
deliberation. It implies equality and mutual respect between participants. 
This degree of participation is the one implicitly or explicitly addressed by 
many scholars concerned with (effective) public participation and 
(deliberative) democracy. It can be considered as reflecting the earlier 
 
   
8 citizen control  
   
7 delegated power citizen power 
   
6 partnership  
   
5 placation  
   
4 consultation tokenism 
   
3 information  
   
2 therapy  
  non-participation 
1 manipulation  
   
 
 
Figure 1.1  Arnstein’s Ladder of Citizen Participation (1969) 
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mentioned theory of communicative action by Jürgen Habermas (1975; 
1984; 1987). 
 
 
Table 1.1  Five levels of patient participation in decision-making on biomedical 
research, as based on Arnstein (1969). 
Patient control Patients control decision-making on biomedical research agendas. 
Delegated power Patients gain a dominant position in the decision-making process to ensure 
the accountability of research programmes or projects to their needs. 
Partnership There is actual power sharing between patients and professionals within 
decision-making processes, for example in joint policy or planning 
committees. Final outcomes are the result of genuine negotiations between 
both parties. 
Placation Patients participate in decision-making or advisory structures in a formal 
way, without any guarantee that their inputs are being honoured. In practice 
professionals dominate the actual decision-making. 
Consultation Patients are consulted for their research needs, judgements, priorities, etc., 
without implying that these inputs are actually taken into consideration. 
Professionals decide on whether or not to use patients’ inputs in their 
decisions. 
 
 
A still higher level of patient participation is delegated power, which 
refers to a situation in which patients rule certain parts in the decision-
making process. They for example get appointed decision-making 
authority on certain issues or a kind of veto-power. The delegated research 
priority setting within the QRD programme of the Alzheimer’s Society in 
the UK could be considered a form of delegated power. 
The highest level refers to patients’ control of decision-making on 
biomedical research. Arnstein admits that absolute citizen control of 
decision-making is not realistic, nor is absolute control of decision-making 
on biomedical research by patients. Absolute patient control over 
biomedical research may endanger the professional autonomy of 
biomedical researchers and might result in the loss of scientifically 
important basic research directions. In addition, it might not be labelled 
participation since, according to Wright (1976), in genuine participation 
“no single person [or community] tends (by definition) to control the 
decision-making process to any extent” (p. 232). Participation requires at 
least some interchange among participants. Therefore, Arnstein’s highest 
level of participation refers to the control over certain programmes or 
institutions instead of absolute control.  
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The different levels of patient participation exhibit some overlap. 
For example, the partaking of patients in decision-making structures can 
comprise either placation or partnership, depending on the actual power 
balance between professional and patient participants. In practice, 
however, it is usually very difficult or even impossible to distinguish 
placation from true partnership, since the actual influence of patients in 
decision-making processes within these structures is hard to estimate (see 
Oliver et al., 2004: 88, 90-91). Within the broader field of patient 
participation, one therefore often uses the term ‘collaboration’ to refer to 
patients’ active involvement in decision-making structures, without 
pronouncing on patients’ actual influence on decision-making (e.g. Oliver 
et al., 2004; Paterson, 2003; Telford et al., 2002).  
In addition, participation exercises may show characteristics of 
more than one level. For example, certain elements within the case of the 
French Muscular Dystrophy Association (box 1.2) could be considered as 
reflecting partnership while other elements indicate a form of patient 
control.  
Other scholars have proposed other frameworks that differentiate 
levels or degrees of participation (e.g. Biggs, 1989; Pretty, 1995). In the 
context of patient participation in biomedical research an interesting 
framework is presented by Michel Callon, who describes three models of 
lay participation in scientific and technological decision-making (1999). 
Instead of focusing on power distribution like Arnstein, Callon focuses on 
knowledge distribution within decision-making. His first and lowest level is 
the ‘Public Education Model’ that refers to the information and education 
of the scientifically illiterate public, thus enhancing the lay people’s trust in 
science. The second level, the ‘Public Debate Model’, refers to the 
participation of lay people in scientific debates and is based on the idea 
that the local or contextual knowledge of lay people could enhance and 
complete scientific knowledge. However, the demarcation between science 
and non-science remains intact. Callon’s third level, the ‘Co-production of 
Knowledge Model’, finally, refers to the active involvement of lay people 
in the creation of knowledge that concerns them. Knowledge production 
takes place in close collaboration between scientists and lay people, each 
having maintained their own tasks, but with the group of lay people as an 
‘obligatory point of passage’. It is characterized by collective learning on an 
equal basis (Callon, 1999). Although there are some similarities between 
the frameworks of Arnstein and Callon, in this study I use Arnstein’s 
participation ladder since it offers a somewhat more extensive 
differentiation of levels of participation.  
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1.2.2 Objectives of participation 
As stated above, stakeholder participation initiatives are undertaken with 
different implicit or explicit aims constituting the rationales for 
participation. Participation can be considered the means to an end or an 
end in itself and can be morally, politically, instrumentally, or substantively 
motivated (Abelson et al., 2003; Fiorino, 1990; Flinterman et al., 2001; 
Telford et al., 2002; Webler and Renn, 1995). Normative (moral or 
political) arguments for stakeholder participation in decision-making, used 
by different scholars in the field of participation studies, usually reflect 
objectives such as the enhancement of the legitimacy of the decision-
making process itself or the accomplishment of some power rebalancing 
(stakeholder empowerment). Substantive arguments focus on the actual 
contribution stakeholders can make to the decision-making process and 
thus to the rationality of the process and the quality of its direct outcome. 
More instrumental arguments usually refer to the achievement of social 
acceptance (and the avoidance of conflicts) of both the process and its 
outcomes, or to the accomplishment of societal knowledge sharing (e.g. 
Abelson et al., 2003; Bickerstaff and Walker, 2001; Collins and Evans, 
2002; Irvin and Stansbury, 2004; Jasanoff, 2003; Renn et al., 1993; Webler 
and Renn, 1995; Webler and Tuler, 2002). These instrumental arguments 
are used by governmental or research-related organizations that have a 
particular interest in stakeholder participation.  
All arguments thus reflect certain objectives that can inspire 
stakeholder participation initiatives. These objectives concern either the 
decision-making process itself or its (direct or indirect) outcomes. The 
objectives that focus on the process and its direct outcomes can be 
considered short-term objectives that concern the particular context of the 
participation initiative. The objectives that refer to societal knowledge 
sharing or power rebalancing are long-term aims that may eventually 
transform societal networks. The different objectives are now further 
elaborated within the framework of patient participation in decision-
making on biomedical research agendas. 
1. Enhancement of decision-making legitimacy 
One of the most frequently mentioned objectives of patient participation 
in the decision process is that it enhances the legitimacy of the process 
itself. A decision-making process can be considered legitimate if its 
justness is generally acknowledged. This justness can concern the people 
involved in decision-making as well as the procedures followed. The 
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acknowledgement of justness can be based on different grounds. Legal 
legitimacy, for example, concerns acknowledgement on the basis of 
consistency with current legislation, while normative legitimacy refers to 
the acknowledgement of justness of a process on normative grounds. 
Although patient participation might not easily contribute to legal 
legitimacy of the biomedical research decision process (except when a plea 
for democratization of biomedical research is somehow incorporated in 
legislation), it certainly might contribute to its normative legitimacy on the 
basis of different normative claims.  
An often mentioned normative claim, pleading for stakeholder 
participation in the decision process in general, is that those affected by a 
decision should have input to that decision (e.g. Fiorino, 1990; Smith, 
1984). This claim implicitly refers to basic values of human self-
determination and autonomy and the assumption that stakeholders 
(citizens, end-users, etc.) are the best judge of their own interests, which 
goes back to John Stuart Mill’s ideas of social liberty (Mill, 1869). Because 
patients’ lives can be strongly affected by biomedical research results and 
outcomes (e.g. by means of new therapies or medicines), patients could be 
ascribed the right to have a say in biomedical research and development 
processes (Barbour, 1992; Bastian, 1994; Goodare and Smith, 1995).  
Another normative value pleading for patient participation in the 
decision process on biomedical research is the ideal of direct democracy, 
dating back to Rousseau (1762). Democracy can be considered an essential 
value within our political culture that calls for the democratization of 
public goods and thus of science (Feenberg, 1995; Fiorino, 1990; Fuller, 
2000; Jasanoff, 2003; Webler and Renn, 1995). Since a large part of 
biomedical science is publicly funded and can be regarded as a public 
good15, decisions on its direction should involve a democratic process with 
all relevant stakeholders or even the public at large. 
2. Enhancement of decision-making rationality 
A possible objective that addresses another quality of the decision-making 
process is the enhancement of the rationality of biomedical research 
decision-making. The sociologist Max Weber (1968) distinguishes two 
forms of rationality of action that apply in this context: goal-oriented (or 
                                                 
15  Research funded by charity funds, although not a public good in the strict sense, has a 
kind of constituency consisting of members and supporters that provide the money. 
This constituency can be ascribed a voting right, thus pleading for a degree of 
democratization as well. 
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instrumental) rationality and value-oriented rationality, which both refer to 
the intention of action, respectively a strategic or utilitarian intention and a 
value-based intention (Oakes, 2003; Weber, 1968). The goal-oriented 
rationality of a decision-making process refers to its purposefulness, 
effectiveness, and efficiency and thus indirectly to the adequacy of 
alternatives and criteria considered and to the ultimate costs and benefits. 
The value-oriented rationality refers to the consistency of decision-making 
procedures with social value systems. The objective of rational decision-
making thus can form the basis of both substantive and normative 
arguments. 
Patient participation could contribute to some aspects of goal-
oriented rationality in biomedical research decision-making. For example, 
patients could increase the purposefulness of decision-making processes 
by helping to specify the purpose a research programme should adhere to 
and ensuring that purpose addresses societal needs (cf. Resnik, 2001). They 
can also contribute to the effectiveness of decision-making by introducing 
relevant alternatives and weighing criteria that professionals may overlook, 
and by steering clear of potential negative consequences that professionals 
may not be aware of (cf. Jasanoff, 2003). In addition, patient participation 
can contribute to the value-oriented rationality of decision-making on 
biomedical research, because it ensures consistency with social values such 
as direct democracy and patients’ rights to participate (cf. Renn et al., 1993; 
Thomas, 1984). However, patients’ contribution to the efficiency of 
decision-making is less obvious. In this respect, biomedical research 
decision-making differs from other decision-making contexts, which 
require stakeholders’ agreement for successful implementation of 
decisions, e.g. environmental planning, sustainability development, or 
clinical research. Within these contexts, early stakeholder participation is 
necessary to avoid dragging conflicts, stakeholder resistance, or objection 
procedures afterwards, thus avoiding extra costs and enhancing the 
efficiency of decision-making processes (Irvin and Stansbury, 2004).  
3. Increase of outcome quality 
A third objective of patient participation in biomedical research decision-
making is to increase the quality of the outcome of the decision-making 
process. This objective constitutes a substantive argument that pleads for 
patient participation because it may lead to ‘better’ decisions, in terms of 
more socially relevant, more inclusive, or more appropriate to the context 
of application. This argument refers to the experience-based knowledge 
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that patients16 can contribute to the decision-making process and that 
complements professional biomedical knowledge by providing alternative 
views on matters of health and illness (Entwistle et al., 1998; Goodare and 
Smith, 1995; Popay and Williams, 1996; Telford et al., 2002). This 
knowledge can be considered ‘contributory expertise’ in terms of Collins 
and Evans (2002). It could include alternative perspectives on the societal 
relevance of certain research priorities or topics. An Australian study, for 
example, shows that breast cancer survivors made the topics “risk factors” 
and “diagnosis” their highest priorities for research whereas clinicians and 
researchers were more focused on the genetic basis of the disease and on 
the development and evaluation of new treatments (Marlin et al., 1996). 
Other scholars also have found that patients’ research priorities differ 
from the priorities of professionals (Grant-Pearce et al., 1998; Griffiths et 
al., 2002; Tallon et al., 2000; Van der Wilt, 1995). In addition, patients’ 
experience-based knowledge could offer alternative and useful insights or 
ideas on etiological questions, triggers for symptoms, the impacts of 
symptoms on daily life, patients’ needs for and values concerning 
technologies, etc. (Entwistle et al., 1998; Popay and Williams, 1996; Van 
der Wilt, 1995). By sharing these ideas, patients can help researchers to 
identify new research questions and to formulate hypotheses.  
Integration of patients’ experience-based knowledge broadens 
decision-making on biomedical research and that may eventually give rise 
to the adoption of alternative, more relevant research directions or the 
development of more appropriate technologies (Van Kammen, 2000). As 
has been argued by Van der Wilt (1995), the omission of patients’ input in 
decision-making on biomedical research agendas easily results in an one-
sidedness of research programmes, that does not take into account 
professional uncertainties, ambiguities, and pluralisms, or meet patients’ 
most urgent needs.  
4. Increase of social acceptance 
A possible instrumental objective of patient participation in decision-
making on biomedical research is related to the general rationale applied to 
public participation in decision-making that informing and involving the 
public will enlarge its confidence in and support of final outcomes, thus 
avoiding societal conflicts (Beierle and Konisky, 2000; Bickerstaff and 
Walker, 2001; Feenberg, 1999; Irvin and Stansbury, 2004; Mitcham, 1999; 
                                                 
16  in particular the (semi-)chronically ill patients who have repeatedly or long-lasting 
experienced their diseases 
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Rowe and Frewer, 2000; 2004). These outcomes might concern 
(biomedical) research agendas but also resulting technologies. Since the 
second half of the twentieth century, problems around the societal 
diffusion and application of certain new biomedical technologies have 
shown that societal acceptance of biomedical technologies is not always a 
self-evident matter (Barns et al., 2000; Mendelsohn et al., 1979; Van Est 
and Van Dijk, 2000). Involving stakeholders in decision-making at an early 
stage of research and development processes might avoid such societal 
conflicts (e.g. Koch, 1995). 
 The social acceptance of a decision is correlated to the social 
perception of a fair decision-making process (Renn et al., 1993) – also 
referred to as the social legitimacy of the decision-making process. This in 
turn can be considered as dependent on both the (legal and normative) 
legitimacy and the rationality of the decision-making process. However, 
since the social acceptance of decisions often has been used as a primary 
and instrumental argument for stakeholder participation, here it is 
mentioned as a separate objective of patient participation in biomedical 
research decision-making. 
5. Increase in human capital 
Besides the short-term objectives described above, a long-term objective 
of patient participation in biomedical research decision-making could be 
the sharing of knowledge between patients and professionals, which might 
result in an increase in societal human capital. Human capital can be 
defined as “the knowledge, skills, competences and other attributes 
embodied in individuals, which facilitate the creation of personal, social 
and economic well-being” (Côté, 2001: 30).17  
Effective participation of patients in decision-making processes on 
biomedical research results in an integration of patients’ experience-based 
knowledge and perspectives with scientific and professional knowledge 
and in mutual learning between both parties involved (Broerse and 
Bunders, 1999; Flinterman et al., 2001). Whereas patients may learn about 
                                                 
17  Although the concept of human capital usually refers to the economic values of 
individuals in particular, which can be assessed by measuring duration of schooling and 
qualification levels (OECD, 1998; Schuller, 2001, The Penguin Dictionary of 
Economics, 1984), within our framework we use a somewhat broader definition that 
includes motivation, moral behaviour, and attitudes, and thus tacit and inter-personal 
knowledge (Côté, 2001). 
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scientific (biomedical) knowledge, perspectives, and procedures, etc., 
professionals might learn from patients’ perspectives, experiences, and 
needs. The second direction of learning is comparable with what Daniels 
and Walker have described as ‘social learning’ (1996). Both parties thus 
benefit from participation processes, resulting in an overall increase in 
human capital that enables a more adequate societal response to 
contemporary complex questions (Irvin and Stansbury, 2004). Or, as Sheila 
Jasanoff (2003: 398) states: “participation can serve to disseminate closely 
held expertise more broadly, producing enhanced civic capacity and 
deeper, more reflective responses to modernity”. Moreover, the resulting 
reduction in language and knowledge gaps between patient communities 
and research communities can smooth future participation processes.  
Another increase in human capital concerns the general increase in 
knowledge on patient participation processes. Successful patient 
participation initiatives may result in the learning of both participants and 
other actors indirectly involved about methods and possible benefits of 
patient participation in biomedical research decision-making. This increase 
in knowledge may facilitate future participation processes as well.  
6. Increase in social capital 
Another possible long-term objective of patient participation in decision-
making on biomedical research is that it might bring about patient 
empowerment (Boote et al., 2002; Morrissey, 2000; Webler and Renn, 
1995) and decrease the power imbalance between patients and biomedical 
professionals. Eventually this ‘power sharing’ might result in a more equal, 
cooperative, and beneficial relationship between the patient community 
and the biomedical research community, characterized by mutual respect, 
trust, and understanding, as well as in an expansion of biomedical research 
decision-making social networks. In this way patient participation could 
contribute to a general increase in social capital (Abelson et al., 2003; 
Coleman, 1988a; Veenstra and Lomas, 1999).  
The objective of patient empowerment forms the basis of 
normative, socialistic arguments. However, since the social capital of a 
society is generally regarded as an important factor that enhances 
economic success and social well-being (Côté, 2001; Putnam, 2001; 
Veenstra and Lomas, 1999), this objective can inspire more pragmatic 
arguments as well.  
In table 1.2 the different objectives for patient participation in 
decision-making on biomedical research are summarized. 
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Table 1.2  Objectives of patient participation in decision-making on biomedical 
research 
Focus Objective Main related arguments 
process decision-making legitimacy normative (moral and political) 
 decision-making rationality normative and substantive 
short-term outcome outcome quality substantive 
 social acceptance  instrumental  
long-term outcome human capital  instrumental  
 social capital normative and instrumental  
 
Relation between objectives 
The six objectives mentioned above are closely intertwined. The first two 
objectives can to a certain extent be viewed as preconditions for the latter 
four. For example, the quality of a decision strongly depends on the 
rationality of the decision-making process, while its social acceptance 
depends on both the legitimacy and rationality of the process. 
Furthermore, the more rational a decision-making process is (in terms of 
including all knowledge and perspectives available) the higher its possible 
contribution to human capital, while both decision-making legitimacy and 
rationality may contribute to patients’ empowerment, and – thus – to 
social capital.  
In addition, increases in social capital and human capital are 
narrowly related. On the one hand patient empowerment (which can be 
related to an increase in social capital) is often thought to depend on the 
increase of patients’ knowledge of their diseases (cf. D'Alessandro and 
Dosa, 2001; Johnston Roberts, 1999; Weiner, 2003). On the other hand 
increases in social capital can facilitate processes of societal knowledge 
exchange (Coleman, 1988b), thus contributing to an increase in human 
capital.  
1.2.3 Arguments contra patient participation 
All objectives described above encompass arguments in favour of patient 
participation in biomedical research decision-making. However, there are 
also some arguments against patient participation. One often-heard 
argument is that participation exercises are expensive and time consuming 
INTRODUCTION 
29 
and thus strongly decrease the cost-effectiveness of decision-making 
processes. Other counter arguments are that lay participants are too 
irrational, ignorant or incompetent to make reasonable decisions on 
technical issues (Futrell, 2003).  
Another argument against patient participation in biomedical 
research in particular is that biomedical research is an ‘esoteric’ science that 
should not be interfered with, especially not by lay people who lack the 
specialist knowledge necessary to contribute anything relevant to 
biomedical knowledge production. Supporters of this opinion usually refer 
to important medical breakthroughs that have been the result of basic 
biomedical science inspired by scientific curiosity only, such as the 
discovery of bacteria and the discovery of DNA and its structure (e.g. 
Weissmann, 1982). Indeed, the intrinsic and potentially utilitarian value of 
isolated, basic biomedical research should not be underestimated. For this 
reason the question could be posed if all basic biomedical research needs 
to be submitted to the influence of patients. Indeed, several scholars who 
study the democratization of science and technology stress that more 
participation is not always better (e.g. Collins and Evans, 2002; Resnik, 
2001; Rip, 2003). For each situation an optimal balance needs to be found 
between excluding patients from any influence and letting them exercise 
total power. This optimal balance could very well turn out to be different 
for basic and applied biomedical research. 
 
1.3 Research design 
 
A first literature search on the topic, resulting in the overview in section 
1.1.2, strengthens the aforementioned assumption that patient 
participation in biomedical research decision-making is exceptional and 
marginal rather than structural and widespread. Patients seem to be 
excluded from the biomedical research decision-making network. If this 
assumption is correct, the question arises why the practice of patient 
participation in the biomedical research agenda setting is lagging behind 
other forms of stakeholder participation in decision-making regarding 
science. Do patients themselves, biomedical researchers, or other actors 
involved ward off (consciously or unconsciously) active patient 
participation in decision-making on biomedical research? If so, what are 
their motives and are these motives valid? If not, what other obstacles 
hamper patient participation in biomedical research agenda setting? These 
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questions ask for/require more research on the current state of patient 
participation in biomedical research decision-making.  
Subsequently, the different arguments that plead for active patient 
participation in decision-making on biomedical research agendas justify 
additional research that addresses conditions and strategies that can 
remove or overcome these obstacles and contribute to effective patient 
participation in decision-making on biomedical research.  
Within this framework I have formulated the following main 
research question that is addressed in this book: 
“To what extent is effective patient participation in biomedical 
research decision making possible?” 
In order to answer this question, I have formulated three sub-questions 
that determine the outline of the study: 
I. What causes the apparent limited participation of patients in 
decision-making on biomedical research agendas? 
II. What strategy could be devised to include them more actively 
and effectively in biomedical research decision-making processes? 
III. What can we learn from the practical implementation of this 
strategy, in particular in terms of effectiveness?  
Since these sub-questions are qualitative questions, answering them 
demands a qualitative research design. This study followed a so-called 
interactive model of research design (Maxwell, 1996; 1998). Central to this 
model is the idea that the essential elements of a study (context, objectives, 
research questions, methods, and validity checks) form an integrated 
whole, rather than being linked to each other in a linear or cyclic sequence. 
The research questions form the centre of the model. On the one hand 
they are inspired by the objectives of the study and informed by the 
cumulating knowledge about the context in terms of theories and findings. 
On the other hand they take into account the feasibility of methods and 
the seriousness of particular validity threats.  
The broader societal and conceptual context of this study on 
patient participation in biomedical research decision-making has already 
been described in the previous sections. Knowledge and theories on 
additional contextual aspects, such as current strategies to realize patient 
participation in biomedical research decision-making, the potential value of 
patients’ experience-based knowledge for this decision-making, factors that 
hamper or facilitate effective patient participation in this decision-making, 
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etc., will be developed during the study. Below I will describe the 
objectives of the study, its scientific and societal relevance, the research 
questions, the methods used, and the validity checks which were built in. 
1.3.1 Objectives and relevance of the study 
The primary objective of the study is to reflect on and experiment with 
patient participation strategies, building on the experiences of both current 
patient participation initiatives and successful stakeholder participation 
strategies that are applied within other scientific fields, in order to gain 
increased insight into how to design an appropriate strategy18 for effective 
patient participation in biomedical research decision-making. Sub-
objectives within this framework are increased understanding of (1) the 
validity and value of patients’ experience-based knowledge and its relation 
to scientific biomedical knowledge; (2) obstacles that hamper effective 
patient participation in biomedical research decision-making; and (3) 
conditions and methods conducive to the implementation of effective 
patient consultation and participation within the biomedical field.  
The study described in this dissertation is both scientifically and 
societally relevant. The scientific relevance is that it contributes to the on-
going debate on one of the central themes within the field of Science and 
Technology Studies (STS): broadening decision-making processes 
concerning science and technology. The societal relevance of the study is that 
it contributes to the formulation and practical implementation of a strategy 
for effective patient participation in decision-making on biomedical 
research, which may eventually contribute to the induction of a transition 
of the biomedical research decision-making network towards the structural 
inclusion of patients.  
1.3.2 Research questions 
The three sub-questions specified above determined the outline of the 
study design, which can be divided into three parts as well. The first part 
of the study focused on the current situation concerning patient participation 
in decision-making on biomedical research agendas. The second part of 
                                                 
18  The term ‘strategy’ is used in order to stress the pursuit of a societal objective, namely 
effective patient participation in decision-making on biomedical research. From a pure 
scientific perspective, the strategy to be formulated can be considered a new and 
effective participation methodology.  
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the study focused on the design of a new strategy for effective patient 
participation. In the third part of the study, subsequently, the proposed 
strategy was implemented and evaluated in a concrete practical situation.  
In order to answer the three sub-questions, a range of detailed 
research questions had been addressed following an ‘emergent design’ (cf. 
Guba and Lincoln, 1989); each question was formulated in close 
interaction with the overall objectives of the study and the developing 
knowledge on the context. Below, the subsequent research questions are 
described in relation to the main contextual aspects that have influenced 
their formulation. 
A more thorough investigation of the current situation comprises 
investigating current attempts of, and strategies applied for, patient 
participation. This led to the following three research questions:  
1. To what extent are patients actually involved in biomedical 
research decision-making? 
2. What strategies are followed to involve patients in decision-
making on biomedical research? 
3. To what extent can these strategies be considered as realizing 
effective participation? 
The answers to these questions indicated that currently patients are 
involved in biomedical research decision-making only rarely and that 
current strategies followed hardly result in effective patient participation. 
Apparently, effective patient participation in decision-making on 
biomedical research is hampered. A subsequent research question 
therefore addressed the obstacles that hamper effective patient 
participation in decision-making on biomedical research: 
4. What obstacles hamper effective patient participation in decision-
making on biomedical research?  
A main obstacle turned out to be the general adhered 
presupposition that patients lack the knowledge necessary to contribute 
anything relevant to decision-making on biomedical research. This 
presupposition thus contradicts the substantive argument for patient 
participation in this decision-making, which is considered a very essential 
one since it refers to the (potential) expert-role of patients. In order to 
investigate the validity of the substantive argument, the next research 
questions focused on patients’ experience-based knowledge and its 
potential value for biomedical research: 
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5. What are characteristics of patients’ experience-based knowledge 
and what could this knowledge contribute to decision-making on 
biomedical research? 
6. Is there any evidence that patients’ experience-based knowledge 
has influenced decision-making on biomedical research agendas? 
The findings within the framework of these questions suggested that 
patients’ experience-based knowledge could in principle contribute to 
decision-making on biomedical research. However, the utilization and 
integration of this knowledge into biomedical decision-making processes 
appeared to be still far from optimal.  
The second part of the study therefore focused on the design of a 
new strategy that could successfully involve patients and their experience-
based knowledge in decision-making on biomedical research agendas. For 
that reason, subsequent research questions addressed necessary elements 
of a strategy for effective participation and knowledge integration: 
7. What procedure could be followed in order to involve patients in, 
and integrate their experience-based knowledge into, biomedical 
research decision-making processes? 
8. What further conditions need to be met for effectively integrating 
patients’ experience-based knowledge with biomedical knowledge 
into biomedical decision-making? 
Finally, in the third part of the study, the proposed strategy for 
patient participation in decision-making on biomedical research agendas 
was implemented in a concrete practical situation and the effectiveness of the 
participation exercise was evaluated. The implementation took place in the 
context of a broader interactive health research agenda-setting project that 
was commissioned by the Netherlands Asthma Foundation and co-
financed by the Netherlands Organization for Health Research and 
Development (ZonMw). An essential part of this project was the explicit 
consultation of patients for their research priorities. Research questions 
addressed during this consultation comprised the capability of patients to 
participate adequately in biomedical research agenda setting. 
9. To what extent are patients capable of adequately identifying and 
prioritizing health research topics in general and biomedical 
research topics in particular? 
10. To what extent do patients value biomedical research? 
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Finally, research questions addressed by the overall patient participation 
exercise were: 
11. What do patients contribute to (biomedical) research agenda 
setting? 
12. To what extent can the strategy proposed and implemented be 
considered appropriate for realizing effective patient participation? 
1.3.3 Methodology 
Since the study aimed both to analyse, and to formulate and develop 
decision-making processes, it included a variety of methods. The first part 
of the study, focussing on the current situation, involved mainly 
descriptive-analytical case study research. The second part of the study, 
focussing on the development of a new strategy, consists of more 
‘conceptual’ research19. The third part of the study, involving the testing 
and evaluation of the formulated strategy in a practical situation, 
comprised a social experiment. This section describes the different 
methods used in these three parts of the study as well as the research team 
involved and the research relationships with participants established during 
the study. 
Methods  
The study covers the period from November 1999 until July 2004. 
Methods used during the descriptive-analytical part of the study (research 
questions 1-6) included extensive desk studies, interviews, informal 
dialogues, and an exploratory workshop, which was held in September 
2000. Below I shortly describe the different methods used, including the 
ways of sampling, data collection and data analysis. Further details can be 
found within the different chapters. 
Desk studies comprised both literature and Internet research, 
searching for background information about relevant actors and their 
relationships, as well as for theories on, and examples of, (patient) 
participation in decision-making processes.  
Interviews included both exploratory and explanatory interviews with 
patients, patient representatives, biomedical researchers, health care 
professionals, representatives of intermediary organizations such as 
                                                 
19  With the term ‘conceptual research’ I refer to a form of designing research that aims to 
build models or strategies to solve problems. 
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research councils, research funding agencies, and (socio-cultural) 
researchers in the field of patient participation. All interviews were semi-
structured, thus leaving room for interviewees’ narrations while still being 
able to focus on topics relevant for the various research questions 
(Saunders et al., 2003). Topics addressed during the interviews included 
interviewees’ perspectives on, and experiences with, (biomedical) research 
and the (possible) role of patients in this research, the content and the 
value of patients’ experience-based knowledge, examples of patient 
participation in decision-making on biomedical research, etc. Interviewees 
were either purposively selected, or selected by using the snowball method 
(Saunders et al., 2003). While some interviewees were selected based on 
their (expected) experience with, or possible interest in, patient 
participation in decision-making on biomedical research, others had been 
interviewed because of their representation of a relevant stakeholder 
group. Interviews were either fully transcribed from tape recordings or 
extensively reported from minutes directly afterwards. Interview reports 
were always returned to interviewees for validation in order to justify 
descriptions and interpretations. 
Interview data were analysed by both contextualizing and 
categorizing (cf. Maxwell, 1996). During contextualization, main messages 
and perspectives of interviewees were estimated by trying to understand 
their stories as small case studies. In order to investigate general themes 
more thoroughly, interview data were subsequently categorized. Categories 
used included issues such as ‘previous experience with patient participation 
in decision-making processes’ and ‘acknowledgement of the value of 
patients’ experiential knowledge’, which were inductively generated during 
the study (inspired by the grounded theory approach of Strauss and 
Corbin, 1998). In addition, categorized interview data were often placed in 
matrices in order to obtain more overview and insight. 
The exploratory workshop included three semi-structured group 
discussions between representatives from patients’ organizations, health 
care professionals, medical and biomedical researchers, representatives 
from intermediary organizations, and a representative of the 
pharmaceutical industry, and aimed to identify opinions and visions on 
patient participation in biomedical research. Discussions focused on the 
current situation concerning patient participation in decision-making on 
biomedical research as well as the desirability and feasibility of enhancing 
this patient participation. Workshop data were processed and analysed 
similar to the interview data described above.  
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The second part of the study, involving the development of a new 
strategy, was based on literature research and the analysis and 
interpretation of earlier findings and experiences. The third part of the 
study, focussing on the testing of the new strategy, consisted of a social 
experiment that was conducted and evaluated in the period December 
2002 – July 2004.  
The social experiment comprised the implementation and evaluation 
of a newly developed patient participation strategy within the context of a 
health research agenda-setting project commissioned by the Netherlands 
Asthma Foundation (NAF – ‘Nederlands Astma Fonds’) and co-financed 
by the Netherlands Organisation for Health Research and Development 
(ZonMw). The participation strategy was an adapted version of the 
Interactive Learning and Action (ILA) approach20; a methodology aiming at 
involving marginal stakeholders in decision-making on science and 
technology, developed by Joske Bunders and Jacqueline Broerse from the 
Athena Institute of the Vrije Universiteit Amsterdam21 during the 90s 
(Broerse and Bunders, 1999; 2000).  
The newly developed participation strategy consisted of six phases 
in which different research tools can be used:  
1. a preparation and initiation phase; 
2. a consultation phase; 
3. a collaboration phase; 
4. a prioritization; 
5. a specification phase; and 
6. an implementation phase. 
The research agenda-setting project comprised the first four phases only.  
During these phases different methods have been used. In the first 
phase, data collection took place by means of desk studies and interviews, 
focusing on the current state of affairs concerning (decision-making on) 
biomedical research on asthma or COPD22 and on opportunities for 
patient participation within this research. Methods used in the consultation 
phase included interviews, focus groups, a questionnaire, and several 
homogeneous group discussions. The collaboration phase involved an 
integration meeting that consisted of three heterogeneous group 
discussions. In the latter two phases the main focus was on priorities for 
                                                 
20  previously called the ‘Interactive Bottom-Up approach’ 
21  Athena Institute for Research on Innovation and Communication in Health and Life 
Sciences 
22  Chronic Obstructive Pulmonary Disease 
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research on asthma or COPD. The fourth phase consisted of a written 
prioritization exercise. 
Focus groups were used to gain insight in the experienced problems 
of asthma/COPD patients that may form a basis for their research 
priorities. The organization of different focus groups geographically spread 
across the country had to neutralize local biases. Participants were selected 
on the basis of their NAF membership and the region they were living in. 
Although we originally planned to form separate groups of asthma and 
COPD patients, this became infeasible in practice because in two of the 
three regions only a few COPD patients were able to participate. Other 
demographic characteristics were considered irrelevant for segmentation. 
Each focus group was chaired by an experienced facilitator, who was 
assisted by a monitor and a minute. The focus group design was 
standardized and averagely structured (cf. Morgan, 1996) using six pre-
established questions and exercises. Issues discussed were personal 
experiences and problems encountered with asthma or COPD, 
interpretations of those problems, and ideas for research questions. 
Exercises involved the prioritization of problems in terms of their urgency 
to be solved. 
Focus group discussions were monitored in order to analyse 
interactions between participants. In addition they were recorded in 
handwritten minutes as well as on video and cassette for further analysis. 
All participants consented to these recordings on conditions of anonymity 
and deletion after the project. The discussions were analysed by searching 
the minutes and tape recordings for mentioned causes of, and mutual 
relations between, identified problems. Summarizing reports of the 
discussions and its outcomes were sent to all participants for feedback. All 
problems, causes, and mutual relations mentioned were logically analysed 
in a so-called ‘causal tree’ (e.g. Klinkers, 2002). 
The questionnaire aimed to investigate patients’ priorities on 
(potential) health research topics or directions in a quantitative and 
representative way. Besides some introductory questions on demographic 
characteristics, the main part of the questionnaire consisted of 
prioritization exercises in which respondents are asked to divide a 
maximum number of points among different items (a variant of the 
'budget pie' method, see Mullen, 1999). These items were based on main 
problems mentioned in the focus groups. The questionnaire was tested 
beforehand, and after some minor revisions ad randomly sent to members 
of the NAF and to focus group participants. An accompanying letter and a 
stamped return envelope were included. The questionnaire results were 
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analysed in a stratified way in order to identify possible influences of 
demographic characteristics on research priorities.  
Group discussions had been conducted in order to consult scientists 
and professionals on their research priorities. These discussions had partly 
an exploratory character, focusing on experienced deficits in knowledge or 
health care inadequacies as well as on research priorities, and partly a 
deepening character, focusing on mutual relationships between deficits, 
arguments for priorities, and consensus on priorities. Participants were 
selected on the basis of their central position within a discipline, while all 
scientific and health care disciplines involved with asthma and COPD were 
sought to be covered. All discussions were recorded in minutes and on 
tape. Discussion minutes were sent to all participants for feedback. Final 
analysis included the incorporation of experienced deficits or problems in 
causal trees and the listing of agreed priorities. 
Additional interviews aimed at investigating the priorities of relevant 
stakeholders who had attended group sessions or at gaining more in-depth 
insight in priorities of stakeholders involved. All interviews were 
conducted and analysed as the interviews described above. 
A subsequent integration meeting, including patients, scientists, and 
health professionals, aimed to discuss perspectives and priorities of 
different stakeholders, to accomplish mutual respect, understanding, and 
learning between the different stakeholders, to integrate the different 
research priorities into one research agenda, and to identify criteria for 
further prioritization of the research agenda. For this meeting 
professionals were selected based on their backgrounds and on their 
indicated willingness to share decision-making with patients. Patients were 
selected from focus group participants based on their indicated wish to 
attend an interactive meeting and on their capability to express themselves 
clearly as assessed during the focus groups.  
The meeting consisted of three parallel, heterogeneous group 
discussions. These discussions were carefully guided by experienced 
facilitators and recorded in minutes and on tape. Afterwards all 
participants were interviewed in an in-depth way in order to evaluate the 
overall process (see below) and to assess their agreement with final 
outcomes. 
The final step in the research agenda-setting project comprised a 
written priority setting exercise. For this purpose a prioritization matrix was 
sent to all professionals that had participated in the agenda setting process 
as well as to patients who had indicated to be willing to participate in 
dialogues with professionals. Vertically in the matrix the different research 
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topics of the overall health research agenda were listed, while horizontally 
respondents were asked to rate the different research topics of the agenda 
by giving marks and to indicate in the matrix which criteria determined 
their priority setting. Final priorities were determined by the frequencies 
research topics had been prioritized, as well as by the total scores (added 
marks) of the different research topics.  
Methods used within the evaluation of the agenda-setting project 
comprised (comparative) documentary analysis, observation, video and 
cassette tape analysis, and interviews with participants.  
Comparison between intermediary results of the consultation 
phase and the end results of the project provided insight in the actual 
influence of the different stakeholders on the final integrated research 
agenda. Analysis of feedback reports and evaluation forms provided 
additional information on participants’ opinions concerning the adequacy 
of the procedures used, the quality of the analysis of results, etc.  
(Direct) observation and tape analysis were used to investigate 
social aspects of the process more thoroughly, such as the equal approach 
of, and interaction between, participants and their actual inputs in 
discussions as well as the functioning of the discussion facilitators. 
Observations were made by both facilitators and monitors. Although 
observation holds the danger of leading to subjective and biased results, it 
also provides important additional research opportunities (e.g. personal 
experience) that might be missed when restricting to more objective and 
retrospective evaluation methods only. Furthermore, observations do not 
depend on people’s willingness to respond to questions (Taylor-Powell and 
Steele, 1996). 
In-depth interviews with all participants of the integration meeting 
and two NAF-managers were used to collect visions on both the process 
and its outcomes more thoroughly. All interviews were held in the period 
April to June 2004 and carefully recorded. Interview reports were returned 
to the interviewees for feedback in order to validate any interpretations 
and conclusions. Interview reports were analysed as described previously. 
Research team 
During the entire study, the research team involved different people. The 
major part of the descriptive-analytical study (both interviews and desk 
studies) was conducted by the author of this book. Thereby I was 
occasionally assisted by MSc students who did some desk studies or 
performed some interviews within the framework of a traineeship.  
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The social experiment was a team effort. Besides me, Jacqueline 
Broerse and Tjard de Cock Buning of the Athena Institute were involved 
in the overall design and management of the project and were facilitators 
during several focus groups and group discussions. A junior researcher, 
Julia Teerling, was responsible for the main part of the practical 
management, including the invitation of, and communication with, 
participants, the organization of meetings, the processing of results, etc. 
Three MSc students, Melissa van Alst, Simon Klaasen, and Edwin Swart, 
were involved in the project as trainees for a six-month period and 
conducted amongst others the evaluation interviews. In addition, a group 
of six MSc students assisted in the organization and processing of patient 
focus groups within the framework of a course on interactive research 
methodologies. This intensive collaboration with both colleagues and 
students explains the use of the personal pronoun ‘we’ in the remaining 
part of this dissertation.  
Research relationships 
During the study there was intensive interaction with patients, patients’ 
organizations, biomedical researchers, health professionals, policy-makers, 
and other relevant actors in the fields of patient participation and 
biomedical research. Since these relationships may have influenced the 
research results, it is necessary to elaborate on this issue (cf. Maxwell, 
1996). 
Relationships with the patient community as well as with 
biomedical researchers had to be built up carefully. Interpersonal aspects 
such as mutual respect and trust appeared determining for the success of 
interactive data collection and the quality of data gathered. In time, many 
patients had become reserved towards researchers because of their 
experience of not being taken seriously by them. They thus needed to be 
approached as experts in an open-minded and respectful way. At the same 
time, some biomedical researchers appeared to feel uncomfortable by the 
idea of patients interfering in their domains and co-determining research 
agendas. They as well needed to be treated with respect and with 
acknowledgement of their autonomy and concerns. 
In addition, the choice of words appeared to be very important for 
the quality of results. For example, during my search for a patient group 
that was willing to participate in a social experiment, I experienced that it 
was essential not to introduce myself as a ‘researcher’ since many patients 
and patients’ organizations have become tired of being involved in 
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research, as they tend to be overloaded with requests from (clinical or 
social) researchers that seek their collaboration and information but often 
fail to communicate the results. However, when speaking to biomedical 
researchers or health professionals, it was important to present myself 
clearly as an academic researcher in order to be taken more seriously. 
In addition, the explicit focus of this study on biomedical research 
appeared to be rather restrictive for constructive interaction with patients. 
Firstly, the term ‘biomedical’ puts many patients off since they are not 
familiar with this term. Secondly, patients’ perspectives on, and interests in, 
research usually are much broader than biomedical research only. 
Therefore for the consultation and participation of patients it was quite 
convenient that the agenda-setting process in the last part of this study 
focused on health research instead of on biomedical research (as was also 
an explicit wish of the NAF and ZonMw). 
1.3.4 Validity 
Within this study, different strategies have been used in order to enhance 
the validity of results and conclusions and to minimize effects of 
researcher bias and influence (Maxwell, 1996). The following strategies will 
be shortly described: triangulation, member checks, and the use of rich 
data. 
Triangulation 
A first methodological strategy that strengthens the validity of this study is 
triangulation: the exploration of various data sources, with various 
methods. Triangulation reduces the risk of systematic biases or limitations 
of a specific method (Maxwell, 1996). 
In the descriptive-analytical part of the study, triangulation was 
achieved by collecting information from literature, websites, as well as 
from many individuals with different backgrounds and perspectives, 
respectively through desk studies and interviews.  
In the social-experimental part of the study, there was some 
triangulation during the evaluation of the participation project, by 
combining different data collection methods such as documentary analysis, 
(direct) observation, and interviews with a diversity of participants, such as 
patients, scientists, and health care professionals. Furthermore, since 
different team members were involved in this evaluation, there was a 
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triangulation among investigators as well, which further minimizes effects 
of personal researcher bias or influence. 
Member checks 
Another strategy that was frequently applied concerns the so-called 
‘member checks’ (Guba and Lincoln, 1989; Maxwell, 1996), consisting of 
systematically soliciting feedback on data and conclusions from the people 
who were studied. In this study, after each interview, focus group, or 
group discussion, interviewees or participants received draft reports in 
order to check interpretations of opinions or perspectives. In this way 
misinterpretations or mistaken conclusions through researcher bias or 
misunderstanding were minimized. 
Rich data 
An important strategy followed in this study in order to enhance the 
validity of results was the extensive documentation of primary data, such 
as authorized verbatim transcripts of interviews.  
 
1.4 Outline of the book 
 
The chapters 2-6 of this dissertation are based on separate articles and a 
report that have been published or submitted for publication before. They 
successively address the different research questions described above.  
The chapters 2 and 3 comprise the descriptive-analytical part of the 
study. Chapter 2 focuses on the first four research questions, by 
elaborating on current strategies for patient participation in biomedical 
research decision-making and on obstacles that hamper more effective and 
structural patient participation. At the end of this chapter I reflect on some 
strategic elements that could contribute to overcoming these obstacles. 
Subsequently, chapter 3 deals with one of the main obstacles identified by 
investigating, and reflecting on, the potential value of patients’ experience-
based knowledge for decision-making on biomedical research, thus 
addressing research questions 5 and 6. 
Chapter 4 involves the second part of the study and addresses 
research questions 7 and 8. Building on the findings of the first part of the 
study, literature research, and on earlier experiences with participatory 
strategies, I discuss the possible design of, and conditions for, an 
appropriate strategy to involve patients and integrate their experience-
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based knowledge within decision-making on biomedical research in an 
effective way.  
Subsequently, the chapters 5 and 6 comprise the social 
experimental part, describing the implementation and evaluation of the 
developed strategy within the context of an interactive agenda-setting 
project concerning research on asthma or COPD. While chapter 5 deals 
with the consultation of patients on their health research priorities and 
thus addresses questions 9 and 10, chapter 6 describes the overall 
participation trajectory and its evaluation, thus addressing questions 11 and 
12.  
In chapter 7, finally, the main findings that answer both the 
different research questions and the main research question are presented 
and discussed. In addition some suggestions for further research are given. 
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CURRENT STRATEGIES AND OBSTACLES23 
This chapter elaborates on the current situation concerning patient 
participation in decision-making on biomedical research, and in 
particular on the situation in the Netherlands. Subsequently, the role of 
patients in the current biomedical decision-making network, strategies 
followed to implement patient participation, and obstacles that hamper 
optimization of this participation are investigated and described. The 
findings indicate that user participation in decision-making is not a 
widespread phenomenon in the biomedical field. The examples found 
suggest that in the Netherlands three main strategies for patient 
participation can be distinguished. We argue that these strategies concern 
rather minimal levels of participation, since they do not entail 
partnership, ensuring patients’ structural influence on decision-making. 
They could be applied because they involve little or no change in the 
current biomedical decision-making network. In addition, we identified 
various obstacles that hamper a more effective involvement of patients in 
decision-making on biomedical research. The majority of these obstacles 
seem to reflect the resistance of the biomedical decision-making network. 
In the last section of this chapter the concept of transition management is 
introduced in search for clues on how to change the network towards 
more equal partnership between patients and professionals in decision-
making processes concerning biomedical research. 
 
 
As stated in the introduction of this book, patient participation in 
biomedical research decision-making is rarely described in academic 
literature. This suggests that patients are largely uninvolved in decision-
                                                 
23  The text of this chapter is based on Caron-Flinterman, J.F., Broerse, J.E.W., and 
Bunders, J.F.G. (submitted). Patient partnership in decision-making on biomedical 
research: Changing the network. Science, Technology, & Human Values. 
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making on biomedical research. In order to investigate this assumption more 
thoroughly, we focused on the situation in the Netherlands during the 
period 2000-03 as a case. For this purpose, this chapter subsequently 
elaborates on (1) the decision-making network in the Netherlands and the 
role of patients in this network, (2) the strategies followed for the 
implementation of patient participation in decision-making on biomedical 
research, and (3) the obstacles that hamper the implementation of a more 
effective participation. In the final section of this chapter we discuss a 
possible route to overcome these obstacles.  
Data were collected by means of an exploratory workshop, which 
was held in September 2000, 61 semi-structured interviews and more than 
20 informal dialogues with relevant actors – biomedical scientists, patients, 
and representatives from ‘intermediary organizations’24 –, all conducted in 
the period 2000-2003, as well as some additional desk studies. In the 
workshop five biomedical scientists, four medical doctors, one 
representative of the pharmaceutical industry, five patients and patient 
representatives, two representatives of intermediary organizations, and four 
researchers of health-related inter- or transdisciplinary research fields were 
invited. In three heterogeneous discussion groups participants discussed the 
current situation concerning patient participation in decision-making on 
biomedical research as well as obstacles and opportunities for increasing the 
involvement of patients in this decision-making. Participants had been 
selected partly on their possible interest in patient participation and partly on 
their representation of a relevant organization or professional community. 
Informal dialogues aimed at exploring stakeholders’ views on patient 
participation in biomedical research decision-making. Interviews included 
both exploratory and explanatory, semi-structured interviews with 22 
patients and patient representatives, 19 biomedical researchers, 3 health care 
professionals, and 17 representatives from intermediary organizations. They 
aimed at investigating more thoroughly stakeholders’ roles and interactions 
within the biomedical research decision-making network, as well as their 
views on obstacles and strategies for patient participation in this network. 
Interviewees were selected on the basis of their involvement or interest in 
biomedical research decision-making and the possible role of patients in this 
decision-making.  
                                                 
24  With the term ‘intermediary organizations’ we refer to all organizations that are 
somehow concerned with the interface between science and society, such as 
governmental research councils, research funding agencies, and social research institutes 
or departments working on the democratization of science. 
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Desk studies provided additional information on the structure of the 
biomedical research decision-making network and on possible routes to 
implement patient participation within this network.  
 
2.1 Decision-making on biomedical research in the 
Netherlands 
 
As described in section 1.1, decision-making on biomedical research 
involves a network of actors that interact in a more or less stabilized 
manner. Each actor has its own interests, role, and degree of involvement 
within the network. The most involved actors are, of course, the biomedical 
researchers, who work at universities, research institutes, or industries, and 
are the initiators, designers, and executers of individual research projects.  
Other key actors are the various biomedical research sponsors, 
comprising federal funding agencies, charity funds, and industry. The 
Netherlands Organisation for Health Research and Development (ZonMw) 
is the largest public research-funding agency involved with biomedical 
research in the Netherlands. It formulates and executes both basic and 
applied health research programmes with an annual budget of about € 70 
million (ZonMw, 2003). The majority of ZonMw’s commissions come from 
the Ministry of Health, Welfare and Sport (VWS – ‘Ministerie van 
Volksgezondheid, Welzijn en Sport’) and the Netherlands Organisation for 
Scientific Research (NWO – ‘Nederlandse  Organisatie voor 
Wetenschapplijk Onderzoek’). The Ministry’s main concern is to contribute 
to public health, including prevention and health care services, by funding 
applied biomedical and other health research. NWO, as the national research 
council, is concerned with fundamental and strategic research. In terms of 
health research and development – and thus in its relation with ZonMw – its 
main interest lies in contributing to cure, care and prevention by gaining a 
better understanding of disease and its underlying processes, and supporting 
research related to medical or health technology assessment.25  
Examples of large Dutch charity funds involved with biomedical 
research are the Dutch Diabetes Research Foundation (‘Diabetesfonds’), the 
Netherlands Alzheimer Foundation (‘Stichting Alzheimer Nederland’), the 
Dutch Cancer Society (‘KWF kankerbestrijding’), the Netherlands Asthma 
Foundation (‘Nederlands Astma Fonds’), the Netherlands Heart Foundation 
                                                 
25  www.zonmw.nl 
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(‘Hartstichting’), the Dutch Kidney Foundation (‘Nierstichting Nederland’), 
and the Dutch Arthritis and Rheumatism Foundation (‘Reumafonds’). In the 
Netherlands, most charity funds are independent of patients’ organizations, 
although they often do provide support and information to, and sometimes 
collaborate with, patients and patients’ organizations. Decisions on research 
programmes and fund appraisal are usually taken by scientific advisory 
committees or programming committees consisting of experts, i.e. 
renowned biomedical researchers and medical practitioners, only.  
At a less centre stage, but still quite influential in decision-making on 
biomedical research, is the Dutch government. The Dutch Ministry of 
Education, Culture and Science (OC&W – ‘Ministerie van Onderwijs, 
Cultuur en Wetenschap’) regulates, coordinates, and finances academic 
scientific research in general. It provides both direct (basic) funding to 
universities and indirect funding via intermediary organizations such as 
NWO and the Royal Netherlands Academy of Arts and Sciences (KNAW – 
‘Koninklijke Nederlandse Akademie van Wetenschappen’) (Ministry of 
Education Culture and Science, 2004). In the Netherlands non-allocated 
governmental contributions to universities forms a major source of research 
funding, providing the (biomedical) research community a lot of freedom in 
the choice of research topics and projects (Cabello et al., 1999; Ministry of 
Education Culture and Science, 2004). In addition, the Ministry of Health, 
Welfare and Sport (see above) and, at a smaller scale other ministries, such 
as the Ministry of Economic Affairs fund specific (more applied) biomedical 
research programmes or projects (Van Hoëvell-van Dapperen, 1998). An 
influential advisory council is the Advisory Council on Health Research 
(RGO – ‘Raad voor Gezondheidsonderzoek’), which advises the 
government on national health research priorities and programmes.26 
Another role of the Dutch government in the biomedical decision-
making network is as main client of (semi-) governmental (bio)medical 
research institutes, such as the National Institute for Public Health and the 
Environment (RIVM – ‘Rijksinstituut voor Volksgezondheid en Milieu’) and 
TNO Prevention and Health, the medical research institute of the 
Netherlands Organization for Applied Scientific Research (‘TNO Preventie 
en Gezondheid’).  
Other actors that occasionally influence decision-making on 
biomedical research in an indirect way, are medical professionals, patients 
and patients’ organizations, supporters of charity funds, and pressure 
                                                 
26  www.rgo.nl 
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groups, such as the Dutch Society for the Protection of Animals 
(‘Dierenbescherming’) (see section 1.1).  
Both the interviews and the literature research confirmed that 
patients and patients’ organizations, although highly involved in the 
biomedical research field as end-user group, are less influential in terms of 
decision-making on biomedical research. While at a national policy level, 
some patients’ organizations lobby for certain types of research (e.g. 
research on genetic therapy), they are not structurally involved in formal 
decision-making processes. At a project level, patients’ roles usually remain 
restricted to supplying research substrates and being the ultimate target 
group of the research outcomes. Decision-making on biomedical research 
agendas, on individual levels as well as on institutional and national levels, is 
mainly the territory of experts. It resembles a technocratic or expert-model 
of governance (see also Salomon, 2000). Only at a very limited scale research 
funding agencies, patients’ organizations, and advisory councils experiment 
with involving patients in decision-making on biomedical research (see 
below).  
 
2.2 Current strategies for patient participation  
 
Although in general patients are marginally involved in decision-making 
processes concerning biomedical research in a formal way, in our study we 
identified various concrete Dutch cases of patient participation in decision-
making on biomedical research. Though in all these cases patients or their 
inputs have been involved in decision-making processes, the cases differ in 
strategies (implicitly) followed. We found that in the Netherlands, patient 
participation in biomedical research is mainly achieved in three ways: (1) the 
successful lobbying of patient organizations, (2) the ad hoc use of patients’ 
ideas and demands through intermediaries, and (3) the inclusion of patient 
representatives in existing decision-making committees or councils. Below, 
we describe these strategies and illustrate them by mentioning some 
concrete examples (see tables 2.1-2.3). Although these examples do not 
reflect an exhaustive investigation, we think they together give a reasonable 
impression of the current status quo concerning patient participation in 
decision-making on biomedical research in the Netherlands.   
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1) Successful lobby of patients’ organizations 
The first strategy comprises patient organizations who take the initiative to 
participate in decision-making on biomedical research. They push forward 
their demands concerning research priorities by strongly lobbying for the 
general acknowledgement and subsequent expansion of a certain type of 
biomedical research. In table 2.1 we shortly describe two examples of this 
strategy.  
 
 
Table 2.1  Examples of the successful lobby of patient organizations 
- After years of lobbying the Dutch Alliance of Parents' and Patients' Organisations 
(VSOP – ‘Vereniging Samenwerkende Ouder- en Patiëntenorganisaties’) is 
increasingly consulted in national and international policy making on genetic 
research. It has also established seven academic chairs on topics such as clinical 
genetics and rare diseases. 
- During the past ten years the Dutch Society of Haemophilia Patients (NVHP – 
‘Nederlandse Vereniging van Hemofilie-Patiënten’), alongside other patient 
organizations, has successfully lobbied for more governmental support for research 
on genetic therapy. 
 
 
More examples of this way of influencing biomedical research policy 
exist, both on national and international level. They mainly concern the 
lobby for genetic research. Genetic research is generally expected to give rise 
to important breakthroughs concerning the cure of genetic illnesses and is 
therefore strongly advocated by many patient organizations concerned with 
genetic diseases. At the same time, patient organizations feel the need to 
influence policymaking on genetic research since this type of research has 
several controversial and complicating aspects that may delay governmental 
permission of its adoption.  
According to several respondents, in the cases identified the strategy 
of lobbying is successful due to the professionalism and perseverance of the 
patient organizations involved. Although these patient organizations are not 
actually included in (formal) biomedical decision-making structures, they 
increasingly are considered stakeholders that should be taken into account in 
national or international policy making. 
 
2) Ad hoc use of patients’ ideas and demands through intermediaries 
In the second strategy individual professionals or organizations, such as 
medical researchers, science shops, or research funding agencies, take the 
initiative to involve patients’ inputs in decision-making on biomedical 
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research programmes or projects. They ask for and/or take up patients’ 
demands or ideas and translate these into questions, topics or priorities that 
fit into current biomedical research practices, thus acting as intermediaries 
between the patient community and the research community. In table 2.2 we 
shortly describe four examples that reflect this strategy.  
 
 
Table 2.2  Examples of the ad hoc use of patients’ ideas and demands through 
intermediaries 
- In consequence of many complaints and questions from patients with 
neuromuscular diseases about the severe fatigue they suffered from, a medical 
specialist of the Neuromuscular Centre Nijmegen (University Medical Centre 
Nijmegen) launched a new research project on central and peripheral aspects of 
muscular fatigue. 
- The Dutch Addison and Cushing Society (NVACP – ‘Nederlandse Vereniging 
voor Addison en Cushing Patiënten’) approached a science shop in Utrecht with 
the request for a study on drug administration methods in order to search for 
improved medication of Addison's disease. The study was executed by a pharmacy 
student. The professor that had supervised the study subsequently established a 
research project on a new delayed release tablet. 
- After consulting the members of the Dutch Kidney Patient Organisation (NVN – 
‘Nierpatiënten Vereniging Nederland’) on the relevance of the subject via an article 
in their magazine, a biomedical researcher launched a research project on causes of, 
and therapies for, 'restless legs' as a symptom of kidney disorders. The study is 
funded by the Dutch Kidney Foundation (‘Nierstichting Nederland’). 
- A programming committee of the Netherlands Organisation for Scientific Research 
(NWO – ‘Nederlandse Organisatie voor Wetenschappelijk Onderzoek’) consulted 
the United Patients’ Organisations of the Chronically Ill (WOCZ – ‘Werkverband 
Organisaties Chronisch Zieken’) for formulating a research priority for a remaining 
part of an integral research programme on chronic illnesses. After consultation of 
its grassroots, the WOCZ introduced research on co-morbidity as a research 
priority, which was adopted. 
 
 
In our study most interviewees stated that mediation by 
intermediaries is essential for introducing patients’ ideas and demands into 
the research field: 
”An intermediary needs to translate individual patient questions into more 
general and researchable questions. Such an intermediary thus has to be 
familiar with both research and patient worlds” (a representative of an 
intermediary organization). 
At the same time intermediaries can help to distinguish useful from not 
useful ideas and demands, for example by searching for inter-subjectivity or 
by estimating scientific tenability.  
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3) Patients’ membership of decision-making committees or councils 
The third strategy comprises the involvement of patient representatives in 
formal decision-making structures, such as national or institutional 
committees or councils that advice or decide on research policy, 
programmes, or priorities. In table 2.3 we give four examples of this 
strategy. In the examples described, initiators were either the government or 
research funding agencies, which stimulated, required, or even realized 
patient participation in decision-making structures.  
 
 
Table 2.3  Examples of the inclusion of patients in decision-making committees 
or councils 
- The Advisory Council on Health Research (RGO – ‘Raad voor 
Gezondheidsonderzoek’) in the Netherlands, that advises the government on 
national research programmes and priorities, has one patient member. Also in 
temporary programming and priority setting subcommittees, patients are involved. 
- In response to a governmental request to involve patients as much as possible in 
research decision-making, the societal advisory council and several programme 
committees of the Netherlands Organisation for Health Research and 
Development (‘ZonMw’) now have several patient members. 
- The Rheumatism Foundation (‘Reumafonds’) in the Netherlands has two patients 
participating in the scientific advisory council that appraises research proposals on 
both scientific quality and societal relevance and advises the board of the 
Foundation about financing research. 
- Four representatives of the Dutch Neuromuscular Diseases Association (VSN – 
‘Vereniging Spierziekten Nederland’) participate in the board of the Dutch 
Neuromuscular Research Foundation (SONMZ – ‘Stichting Onderzoek 
Neuromusculaire Ziekten’) that aims to stimulate and communicate scientific 
research on causes of, and therapies for, neuromuscular diseases. 
 
 
Respondents involved within this strategy stressed that proto-
professionalization27 of the patient participants is a prerequisite for 
successful participation in biomedical research structures that are dominated 
                                                 
27  The concept of proto-professionalism refers to the degree lay-people have internalized 
the thinking of a certain professional group and organize, experience, and express their 
daily lifes according to this thinking. Although this concept originally has been applied 
within the context of health care, referring to patients that have internalized medical 
technical insights, which causes them to redefine their own health and illness (De Swaan, 
1979), in this chapter we use the concept of proto-professionalism to refer to patients’ 
internalization of biomedical scientific language and principles. 
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by scientists. In a process of proto-professionalization, patients learn about 
research procedures and principles and get used to scientific language and 
thinking. They thus adapt themselves to current biomedical research 
practices.  
 
2.3 A reflection on current strategies  
 
For the further characterization of the three strategies for patient 
participation described above, we use the ‘Ladder of Citizen Participation’ of 
Sherry Arnstein (1969) as a framework (see section 1.3). According to 
Arnstein, true participation should at least reflect a level of partnership, 
referring to some power sharing between patients and professionals.  
Within this framework the first two strategies for patient 
participation can be considered consultation. Patients or patients’ 
organizations either push forward their views (enforced consultation) or are 
consulted on their views by intermediaries. In both strategies professionals 
eventually decide about using these views. In addition, these forms of 
consultation usually occur in a rather ad hoc and non-structural manner.  
The inclusion of patients themselves in formal decision-making 
structures, such as in committees or councils, implies a higher participation 
level of at least placation or even partnership, depending on the actual and 
structural influence of patients in decision-making processes28. However, 
most interviewees stressed that this kind of participation usually takes the 
form of placation rather than partnership, which was criticized by many of 
them. Only strongly proto-professionalized patients are regarded and treated 
as real partners by professionals. As one of the involved patient 
representatives stressed, lack of professionalism easily results in the 
premature resignation of patients from committees:  
“Unfortunately 4 out of 5 patient participants give up prematurely 
because they do not manage; they don’t speak the language, focus too 
much on their own illness and don’t feel taken seriously” (a patient 
representative). 
                                                 
28  In the literature on patient participation, one often refers to this strategy by using the 
term ‘collaboration’ (e.g. Boote et al., 2002; Hanley et al., 2000; Oliver et al., 2004; 
Telford et al., 2002; Williamson, 2001). Although this collaboration is usually defined as 
‘active partnership’, in practice it also comprises forms of placation since the actual 
influence of patients on research agendas usually remains obscure (see Oliver et al., 2004: 
88). 
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At the same time, some respondents questioned the representativeness of 
strongly proto-professionalized patients and thus of their inputs in decision-
making. Proto-professionalism easily leads to the loss of patient perspectives 
(Abelson et al., 2003; Mullen, 2000).  
“Patients, who are very active and often surf the Internet sometimes 
know more about their disease than their medical specialist. However, 
such patients usually no longer talk from the perspective of patients” (a 
representative of an intermediary organization).  
But do these strategies result in effective patient participation in 
decision-making in biomedical research? The term ‘effectiveness’ refers to 
the degree intended effects or objectives are achieved. In correspondence to 
the participation objectives defined in section 1.2.2 we consider participation 
in decision-making effective if it enhances both the legitimacy and rationality 
of the decision-making process and improves the quality of decision-making 
outcomes. This in turn will enhance the social acceptance of the outcomes. 
Eventually, effective participation will result in enhanced human and social 
capital as well. Based on similar objectives, scholars dealing with 
participation in science and technology decision-making state that effective 
participation should accomplish a form of partnership, entailing the direct 
and early involvement of patients in fair decision-making processes that 
include negotiation, deliberation and power-sharing. At the same time 
effective participation should involve the structural integration of 
participants’ knowledge in, and thus their actual influence on, process 
outcomes (e.g. Abelson et al., 2003; Fiorino, 1990; Laird, 1993; Rowe and 
Frewer, 2000; Salomon, 2000; Webler and Tuler, 2000).  
The three strategies described above cannot be considered as 
realizing effective participation in this respect. The first two strategies result 
in some actual influence of patients on biomedical research agendas but only 
in an ad hoc manner without realizing any partnership, while the third 
strategy structurally involves patients in decision-making but cannot warrant 
their actual influence on the outcomes.  
There are, however, strategies for user participation being applied in 
other research fields that have successfully realized partnerships between 
professionals and non-professionals in decision-making. Well-known 
examples concern participatory research within the context of development 
studies (see for example Broerse, 1998; Cornwall and Jewkes, 1995; De 
Koning and Martin, 1996) and participatory approaches within the fields of 
sustainability research (Kasemir, Jaeger et al., 2003; Tress and Tress, 2003) 
and environmental research (Johnson et al., 2003; Till and Meyer, 2001). 
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Since we did not come across examples of the application of such strategies 
within the framework of biomedical research, we asked our respondents 
what reasons they could give for this observation.  
 
2.4 Obstacles to patient partnership  
 
The interviewees mentioned a number of obstacles that hamper true 
partnership. These obstacles are related to dominant practices and cultures 
within biomedical decision-making structures as well as to characteristics of 
patients that are to be involved in those structures. Below we describe the 
main obstacles identified, illustrated by some quotations29 of interviewees.  
Sense of urgency 
Maybe the most obvious ‘obstacle’ is that not all actors do consider it 
necessary to change the current situation and involve patients in decision-
making on biomedical research. Referring to the many biomedical successes 
of the last century, achieved without any interference of patients, some 
interviewees did not see any surplus value of patient participation in 
decision-making on biomedical research. On the contrary, they argued that 
patient participation only would delay and complicate efficient decision-
making processes.  
Financing structures and procedures 
More practical obstacles mentioned refer to the current research financing 
structures and procedures. Financing structures and procedures are 
dominated by academics and are almost exclusively based on scientific 
criteria. Patient relevance is rarely an important criterion, and the active 
involvement of patients is rarely propagated: 
“The scientific board consists of scientists only. […] In itself patients’ 
input could mean something but since the appraisal of research project 
proposals mainly concerns the scientific content it is not useful to involve 
patients in this process.” (a biomedical researcher who is member of the 
scientific board of a research fund) 
Patient participation in decision-making on biomedical research topics or 
questions is also hampered by the fact that biomedical research funding 
                                                 
29  The original quotations were in Dutch and were translated by the author. 
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agencies do not provide extra means in terms of money or time for the 
involvement of patients. 
Characteristics of the biomedical research community 
Other obstacles brought forward by several interviewees concern the 
structure of the biomedical research community, reflected in the presence of 
more or less specialized national research schools, intra- or inter-university 
research institutes, research departments, specific research organizations, 
etc., which links individual researchers to national and institutional research 
lines and minimizes the room for researchers to take up other research 
topics that might be relevant to patients. This structure reflects trends of 
reductionism and specialization within the biomedical research community. 
As one patient representative noted:  
“The problem of patient participation […] is to be found in the fact that 
medical specialists have a rather reductionist way of thinking. They only 
deal with their own, often narrow discipline and are blind to the broader 
context. Patients, on the other hand, argue just starting from that context. 
For them the biography is the point of departure.” 
Reductionism and specialization are regarded as holding back the attention 
for disease-transcending research topics, such as co-morbidity or fatigue 
(often mentioned as topics of high relevance to patients). In addition, the 
award structure within the biomedical research community was often 
mentioned as an obstacle to patient participation in biomedical research. 
Researchers tend to prefer dealing with research topics and questions that 
ensure scientific acknowledgement and increase publication rates, thus 
improving their career perspectives, to dealing with topics that might be 
relevant for the patient community.  
At a more implicit and cultural level, interviewees designated shared 
views, norms, and values among professionals as serious obstacles to patient 
participation in biomedical research. Generally adhered scientific paradigms 
that determine thinking on science and knowledge, were said to hamper the 
inclusion of patients and their experiential knowledge into decision-making 
on biomedical research at all levels (both policy and project management).  
“If you want to involve patients in research, you have to counter the 
current scientific paradigm as well as prejudices and patterns of acting 
and thinking of individual professionals […]. Professionals ascribe a 
certain position to patients: patients may say how they want to be treated 
but may not interfere in decisions. They do not possess the necessary 
knowledge to say anything relevant about [research].” (an intermediary 
person working on patient participation in mental care research) 
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Furthermore, researchers interviewed attach great value to their autonomy 
and stressed the importance of following scientific curiosity: 
“One of the dangers of patient participation in research decision-making 
is the loss of basic scientifically high-qualified research projects. Basic 
research, originating from the wish to satisfy scientific curiosity, is very 
essential. It has proven to be a main source of very important 
breakthroughs in knowledge development and innovations.” (a 
biomedical scientist) 
This scientific curiosity, however, does not necessarily correspond with 
patients’ interests. A patient representative said the following about this: 
“One of the problems of biomedical research is that some research 
questions might be relevant from a scientific perspective, but these don't 
have to be relevant at all from a patient's perspective within the 
framework of his diagnosis or therapy. One gratifies scientific curiosity 
and produces knowledge but one hardly looks at the interest of the 
patient.” 
Characteristics of the patient community 
A last category of obstacles that were mentioned by several interviewees 
refer to characteristics of the patients that are to participate in biomedical 
decision-making structures, such as their interests, knowledge, and 
competencies. Firstly, very few patients were said to be willing and able to 
formulate demands and ideas for biomedical research:  
“Among patients only now and then the wish exists of thinking along 
with biomedical research. Nor can you usually say that [individual] 
patients have explicit ideas or demands regarding biomedical research. At 
a managerial level there will be many more ideas with respect to scientific 
research, since at that level most questions of patients collect.” (a patient 
representative) 
Secondly, various interviewees stressed that most patients lack the 
knowledge that is considered crucial for adequate participation in decision-
making on biomedical research: 
“Patients usually lack the detailed professional knowledge to put their 
question in a scientific relevant context.” (a biomedical scientist) 
In addition, patients were said to lack the required objectivity and level of 
abstraction: 
“Many patients are pre-occupied with their own disease, bring that 
subject up repeatedly and are not able to look somewhat ‘broader’.” (a 
patient representative) 
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Finally, lack of self-confidence and empowerment, which is 
considered a prerequisite for adequate communication with professionals by 
most interviewees, was mentioned as an important obstacle. In table 2.4 the 
different obstacles are summarized. 
 
 
Table 2.4  Obstacles to patient partnership in biomedical research decision-
making  
Sense of urgency 
- no observed surplus value of patient participation  
- fear for delay and complication of decision-making processes 
 
Financing structures and procedures 
- financing structures dominated by academics 
- financing procedures based on scientific criteria 
- no additional means for patient involvement 
 
Characteristics of the biomedical research community 
- strong specialization of research community 
- importance of scientific achievements and publication rates 
- importance of scientific autonomy and curiosity 
- undervaluation of patients’ experiential knowledge 
 
Characteristics of the patient community 
- limited will to participate 
- lack of scientific knowledge 
- limited ability of objectification and abstraction 
- lack of self-confidence and empowerment 
 
 
Scholars who have analysed obstacles to stakeholder involvement – 
mainly from the field of participatory research – largely confirm our 
findings. They refer to limited resources as well as structural and cultural 
characteristics of the scientific community as possible obstacles towards 
effective lay (e.g. patient) involvement in decision-making. Limited resources 
usually concern time, money, and knowledge (Graham et al., 2001; Gray et 
al., 2000; Israel et al., 1998). Structural barriers mentioned refer to strong 
institutionalization and stabilized procedures that hampers any change 
towards embracing interactive approaches (e.g. Bunders and Van 
Eijndhoven, 1987; Gaventa, 1998; Gregory, 2000; Israel et al., 1998). 
Cultural barriers refer to generally accepted values, views, and attitudes of 
professionals that hamper a successful implementation of interactive 
approaches (e.g. Cozzens and Woodhouse, 1995; Gray et al., 2000; Israel et 
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al., 1998). In addition, inappropriate characteristics of the ‘lay’ community 
have been mentioned as obstacles to its effective involvement in 
participatory processes (Boote et al., 2002; Gray et al., 2000; Gregory, 2000; 
Israel et al., 1998). 
The different obstacles together seem to reflect a kind of resistance 
of the current biomedical research decision-making network towards the 
structural involvement of patients. This network consists of a more or less 
fixed number of actors that interact in a stabilized manner, sharing scientific 
paradigms and following standardized procedures. The whole of shared and 
stabilized rules and practices within a network is often designated a ‘regime’ 
(Geels and Kemp, 2000; Rip and Kemp, 1998). Obstacles attributed to 
characteristics of the patient community mainly refer to incongruence with 
the regime of the network. The resistance of networks and regimes towards 
change has been described before within the framework of socio-technical 
network theories (Callon, 1991; 1995; Elzen et al., 1996; Geels and Kemp, 
2000; Grin et al., 2003; Rip and Kemp, 1998). Actors involved in a socio-
technical network tend to adapt themselves to each other and to standardize 
or normalize their interactions. Changes of interactions within a network, 
for example by involving new actors, often are felt as destabilizing ‘threats’ 
and therefore countered by actors involved (Callon, 1991; 1995; Elzen et al., 
1996). 
 
2.5 How to proceed?  
 
The results described above seem to imply that the three identified strategies 
for patient participation in biomedical research are relatively easily applicable 
because they largely leave the current biomedical research decision-making 
network with its dominant regime intact and thus hardly encounter 
aforementioned obstacles. Actors in the network hold on to familiar ways of 
thinking and acting, while patients have to adapt themselves to these ways of 
thinking and acting or to call in an adequate intermediary in order to be 
heard. This precludes equal partnership, as is clearly phrased by one of the 
interviewed patients:  
“All ‘rules of the game’, the objectives, composition and activities [of the 
committee] had been determined before patients were involved at all. 
Now the situation has been created that patients are ‘allowed to join’ 
while the scientists themselves have decided long ago on what counts as 
science and good research, what is interesting, etc. Good and effective 
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participation is possible only if you have decided or re-decided upon the 
objective and presuppositions together.” (a patient member of a national 
research council) 
Making patients equal partners in decision-making processes 
concerning biomedical research, ensuring that patients’ knowledge is used in 
a more structural way, implies a rather radical change of the current 
decision-making network and its regime. Because of the resistance of the 
network described above, such a change may not be uncomplicated. The 
question we try to answer in this final section of the chapter is how such a 
change might be induced and which actor could take the initiative? 
For this purpose we searched the literature on socio-technical 
networks for some clues on how the resistance of networks could be 
breached and considerable changes could be induced. We found that in 
particular the rather new field of transition management may provide some 
interesting insights on this matter. Rotmans et al. (2000: 19) define a 
transition as “a gradual process of societal change in which society or an 
important subsystem of society structurally changes”. Such a change 
comprises economic, cultural, technological, institutional, and environmental 
changes. We regard the stabilized biomedical research decision-making 
network as a societal subsystem (or subsystem of a subsystem). Changing 
this network towards a structural involvement of patients in decision-making 
processes can be considered a transition that includes changing dominant 
cultures, stabilized patterns of interaction, usual practices, and established 
institutions. Transition management is about how to manage or induce such 
a transition and thus might provide some clues on how to realize structural 
patient participation in decision-making on biomedical research.  
Scholars in the field of transition management describe transitions as 
multi-phase and multi-level processes. The multi-phase concept 
distinguishes four different stages in the long-term transition process (Kemp 
and Loorbach, 2003; Rotmans, 2003; Rotmans et al., 2000): 
1. a predevelopment phase, in which the status quo does not visibly change; 
2. a take-off phase, in which the process of societal change makes a start;  
3. an acceleration phase, in which visible structural changes take place 
through an accumulation of socio-cultural, economic, technological, 
environmental, and institutional changes that influence each other. 
The acceleration phase includes processes of collective learning, 
diffusion, and embedding; 
4. a stabilization phase, in which the speed of social change decreases and 
a new dynamic equilibrium is reached. 
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The multi-level concept distinguishes three levels of social 
organization that are involved in transitions (Berkhout et al., 2003; Geels 
and Kemp, 2000; Rotmans, 2003; Rotmans et al., 2001): 
1. the micro level concerns individual actors and their actions and 
practices that may develop ‘niches’ in which technological, social, or 
policy innovations can arise. 
2. the meso level is constituted of networks of actors that have shared 
assumptions and interact via dominant practices and rules 
(‘regimes’). 
3. the macro level, finally, shapes the broad context for niches and 
regimes, consisting of material infrastructure, the macro economy, 
demography and the natural environment as well as shared cultures, 
worldviews, values and paradigms, often referred to as ‘landscapes’.  
Changing the biomedical research decision-making network and its 
‘regime’ implies changing the meso level. However, in accordance with 
network theories mentioned earlier (Callon, 1991; 1995; Elzen et al., 1996), 
the meso level is ascribed considerable resistance against change due to the 
tendency of existing networks to stabilize and to hold on to current regimes. 
Therefore in the predevelopment phase, regimes at the meso level act as an 
inhibiting factor to transitions (Geels and Kemp, 2000; Grin et al., 2003; 
Rotmans, 2003).  
At the same time changes at the macro level or at the micro level can 
disturb the equilibrium and exert pressure on the regimes, thus inducing a 
transition (Geels and Kemp, 2000; Rotmans, 2003; Rotmans et al., 2001). 
Changes at the macro level comprise relatively slow political or societal 
trends and developments that can play a role in speeding up or slowing 
down a transition. Changes at the micro level concern the development of 
innovations within niches, such as new technologies, new initiatives, and 
new forms of policy, which could gradually transform dominant networks 
and their regimes in a bottom-up way. Only when changes coincide at all 
three levels, a transition may occur (Berkhout et al., 2003; Rotmans, 2003). 
Concerning a transition towards structural patient participation in 
decision-making on biomedical research, changes are visible both at the 
macro and at the micro level. At the macro level trends towards 
democratization of science and patient empowerment, as we described in 
the introduction, play a stimulating role. At the micro level, individual actors 
experiment on involving patients in decision-making on biomedical research 
programmes, priorities, or topics, as has been the case in some examples 
described in table 2.1. When successful, these initiatives can be considered 
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possible inducers of a transition. These changes at both levels suggest that 
we might be near the start of a take-off phase of a transition towards patient 
participation in decision-making on biomedical research.  
But what can we contribute to this process? A premise of transition 
management is that although transitions cannot be controlled, they can be 
influenced. Transition management aims at influencing speed and direction 
of transition processes. It creates the necessary conditions for societal 
change by taking the right initiatives at the right time (Rotmans, 2003: 51). 
Thereby it “joins in with ongoing dynamics and facilitates and builds on 
bottom-up initiatives” (Kemp and Loorbach, 2003: 11). 
Rotmans (Rotmans, 2003) describes a kind of step-by-step guide for 
transition management comprising four main activities: 
1. the design, organization, and management of a ‘transition arena’ – a 
small innovation network of actors that are selected on the basis of 
their competences, interests, and backgrounds, and that form the 
leaders of the transition; 
2. the development of a long-term vision concerning the transition 
targets and pathways; 
3. the steering at learning processes and knowledge production via the 
planning and execution of innovation experiments; and  
4. the monitoring and evaluation of the transition process. 
The idea of forming a small innovation network as an initial step in 
inducing a transition corresponds with one of the conclusions of Elzen et al. 
(1996) that the establishment of a new socio-technical network, besides the 
old network, is the most suitable way to bring about radical socio-technical 
change. These participants all need to share a commitment to the overall 
targets of the transition. Within the transition arena, there must be enough 
room for experimentation and innovation on methods for patient 
participation. At the same time processes of constructive interaction and 
mutual learning between the different actors need to be facilitated and 
stimulated.  
According to Elzen et al. (1996: 133) the driving force behind the 
emergence of a new network is one or more so-called ‘dedicated network 
builders’, who have a sense of urgency and are prepared to “work against the 
odds”. However, the role of ‘dedicated network builders’ is a very complex 
and delicate one. Firstly, they need to have enough power of persuasion to 
detach other actors (partly) from their stabilized regimes in the old network 
and to motivate them to participate in a new network. Secondly, they should 
be intermediaries that are capable of bridging cultural gaps between the 
CURRENT STRATEGIES AND OBSTACLES 
63 
actors and stimulate and facilitate processes of constructive interaction and 
experimentation. In other words they have to counter the resistance of the 
current network and overcome the obstacles identified. Since these 
conditions are difficult to meet, network builders easily fail in their actions. 
As an example, a small Dutch knowledge agency on research for patients’ 
organizations that was established in 2001 with one of its aims to enhance 
patients’ influence in decision-making on research processes was dissolved 
recently because of lack of visible success30.  
Inducing the take-off phase of a transition towards patient 
participation in decision-making on biomedical research could thus entail 
the creation of a small innovation network (a ‘transition arena’) including, 
for example, some interested and open-minded biomedical researchers, 
patients, intermediary persons, and representatives from research funding 
agencies and governmental organizations, but also experts from the field of 
participatory approaches. Actors involved need to acknowledge the 
possibilities and benefits of patient participation in biomedical research and 
be willing to experiment with participation strategies. Potentially successful 
dedicated network builders could be intermediary organizations or academic 
institutions that have made network building, transition management, or 
interactive approaches their core activity. Also charity funds that implement 
their own research programmes could be in a position to fulfil this role. 
Since these funds usually have close relations with both a patient community 
and a research community, they might be able to influence both parties and 
to bridge cultural and structural gaps effectively31. Interviews with 
representatives of the Dutch Kidney Foundation, the Dutch Arthritis and 
Rheumatism Foundation (RF), and the Netherlands Asthma Foundation 
(NAF) have shown that these charity funds seek to legitimize their funding 
practices by involving patients in decision-making. As a result, both the RF 
and the NAF are already taking initial steps towards patient participation in 
research programming and prioritizing. In a subsequent acceleration phase 
                                                 
30  Stichting de PatiëntenPraktijk; www.patientenpraktijk.nl 
31  Although in the Netherlands most charity funds and patient organizations constitute 
separate organizations, in many other countries, patient associations combine the 
functions of research fund and patient society. This combination of functions may 
facilitate patient involvement in decision-making on research programmes or priorities, 
in particular if patients are on the board of the organization. Two successful examples of 
patient associations that structurally influence research agendas in this way are the 
Alzheimer’s Society in the United Kingdom (Alzheimer's Society, 2002) and the French 
Muscular Dystrophy Association (AFM – ‘Association Française contre les Myopathies’; 
see box 1.2) (Rabeharisoa and Callon, 2002; 2004). 
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the small innovation network could, by establishing new and successful 
participation practices (such as the launching of an appropriate strategy for 
participatory programming of biomedical research that leads to relevant and 
societal embedded research programmes), convince and include ever-more 
actors out of the old network, thus gradually substituting the current 
biomedical research decision-making network.  
 
2.6 Concluding remarks 
 
In this chapter we reflected on the current situation concerning patient 
participation in decision-making on biomedical research. Thereby we 
focused on the situation in the Netherlands. In spite of possible differences 
concerning specific situations in other countries, informal communication 
and additional literature research have indicated that most findings and 
conclusions are broadly applicable (e.g. Boote et al., 2002; Kent, 2002; 
Oliver et al., 2004). Although different initiatives indicate that actors 
experiment with patient participation, we found that the implementation of 
patient participation in a structural and effective way is hampered by the 
resistance of the current biomedical decision-making network and its regime. 
Structural and effective patient participation in decision-making on 
biomedical research requires a more radical change of this network, which 
could be considered a transition.  
Transition management thus may offer a way to breach the 
resistance of the biomedical research decision-making network and to realize 
a change of the network towards patient participation. Thereby one could 
join in with ongoing trends of user participation in science and build on 
current bottom-up initiatives identified above. A possible outcome is the 
emergence of a new biomedical research decision-making network that 
structurally includes patients as partners in decision-making processes.  
A precondition for a successful transition, however, is that patient 
participation really and visibly contributes to the quality and relevance of 
research and research agendas. This would support the substantive argument 
for patient participation in decision-making on biomedical research. For this 
purpose additional research should focus on the potential contribution of 
patients to decision-making on biomedical research. Therefore we elaborate 
on this issue explicitly in the next chapter. 
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THE EXPERIENTIAL KNOWLEDGE OF 
PATIENTS32 
One of the arguments in favour of patient participation in decision-
making on biomedical research concerns the contribution that patients 
could make to the relevance and quality of biomedical research based 
on their ‘experiential knowledge’. This chapter reflects on the validity 
of patients’ experiential knowledge in the context of biomedical 
research processes. Since a conclusive argument on the validity of 
patients’ experiential knowledge could not be reached on the basis of 
only theoretical reflection, a pragmatic approach was chosen that 
assessed this validity in terms of its practical usefulness for biomedical 
research. Twenty-three cases of patient participation in biomedical 
research were identified and analysed for a concrete contribution of 
patients to the research process. In nine of these cases, the concrete use 
of patients’ experiential knowledge could be traced. The findings 
suggest that patients’ experiential knowledge, when translated into 
explicit demands, ideas, or judgements, can contribute to the relevance 
and quality of biomedical research. However, its deliberate use would 
require additional research on a more structural and interactive 
approach to patient participation. 
 
 
In the introduction of this book, different arguments for involving patients 
in decision-making on biomedical research have been mentioned. 
Normative arguments can refer to the moral right of patients to participate 
in decisions that may substantially affect their lives and bodies, as well as 
                                                 
32  The text of this chapter is based on: Caron-Flinterman, J.F., Broerse, J.E.W., and 
Bunders, J.F.G. (2005). The experiential knowledge of patients: a new resource for 
biomedical research? Social Science & Medicine 60: 2572-2584. 
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to democratic ideals that plead for the participation of stakeholders in 
decision-making on science in general. Instrumental arguments usually 
refer to the increased social acceptance of biomedical research directions 
and outcomes when stakeholders (and thus patients) are involved in 
decision-making processes. Substantive arguments, finally, refer to the 
contribution patients could make to the quality and relevance of 
biomedical research, especially through the specific kind of knowledge and 
expertise that patients gain as a result of experiences with their illness. This 
knowledge could complement the knowledge of researchers by providing 
wider perspectives and options (Entwistle et al., 1998; Goodare and 
Lockwood, 1999; Popay and Williams, 1996). 
This last type of argument is of specific importance since it refers 
to the (potential) expert status of patients within biomedical research 
decision-making, which distinguishes patients from other stakeholders 
such as the public at large. However, at the same time this type of 
argument is debated. Given its technical character, decision-making on 
biomedical research is generally considered to require highly specialist 
knowledge, which makes it a less obvious option for patient participation. 
As has been shown in the previous chapter, both biomedical researchers 
and patients themselves often argue that patients lack the knowledge and 
objectivity that would enable them to make any relevant substantive 
contribution to biomedical research processes, which is clearly illustrated 
by the remark of a biomedical researcher we interviewed:  
“Patients should not interfere in processes of which they know nothing 
about.” 
This opinion, also observed by Boote et al. (2002) and Oliver et al. (2001), 
constitutes one of the main obstacles that hamper the implementation of 
effective patient participation in decision-making on biomedical research.  
However, others argue in line with the substantive argument 
mentioned above that the specific knowledge of patients is a rich source of 
information that should not be missed in biomedical research, and that the 
fact that it may be difficult and complex to realize is a poor excuse for not 
pursuing the integration of patient knowledge into biomedical research 
processes (cf. Entwistle et al., 1998; Flinterman et al., 2001). One patient 
whom we interviewed, a member of several consumer-oriented and 
patient-oriented organizations, remarked:  
“Biomedical science is very reductionist. This leads to useful knowledge 
and innovation, but the broader context – the overarching ‘system’ – is 
ignored. Patients have specific knowledge about what it is like to live 
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with one or more ailments. By not involving patients, biomedical 
research is overlooking an important source of knowledge.” 
These contrasting views call for closer scrutiny.  
This chapter therefore focuses on the added value of patient 
participation for biomedical research: what knowledge can patients 
contribute to the biomedical research process? After a theoretical 
reflection we investigate the validity of patients’ knowledge by analysing its 
potential value for biomedical research in practical examples. To this end 
interviews were conducted with more than 60 (bio)medical scientists, 
patients, representatives from patients’ organizations, and professionals 
from intermediate organizations, such as research councils, research 
financiers, research institutes focusing on patient empowerment or patient 
participation, research knowledge agencies for patients and patients’ 
organizations, etc. The practical feasibility of structurally including patients 
in biomedical innovation processes is discussed in the final reflection. 
 
3.1 A theoretical reflection 
 
Expert knowledge is usually considered more general and objective and 
therefore more accurate than the subjective knowledge of lay persons – 
which some authors call ‘lay’ or ‘non-expert’ knowledge (Entwistle et al., 
1998; Nordin, 2000; Popay and Williams, 1996). To avoid any suggestion 
of inferiority we use the term ‘experiential knowledge’ which directly refers to 
the ultimate source of patient-specific knowledge – the often implicit, lived 
experiences of individual patients with their bodies and their illnesses as 
well as with care and cure. Experiential knowledge arises when these 
experiences are converted, consciously or unconsciously, into a personal 
insight that enables a patient to cope with individual illness and disability. 
When patients share experiential knowledge the communal body of 
knowledge exceeds the boundaries of individual experiences. This body of 
knowledge has been described as ‘experiential expertise’ (Meijer et al., 1993; 
Van der Schaaf and Oderwald, 1999). Both experiential knowledge and 
expertise of patients can be extended by scientific (bio)medical insights, for 
example by reading scientific articles or by discussion with professionals, 
leading to so-called ‘proto-professionalism’.33  
                                                 
33  As has been remarked before (section 2.3) this proto-professionalism at the same time 
easily leads to the loss of original perspectives and thus of experiential knowledge. 
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Whether experiential knowledge can be considered ‘valid 
knowledge’ depends on the definitions of both ‘knowledge’ and ‘validity’. 
Knowledge can be (1) propositional knowledge, (2) procedural knowledge, 
and (3) knowledge by acquaintance (Lehrer, 1990). Propositional 
knowledge – ‘knowing that’ (‘smoke worsens asthmatic symptoms’) – is 
the information part of knowledge, made explicit and communicable 
through speech or writing. Procedural or practical knowledge – ‘knowing 
how’ (‘to use an inhaler correctly’) – is the competence part of knowledge 
and consists of skills and capacities. It is partly implicit and must be 
acquired by training and practice. Finally, knowledge by acquaintance – 
‘knowing’ as being familiar with (‘what it is like to have an asthma attack’) 
– is implicit knowledge that must be acquired by personal or even bodily 
experience. Although in practice the three types of knowledge are closely 
intertwined, below we analyse both experiential knowledge of patients and 
biomedical knowledge of researchers in terms of these three types of 
knowledge in order to be able to compare them more clearly.  
The specific, experiential knowledge of patients emerges when 
patients acquire some knowledge by acquaintance through becoming 
familiar with their own body and illness, with care and cure and with their 
social context. Subsequently patients develop some practical knowledge, 
mainly consisting of physical and mental coping strategies. This type of 
knowledge is important in daily practice, both in the patient’s own life and 
in the support of others. Only after they have made repeated observations 
and experiences explicit and have reflected on them, can patients acquire 
some propositional experiential knowledge about the functioning of their 
bodies, the occurrence of symptoms, the effectiveness of certain therapies, 
etc. This knowledge is confirmed and extended in the repetition of their 
own experience, and by similar experiences of other patients. 
The most obvious and probably most basic part of the biomedical 
knowledge of scientists is propositional knowledge, which is obtained both 
by written and oral knowledge transfer from external sources and by 
personal knowledge acquisition through experimentation, observation, or 
argumentation. It begins to emerge during the first years of academic 
study. Biomedical knowledge also comprises practical knowledge and 
knowledge by acquaintance, both acquired in practical training and 
professional practice and both essential to the practice of biomedical 
research. All three types of knowledge contribute to decision-making in 
biomedical research, but they are not equally explicit. 
Thus, both experiential knowledge of patients and biomedical 
knowledge of scientists comprise the same three types of knowledge, but 
THE EXPERIENTIAL KNOWLEDGE OF PATIENTS 
69 
their distribution and order of genesis differ. Furthermore, biomedical 
knowledge concerns external objects and is mainly acquired through 
detached and impersonal study and observation, while patients’ 
experiential knowledge concerns the personal situation and is acquired 
through personal and bodily experiences. In this sense the experiential 
knowledge of patients can be said to complement the biomedical 
knowledge of professionals (see also Entwistle et al., 1998; Goodare and 
Lockwood, 1999; Popay and Williams, 1996). 
The issue of validity of knowledge belongs to the domain of 
epistemology, which traditionally focuses on propositional knowledge 
only. Within that framework, perspectives on the validity of patients’ 
experiential knowledge depend on the paradigm adhered to. Since Plato, 
many movements and schools within philosophy have debated the issue of 
knowledge and its validity. A still rather influential epistemological 
movement dating from the first half of the 20th century is logical 
positivism or logical empiricism. Logical positivists argue that the only 
source of true knowledge is objective observation and that derived 
knowledge has to be based on rational arguments that follow a logical 
scheme (Carnap, 1966). Similarly, many scholars since then have 
considered scientific knowledge an ideal form of knowledge, as it is built 
on objective scientific methodologies and rational arguments, and strives 
for universality and absolute truth. They may deny the validity of the 
experiential knowledge of patients because of its lack of objectivity, 
verifiability, universality, or rationality. These views also largely determine 
(and explain) the opinion of many biomedical scientists on the knowledge 
of patients (Wilson, 2000). 
However, since the middle of the 20th century thinking about 
knowledge has changed. Sociological studies of science and knowledge 
production and studies of language have argued that objectivist views of 
knowledge do not correspond with the practice of knowledge production 
and the meaning of knowledge in daily life (Barnes and Bloor, 1982; 
Latour and Woolgar, 1979; Wittgenstein, 1953). Even within science pure 
objectivity and neutrality are impossible. Just like non-scientists scientists 
live and work in social contexts and have cultural values and personal 
interests that influence experimentation and observation and, thus, 
processes of knowledge production. These insights led to the emergence 
of new, relativistic perspectives on knowledge and truth. As a result, many 
contemporary scholars refrain from disqualifying patients’ experiential 
knowledge, since they deny the existence of one absolute truth, 
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emphasizing instead the socially constructed or contextual character of all 
knowledge, scientific knowledge included. 
Within these more relativist perspectives on knowledge the 
question arises how to distinguish between ‘non-sense claims’ and 
‘knowledge’. A pragmatist approach offers a solution. Pragmatists reject 
philosophical concerns about ‘how the world really is’, while 
recommending the philosophical importance of what is profitable or 
useful (cf. Rorty, 1982). They argue that a knowledge claim is acceptable if, 
and only if, this acceptation is useful to us. Starting from a pragmatist 
perspective, the experiential knowledge of patients, thus, can be 
considered valid within a certain context, if it proves to be useful within 
that context34. Following this line of argumentation, the validity of 
experiential knowledge of patients is generally acknowledged in different 
contexts, such as the development of individual coping strategies, the 
mutual understanding and mental support of fellow sufferers, and 
individual health care decision-making. But could the experiential 
knowledge of patients be considered useful within the context of 
biomedical research as well?  
 
3.2 A pragmatic reflection 
 
The investigation of the usefulness or practical value of patients’ 
experiential knowledge with respect to its (potential) beneficial 
contribution to the relevance or content of biomedical research requires 
the study of concrete examples of individual biomedical research processes 
that in some way have been changed by the inclusion of this knowledge. If 
we can identify at least a few successful examples, we have an indication of 
the potential value of patients’ experiential knowledge for biomedical 
research.  
3.2.1 Methodology 
The first stage of this study began with a search for cases of patient 
participation in biomedical research. Initially data were gathered by 
conducting an extensive literature and Internet search. However, since this 
                                                 
34 This kind of argument is applicable to all three types of knowledge, whether from 
patients or scientists. 
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topic of study is rather poorly documented, most data had to be collected 
through personal communication. To this end 42 exploratory or 
explanatory, semi-structured interviews were held in the Netherlands and 
the United Kingdom. Interviewees comprised sixteen patients and patient 
representatives from different patients’ organizations, seven medical or 
biomedical scientists, and nineteen other professionals from intermediate 
organizations (such as research councils, societal research institutes, 
research funding agencies, and science shops). Through these interviews 
we obtained a good representation of the different stakeholders within the 
field of patient participation in research. Interviewees were purposefully 
selected or selected by using the snowball method, while searching for 
people with an interest in, or experience with, patient participation in 
research. In the interviews we asked respondents to name examples of 
patient participation in biomedical research processes, and discussed the 
general concept of experiential knowledge of patients and its potential 
value for biomedical research. By this method 23 cases of patient 
participation in biomedical research were identified.35  
Since patient participation does not necessarily imply the use of 
patients’ experiential knowledge, these 23 cases were further investigated 
during the second stage of our study. We measured the concrete input of 
patients’ experiential knowledge and the extent to which this knowledge 
had influenced biomedical research processes, for example by introducing 
new research topics or changing research programmes. Besides additional 
literature research, 20 additional interviews were conducted with previous 
(3) as well as new (17) interviewees (one biomedical scientist, eight 
representatives from patients’ organizations and eleven representatives 
from intermediate organizations). New interviewees were selected on the 
basis of their personal involvement in one of the cases under investigation. 
In this process, many cases dropped out because the concrete input of 
patients was hard to recover. From the 23 cases, we identified nine that we 
considered clear examples of the actual use of patients’ experiential 
knowledge in biomedical research processes. Although a more extensive 
analysis of all cases of patient participation identified would probably have 
resulted in a higher number of concrete examples, a small number of 
examples is considered sufficient for the purpose of making an argument 
for the practical value of patients’ experiential knowledge for biomedical 
research. 
                                                 
35  The interviews conducted as well as the cases identified partly overlap with the 
interviews and findings described in chapter 2. 
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3.2.2 Results 
Table 3.1 shows an overview of the 23 identified cases of biomedical 
research processes in which patients have played a role. 
  
 
Table 3.1  Cases of patient participation in biomedical research 
1. The Advisory Council on Health Research (RGO – ‘Raad voor Gezondheidsonderzoek’) in 
the Netherlands, which advises the government on national research programmes and 
priorities, has one patient member. Patients are also involved in temporary programming 
and prioritization subcommittees.  
2. The United Patients’ Organizations of the Chronically Ill (WOCZ – ‘Werkverband 
Organisaties Chronisch Zieken’) in the Netherlands introduced research on co-morbidity as 
a research priority within an integral programme on chronic illnesses of the Netherlands 
Organization for Scientific Research (NWO-MW). 
3. After years of lobbying, the Dutch Alliance of Parents’ and Patients’ Organizations (VSOP 
– ‘Vereniging Samenwerkende Ouder- en Patiëntenorganisaties’) is increasingly involved in 
national and international policy making on genetic research. It also has established seven 
academic chairs on topics such as clinical genetics and rare diseases. 
4. During the past ten years the Dutch Society of Haemophilia Patients (NVHP – 
‘Nederlandse Vereniging van Hemofilie Patiënten’), alongside other patient organizations, 
has successfully lobbied for more governmental support for research on genetic therapy. 
5. The Canadian Breast Cancer Research Initiative (CBCRI) is the primary financier of breast 
cancer research in Canada. Since the beginning, breast cancer survivors have been an 
integral part of the Initiative, helping to set research priorities alongside researchers and 
clinicians. 
6. In the Netherlands, two patients participate in the Steering Group on Orphan Drugs 
(‘Stuurgroep Weesgeneesmiddelen’), an organization that stimulates and facilitates research 
on, and development of, orphan drugs.  
7. Four representatives of the Dutch Neuromuscular Diseases Association (VSN – 
‘Vereniging Spierziekten Nederland’) are members of the board of the Dutch Foundation 
for Neuromuscular Research (SONMZ – ‘Stichting Onderzoek Neuromusculaire Ziekten’) 
that aims to stimulate and communicate scientific research on causes of, and therapies for, 
neuromuscular diseases.  
8. The Medical Research Council in the UK has its own Consumer Liaison Group that 
advises on research priorities and programmes. 
9. Several patient members participate in the societal advisory council as well as in several 
programme committees of the Netherlands Organization for Health Research and 
Development (ZonMw).  
10. Within the programme ‘Quality research on dementia’ of the Alzheimer’s Society in the 
UK, patients play a central role in research priority setting and in the appraisal of research 
projects. 
11. Through intensive interaction with scientists, patients from the French Muscular Dystrophy 
Association (AFM – ‘Association Française contre les Myopathies’) are actively involved in 
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the agenda setting of biomedical research on neuromuscular diseases in France.  
12. The European Platform for Patients’ Organizations, Scientists & Clinicians and Industry 
(EPPOSI) comprises several patient board members. Among others it aims to find ways to 
promote funding and facilitate the development and availability of innovative medical 
solutions to all individuals in need.  
13. The National Breast Cancer Coalition in the USA has brought about the acceptance of the 
idea that breast cancer survivors must be involved in decision-making on research policy 
and research funding. 
14. In the USA, the Council of Public Representatives (COPR) has been established in order to 
enlarge the influence of the public on the National Institutes of Health (NIH). COPR 
members review and advise on NIH priorities and mechanisms for public input to NIH 
decisions. 
15. The German Retinitis Pigmentosa patient group Pro Retina has been successful in 
influencing scientific research on Retinitis Pigmentosa in Germany. It has been able to 
intervene in the scientific community, lobby for public funding, formulate research 
priorities, and fund innovative research projects. 
16. In the Netherlands, two patients participate in the scientific advisory council of the 
National Rheumatism Foundation (NRF – ‘Nationaal Reumafonds’) that appraises research 
proposals on both scientific quality and societal relevance and advises the board of the 
Foundation about sponsoring. 
17. In Australia, patients participate in several research committees, supported and stimulated 
by the Consumer’s Health Forum. 
18. Complaints and questions from Dutch patients with neuromuscular diseases about the 
severe fatigue they suffered led to the launch of a new research project in Nijmegen on 
central and peripheral aspects of muscular fatigue. 
19. The Dutch Kidney Patients’ organization (NVN – ‘Nierpatiënten Vereniging Nederland’) 
stimulated the launch of a research project on causes of, and therapies for, ‘restless legs’, 
which is funded by the Dutch Kidney Foundation (NSN – ‘Nierstichting Nederland’).  
20. The Dutch Addison and Cushing Society (NVACP – ‘Nederlandse Vereniging voor 
Addison en Cushing Patiënten’) approached a science shop in Utrecht with the request for 
a study on drug administration methods in order to search for improved medication of 
Addison’s disease. This study eventually led to the establishment of a research project on a 
new delayed release tablet. 
21. The mother of a young woman with adenocarcinoma of the vagina suggested that her 
daughter’s disease might have been caused by the drug diethylstilbestrol. This hypothesis 
led to new research on, and the eventually proof of, the teratogenicity of DES. 
22. The Hyperactive Children’s Support Group is a patients’ organization that formulated the 
hypothesis that hyperactivity of children can be caused by a deficiency of essential fatty 
acids. The hypothesis was picked up by the research world, resulting in more research on 
the topic.  
23. Female patients with Crohn’s disease experienced that the metronidazole they received for 
curing a vaginal infection had a positive effect on their bowel disease as well. This led to 
additional research resulting in a new application of the drug.  
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We found that patient participation in biomedical research was 
mainly restricted to decision-making at a national or institutional level in 
stages such as general research policy, research programming, and research 
prioritization (cases 1-17). Within individual research projects, patients 
were occasionally involved in the identification of research topics or 
questions (cases 18-23). No cases were found in which patients 
participated in ‘core’ stages of biomedical research, such as research 
design, execution, and interpretation of results.36  
Within the cases identified, we distinguished three different types 
of patient input:  
- demands concerning (new) research priorities (cases 1-15) or 
research topics (cases 18-20),  
- ideas  on aetiological or therapeutic aspects of diseases or 
symptoms (cases 21-23), and  
- judgements  about the relevance of specific research priorities or 
projects (9-17).  
Since they are based on personal experience of disease, symptoms, therapy, 
etc., we regard these demands, ideas, and judgements as different 
manifestations of patients’ experiential knowledge. They build on both 
implicit and explicit forms of experiential knowledge, thus making this 
knowledge visible and applicable within biomedical research processes. 
However, as mentioned before, the concrete input of patients 
(concrete demands, ideas, or judgements) and their influence was still 
indiscernible within the majority of the cases found. After detailed analysis 
of the cases, we identified nine examples in which the actual contribution 
of patients’ knowledge to, and its impact on, biomedical research processes 
could be clearly traced. These examples are briefly described in table 3.2, 
listed according to the type of input provided. 
                                                 
36  By comparison, patients do increasingly participate in ‘core’ stages of clinical research 
processes, such as trials that involve the testing of new biomedical technologies in 
clinical practice. Within clinical trials, patients are progressively more involved in 
decision-making on research design and evaluation, especially concerning ethical 
aspects, patient information provision, and informed consent procedures (Hanley et 
al., 2001; Koops and Lindley, 2002; Oliver and Buchanan, 1997; Thornton, 1998). One 
of the reasons is that clinical research heavily depends on the recruitment of patients as 
research objects. Apart from increasing the quality and relevance of the research, 
patient participation in research design and evaluation is expected to increase the 
willingness of patients to participate as trial objects (Hanley et al., 2001). 
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The examples mentioned in table 3.2 show that the manifestation 
of patients’ experiential knowledge is able to influence biomedical research 
at different stages of the research process. Patients’ demands (needs or 
concrete questions) for research led to the formulation of additional 
research priorities within national and international research programmes 
(1-3) or new research topics or questions to be investigated and, thus, to 
the launching of new research projects (4-6). Patients’ ideas on aetiological 
or therapeutic aspects were translated into new biomedical hypotheses or 
research questions (7-9).  
 
 
Table 3.2  Examples of the use of patients’ experiential knowledge in 
biomedical research  
Demands 
1. The United Patients’ Organizations of the Chronically Ill (WOCZ) in the Netherlands was 
asked by the Netherlands Organization for Scientific Research (NWO) to formulate 
prioritization criteria for part of an integral programme for research into chronic illnesses. 
The WOCZ put forward the theme of co-morbidity as a research priority, a badly 
researched phenomenon many chronically ill patients have to deal with. Subsequently, 
NWO included this priority in the research programme. 
2. Patients of the Alzheimer’s Society in the UK annually decide on research priorities for the 
programme ‘Quality research on dementia’. Priorities they identified for the research 
programme 2002 were amongst others epidemiological research on risk factors for 
dementia, vaccine research, and research on alternative and complementary therapy 
(Alzheimer's Society, 2002). Research applicants are forced to stick to these priorities since 
they have to state on their application form which priority area their proposal fits into. 
3. In the Netherlands, a national research programme on pain (‘Stimulation of pain research’), 
programmed by the Advisory Council on Health Research (RGO) in 1991, has been 
influenced by patients. The patient community felt that the study of the ‘careers’ of 
patients with chronic pain within the care system should be one of the main priorities 
within the programme. The patient member of the programming committee was able to 
push forward this priority. Even in the current, third stage of the programme, research on 
‘pain careers’ is still a priority (Raad voor Gezondheidsonderzoek, 2001). 
4. Several patients with neuromuscular diseases approached their medical specialist in 
Nijmegen in the Netherlands with complaints and questions about the severe fatigue they 
suffered from. They experienced this fatigue as very disabling and different from ‘normal’ 
fatigue, and asked for more research on this symptom. This made the specialist launch a 
new research project on central and peripheral aspects of muscular fatigue, which is now 
performed by the Department of Neurology, University Hospital Nijmegen. 
5. Many patients with kidney disorders suffer from, and complain about, so-called ‘restless 
legs’, a symptom that causes serious insomnia. A biomedical researcher published an article 
on the subject in the bimonthly magazine of the Dutch Kidney Patients’ organization 
(NVN). A request of the NVN for reactions to this article resulted in a stream of patient 
reports.  Subsequently,  the NVN  made a strong plea  for more research  on this symptom 
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(Want, 1995). In response, the researcher submitted a research proposal on the topic to the 
Dutch Kidney Foundation (NSN). As a result, the Centre for Sleep and Wake Disorders in 
The Hague is conducting a research project on both the prevalence of, and the therapy for, 
restless legs among kidney patients. 
6. Since patients with Addison’s disease need to take substitutive hydrocortisone every few 
hours in order to adequately suppress the different symptoms, many patients complain 
about the need to get up at night to take their medicine. Therefore the Dutch Addison and 
Cushing Society (NVACP) approached the Science Shop for Medicines in Utrecht with the 
request for a study on drug administration methods in order to search for an improved 
medication of Addison’s disease. The Science Shop commissioned an inventory literature 
study on the subject. Subsequently, a professor of pharmaceutics took up the topic and 
launched a research and development project on a new delayed release hydrocortisone 
tablet in collaboration with a small Danish pharmaceutical company. 
Ideas 
7. The mother of a young woman with adenocarcinoma of the vagina suggested that the fact 
that she had taken the drug diethylstilbestrol during her pregnancy might be related to the 
disease of her daughter. The oncologist who treated the young ill woman took the 
suggestion seriously and started a systematic investigation on the relation between the 
exposure to DES in foetal life and the subsequent development of vaginal adenocarcinoma 
(Ulfelder, 1980). Nowadays, the teratogenicity of DES is well known world-wide. 
8. Women with Crohn’s disease experienced that the metronidazole they received for curing a 
vaginal infection had a positive effect on their bowel disease as well. They reported their 
experiences to their medical doctors, who took their finding seriously. This led to the 
execution of additional research on the drug. Nowadays, metronidazole is regularly used in 
the treatment of inflammatory bowel diseases as well. 
9. After an elaborate study on the characteristics of their children and their families, the 
patients’ organization Hyperactive Children’s Support Group formulated the hypothesis 
that the hyperactivity of many of these children was caused by a deficiency of essential 
fatty acids. The hypothesis entered the research world in a scientific article published by 
the Support Group itself (Colquhoun and Bunday, 1981). After additional biomedical 
research, the hypothesis of a relation between a deficiency of essential fatty acids and 
hyperactivity received considerable support (Stevens et al., 1995). 
 
 
Although nine out of the 23 identified cases concerned 
judgements, we did not find any concrete examples of patients’ 
judgements influencing biomedical research processes. Patients’ 
judgements on research priorities and research projects usually play a role 
within the context of a committee. However, because of the complexity 
and opacity of decision-making processes in most committees, it is very 
difficult to determine whether and to what extent the input of patients has 
influenced decision-making (see also Oliver et al., 2004: 18). Final 
decisions are the result of many discussions and negotiations, in which the 
specific contribution of patients is hardly recoverable and usually can only 
be guessed at. A further complication in studying this kind of participation 
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is the privacy agreement implicit in the rules of most committees. 
Members usually do not want to give detailed inside information on 
decision-making processes.  
 
3.3 Concluding remarks 
 
In this chapter it has been argued that patients acquire specific knowledge 
based on their recurrent experience with their body, their illness, and the 
health care system. It is not easy to make a conclusive judgement on 
whether this knowledge can be considered valid, since this judgement 
depends on the paradigm adhered to. Following a pragmatist approach, we 
therefore decided to estimate the validity of patients’ experiential 
knowledge in terms of its practical value and conducted a study for the 
identification and analysis of concrete cases in which this knowledge was 
applied in biomedical research processes, as described in the previous 
section. This study indeed suggests that this knowledge has potential value 
for biomedical research. In the identified examples patients’ experiential 
knowledge had been translated into explicit demands or ideas that formed 
a direct input into biomedical research processes. Whereas the demands of 
patients may be considered as emerging from experienced problems (for 
example co-morbidity and chronic symptoms) or wished solutions (for 
example alternative therapies, vaccines, convenient drug doses) identified 
by patients, in these examples patients’ ideas can be considered as directly 
pertaining to biomedical hypotheses or research questions. Therefore the 
findings refute the notion that contributing to biomedical research requires 
highly specialized knowledge. Since it is chiefly the biomedical researchers 
themselves who in these examples decided to include the manifestations of 
patients’ experiential knowledge in their research processes, they can be 
considered to have (implicitly) acknowledged the relevance (or validity) of 
this type of knowledge. 
In accordance with the findings in chapter 2, the findings in this 
chapter further indicate that the knowledge of patients, in spite of its 
potential, is only rarely included in biomedical research processes and 
often in an ad hoc fashion. In many of the identified cases, patients did not 
participate in research processes deliberately. Doctors in attendance (e.g. 
the neurologist working on neuromuscular fatigue, the oncologist working 
on DES, and the doctors consulted by women with Crohn’s disease), 
patients’ organizations (e.g. the Dutch Kidney Patients’ organization, the 
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United Patients’ Organization of the Chronically Ill and the Hyperactive 
Children’s Support Group), disease specific research foundations (e.g. the 
Dutch Kidney Foundation and the Alzheimer’s Society), or science shops 
(e.g. the Science Shop for Medicines Utrecht) acted as intermediaries 
between individual patients and the research world.37 They (implicitly) 
made a distinction between useful and less useful experiential knowledge 
of patients38 and often pursued a strategy of inter-subjectivity by gathering 
and selecting shared experiences and knowledge of a larger number of 
patients. In cases where no visible intermediary played a role (e.g. the 
example concerning the programming committee on pain research), 
involved patients were often active members of patients’ organizations, 
who internalized and disseminated shared demands, ideas, and judgements 
themselves. 
At the moment, only patients’ judgements are occasionally 
involved in a more structural way when patients participate in specific 
committees, boards, or councils. But this form of participation does not 
ensure the actual use of these judgements. The eventual use of patients’ 
experiential knowledge is influenced by a variety of factors, including the 
proportion of patient members to professional members, patients’ 
empowerment, professionals’ susceptibility to patient views, the actual 
locus of decision-making, etc. 39  
Various interviewees mentioned that successful patient 
participation in research committees requires that the patient has acquired 
a degree of proto-professionalism either by self-education or by training, 
since only such patients are generally regarded as appropriate discussants 
in professional surroundings. However, as has been stated before, proto-
professionalism may lead to non-representation of the patient community 
and to the loss of ‘pure’ experiential knowledge (Mullen, 2000). Several 
interviewees stressed that in order to reduce the risk of losing specific 
patient perspectives, participating proto-professionalized patient 
representatives should stay in close contact with the patient population 
                                                 
37  They thus follow the ‘second’ strategy of patient participation as identified in chapter 2 
(section 2.2). 
38  Both patients and professionals interviewed in our study stressed that ideas and 
questions from naïve – non proto-professionalized – patients are rarely useful for 
biomedical research. 
39  See also the discussion on partnership versus placation in relation to the ‘third’ strategy 
of patient participation represented in sections 2.2 and 2.3. 
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they represent, verifying the mutuality of demands, ideas and judgements 
regularly.  
Due to lack of experience, it is indeed not yet known whether a 
more structural way of patient participation in biomedical research 
processes can be considered ‘efficient’. Several interviewees thought that 
the knowledge of patients might be useful in some cases, but that it is 
hardly worth the trouble; it would take much time and effort to involve 
patients structurally while effecting only occasional or marginal 
improvements. There is thus a clear need for practical proof of principle. 
But it is here that we face an obstacle. Hardly any strategies are currently 
available to facilitate a structural and effective participation of patients in 
biomedical research processes. Many questions were raised by various 
respondents, such as how can we distinguish between sense and non-sense 
information from patients, what type of patients need to be involved, how 
can learning processes between researchers and patients be enhanced. 
Some of these questions might be answered by investigating the specific 
skills and activities of intermediaries that have successfully bridged the gap 
between individual patients and the biomedical research world more 
closely. A closer study of the working practices of committees which 
involve patients in decision-making might also provide some new insights. 
For this purpose, committees should provide more insight into their 
procedures and practices by for example reporting reflections on their 
working practices.  
Another and possibly more profitable way of investigating patients’ 
possible contribution more systematically is by experimenting with 
participation exercises building on experiences within other scientific 
fields. In the remaining part of this book we will take up this challenge. As 
a start, the next chapter will elaborate on a possible methodology for 
effective patient participation in decision-making on biomedical research.
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A TRANSDISCIPLINARY STRATEGY40 
 
Participation of patients in decision-making on biomedical research 
has been rare, and integration of patients’ experiential knowledge in 
these decision-making processes – in the few cases it takes place – 
occurs implicitly and on an ad hoc basis. In order to optimize the use 
of patients’ experiential knowledge in biomedical research, a systematic 
approach is required that comprises both consultation and 
collaboration steps. Since such an approach should systematically, 
explicitly, and deliberately integrate knowledge from different scientific 
and non-scientific sources, it can be called transdisciplinary. This 
chapter elaborates on the concept of transdisciplinarity and on the 
design of a possible transdisciplinary strategy that could be used to 
realize effective patient participation in decision-making on biomedical 
research. For this purpose a possible procedure is proposed and 
necessary conditions and skills are identified. In addition, the 
feasibility of its implementation within the biomedical sector is 
discussed. 
 
 
One of the main findings of this study thus far is that patient participation 
in decision-making on biomedical research is far from being common 
practice. Patients and their experiential knowledge are seldom involved in 
decision-making on biomedical research and if they are, it is in a sub-
optimal way and on an ad hoc basic. As a result, new and relevant ideas or 
directions for biomedical research might be missed. 
                                                 
40  The text of this chapter is partly based on: Flinterman, J.F., Teclemariam-Mesbah, R., 
Broerse, J.E.W., and Bunders, J.F.G. (2001). Transdisciplinarity: The new challenge for 
biomedical research. Bulletin of Science, Technology & Society 21(4): 253-266. 
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In chapter 2 we argued that a more structural and effective 
participation of patients in decision-making on biomedical research 
agendas would imply the inclusion of patients in the biomedical research 
decision-making network, which requires considerable changes in current 
ways of thinking and acting. This change of the current decision-making 
network and its regimes can be considered a transition. We subsequently 
argued that such a transition could be induced, among others, in a bottom-
up way by the execution of successful innovation experiments. The central 
question in this chapter is how such experiments could be designed. 
Therefore this chapter focuses on the development of a participation 
strategy41, based on previous results, on literature research, and on earlier 
experiences of our Institute42 with the development and implementation of 
interactive strategies. 
As has been specified in section 2.3, we consider patient 
participation in decision-making effective if it enhances both the legitimacy 
and rationality of decision-making processes and the quality of decision-
making outcomes. This implies the need for direct and early involvement 
of patients in fair decision-making processes and the actual integration of 
their knowledge in decision-making outcomes. As has been shown in 
chapter 2, current strategies for patient participation in decision-making on 
research agendas usually consist of either consultation or collaboration 
methods (see also Boote et al., 2002; Hanley et al., 2000; Oliver et al., 2004; 
Telford et al., 2002; Williamson, 2001). Consultation methods include 
interviews, questionnaires, focus groups, and citizens’ juries, all aiming to 
identify patients’ perspectives, needs, or priorities. Collaboration initiatives 
usually comprise the membership of one or more patient(s) in decision-
making structures.43 However, both strategies often fall short of realizing 
effective participation according to its definition mentioned above. 
Initiatives that only entail the consultation of patients tend to fail in 
ensuring patients’ influence on research agendas since decisions 
concerning the use of patients’ inputs are entirely in the hands of 
                                                 
41  We use the term ‘strategy’ in order to express the societal relevance of the patient 
participation accomplished. However, from a pure scientific perspective, the strategy 
formulated in this chapter can be considered a methodology for effective stakeholder 
participation in general.  
42  the Athena Institute for Research on Innovation and Communication in Health and 
Life Sciences, Vrije Universiteit Amsterdam 
43  Collaboration thus can refer to both placation and partnership in Arnstein’s 
participation ladder, depending on the degree of power sharing between patients and 
experts. 
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professionals (also mentioned by Abelson et al., 2003; Oliver et al., 2004). 
Initiatives that involve collaboration often fall short of procedural fairness 
and thus of legitimacy of the process. In addition, they neither ensure 
patients’ influence – at least in the way collaboration exercises are currently 
structured. The majority of patients struggle to hold their own when facing 
a team of professionals; they easily become overruled by professionals 
causing the collaboration to degenerate into tokenism (see also Oliver et 
al., 2004: 88). Only considerably proto-professionalized and empowered 
patients are (or feel) treated on equal terms by professionals. However, 
since most reports on collaboration exercises do not distinguish between 
priorities set by patients and those set by professionals, the assessment of 
the actual influence of patients on decision-making outcomes is hampered 
(see also Oliver et al., 2004: 88).  
We argue that a strategy for effective patient participation in 
decision-making on biomedical research should involve at least both a 
consultation and a collaboration phase. In a consultation phase patients’ 
perspectives – consisting of demands, ideas, or judgements – as well as the 
perspectives of other stakeholders are made explicit. In a subsequent 
carefully-guided collaboration phase the deliberate integration of these 
perspectives, and thus of patients’ experiential knowledge, in research 
agendas can be realized. In addition, in order to optimize this use of 
patients’ experiential knowledge, processes of knowledge integration 
should be transparent and explicit, so that they can be studied, influenced, 
and optimized deliberately. A transdisciplinary approach, which by definition 
focuses on the integration of scientific with non-scientific knowledge, may 
offer a way to optimize knowledge integration into decision-making 
processes and thus to increase the effectiveness of patient participation.  
This chapter elaborates on a transdisciplinary patient participation 
strategy that includes both consultation and collaboration steps. We start 
with discussing the concept of transdisciplinarity in the next section. 
Subsequently, we propose a procedure and identify conditions that could 
be part of a successful transdisciplinary strategy. Finally, we discuss the 
feasibility of the implementation of such a strategy within the context of 
biomedical research. We end this chapter with the announcement of a 
social experiment that aims to apply and evaluate the transdisciplinary 
strategy within the context of patient participation in research agenda 
setting. 
 
CHAPTER 4 
84 
4.1 The concept of transdisciplinarity 
 
Transdisciplinarity can be compared with concepts of monodisciplinarity, 
multidisciplinarity, and interdisciplinarity. These concepts are mainly used 
within the framework of scientific research and can be considered as 
referring to different degrees of interaction and integration between 
different knowledge domains.  
Monodisciplinary research is the most common form of scientific 
research. It is restricted to one research discipline, to one branch or 
specialization within a research field. People working within one discipline 
study the same research objects, share the same paradigm, use common 
methodologies, and speak the same ‘language’ (Aram, 2004; Judge, 1991; 
Klein, 1996; Salter and Hearn, 1996). When a variety of disciplines 
collaborate in one research programme without integration of concepts, 
epistemologies, or methodologies, we speak of multidisciplinarity. In 
multidisciplinary research, the degree of integration between disciplines is 
restricted to the linking of research results. Interdisciplinarity is also a 
collaboration of several disciplines, but in this case concepts, 
methodologies, or epistemologies are explicitly exchanged and integrated, 
resulting in a mutual enrichment (Gibbons et al., 1994; Jantsch, 1972; 
Klein, 1996; Salter and Hearn, 1996). Different degrees of 
interdisciplinarity can be distinguished depending on the degree of 
exchange and integration and the differences in paradigms between the 
disciplines involved. 
Transdisciplinarity is a recent trend within interdisciplinarity in 
which boundaries between and beyond disciplines are transcended. It has 
been defined as “a new form of learning and problem solving involving 
cooperation among different parts of society and academia in order to 
meet complex challenges of society” (Klein, 2001: 7). Its goal is to get a 
better understanding of the present world as a whole by integrating various 
scientific and non-scientific perspectives of reality in search of a more 
holistic or ‘socially robust’ knowledge. This knowledge is characterized by 
its stronger orientation towards the context of application, the inclusion of 
stakeholder perspectives, and its problem-solving capability (Gibbons et 
al., 1994; Klein et al., 2001; Nowotny, 2003; Nowotny et al., 2001; 
Rapport, 1997; Scholz et al., 2000)44. Transdisciplinary approaches can be 
                                                 
44  Another frequently used term to indicate this type of transdisciplinary knowledge, 
introduced by Gibbons et al. (1994), is ‘Mode-2’ knowledge. Mode-2 knowledge can be 
opposed to the traditional, academic, mono-disciplinary mode-1 knowledge. 
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practised in academic (research) contexts as well as in societal problem-
solving or decision-making contexts. 
One of the main challenges in transdisciplinary approaches is how 
non-scientific knowledge can be validated and integrated with scientific 
knowledge. Therefore, we elaborate on the concept of knowledge 
integration below. 
Knowledge integration 
In the previous chapter, we have argued that both scientific and non-
scientific knowledge consist of three types of knowledge – propositional 
knowledge, procedural knowledge, and knowledge of acquaintance – that 
can be considered as reflecting different origins and contents, thus 
referring to a substantive dimension of knowledge. These three types of 
knowledge can all be involved in transdisciplinary knowledge production, 
problem solving, or decision-making.  
Within the framework of understanding knowledge integration 
another helpful dimension of knowledge is explicit – implicit (or 'tacit', see 
Polanyi, 1966), which refers to its form of expression. Explicit knowledge 
is ‘codified’ knowledge that can be easily transmitted in formal or 
systematic language. It has also been described as the ‘information’ 
component of knowledge (Weggeman, 1997). Implicit knowledge 
comprises personal and context-specific knowledge that is hard to 
formalize and communicate. It can be considered as comprising 
experiences, skills, or attitudes, (Nonaka and Takeuchi, 1995; Weggeman, 
1997). Propositional knowledge is explicit, while knowledge of 
acquaintance is mainly implicit. Procedural knowledge can be implicit or 
explicit, depending on the degree of conscious reflection and expression.  
 The integration of scientific and non-scientific knowledge thus 
includes the integration of explicit forms of knowledge as well as the 
integration of more implicit forms of knowledge. Integration of explicit 
knowledge could involve processes of translating and transferring of 
information; analyzing, structuring, and clustering of information; 
searching for overlapping, connecting, and supplementing elements; 
making common factors explicit; negotiating; etc. It is what Nonaka and 
Takeuchi have termed ‘combination’ (1995: 67-69). In principle, explicit 
knowledge from different stakeholders, after it has been gathered, could be 
integrated in final decisions or solutions without involving those 
stakeholders themselves in the actual integration process. Methods for 
knowledge integration mentioned in this context include methods that are 
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used as well within interdisciplinary research, such as methods based on 
systems thinking and (computer) modelling (e.g. Scholz et al., 2000).  
Since implicit forms of knowledge cannot be transferred or 
exchanged between stakeholders in an oral or written way, they have to be 
integrated in decisions or solutions by direct, personal involvement of 
these stakeholders in decision-making or problem-solving processes 
(‘socialization’ in terms of Nonaka and Takeuchi, 1995: 62-64). Only the 
knowers themselves are capable of using their implicit knowledge and can 
translate this knowledge into concrete demands, ideas, judgments, etc. that 
influence the outcomes. Within this framework, Regeer and Bunders 
(2003) describe knowledge integration as a process of knowledge creation 
that can only take place within ‘communities of practice’. Methods that 
could be used in order to facilitate or stimulate the inclusion of implicit 
forms of knowledge within transdisciplinary knowledge integration include 
all kinds of participatory and deliberative methods, such as dialogues, 
interactive workshops, consensus conferences, focus groups, Delphi 
techniques, etc. (e.g. Klein, 2001; Zweekhorst et al., 2001). In order to 
ensure the achievement of effective knowledge integration, 
communication and interaction between the different actors involved 
within these methods should be carefully guided. 
An important issue in transdisciplinary knowledge integration 
concerns the validation of the knowledge that is to be integrated as well as 
the validation of the outcomes of the knowledge integration process. 
Discussions about the validity of knowledge usually take place within the 
domain of epistemology, which traditionally focuses on explicit, 
propositional knowledge only. Validation of explicit knowledge claims has 
much to do with their verification by testing on the basis of certain criteria. 
Different types of knowledge ask for different validation criteria (Schipper, 
1999). For example, traditional scientific propositional knowledge, as 
found in the natural sciences, generally strives to be objective and 
universally valid. For this knowledge, important validation criteria will be 
(logical) consistency and empirical adequacy (De Wilde, 1989). On the 
contrary, non-scientific propositional knowledge (and in particular 
experiential knowledge) is more subjective and contextual. Instead of 
universal validity, this knowledge seeks for validity in terms of (practical) 
value. It thus needs other validation criteria, such as applicability and 
contextual adequacy. Validation of this type of knowledge often occurs 
implicitly in society, for example when many people subscribe to the 
adequacy and appropriateness of an explanation, resulting in a degree of 
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inter-subjectivity, or when an explanation proves to be applicable in 
practice.  
Contrary to explicit knowledge, implicit forms of knowledge are 
more difficult to investigate and validate. Since they are hard to 
communicate, they cannot be simply subjected to validation criteria. 
Instead, manifestations of this knowledge – such as demands, judgements, 
or ideas – could be validated, for example on the basis of their applicability 
or contextual adequacy. In this way implicit knowledge can be indirectly 
validated on its practical value (see for example section 3.3). 
Transdisciplinary knowledge, as the result of knowledge integration 
of different types of knowledge, needs to be evaluated on the basis of 
different validation criteria, in order to ensure its validity. Meeting these 
criteria might give rise to interpretations or innovations that are not only 
scientifically adequate but also appropriate to the specific context of 
application and to the needs and demands of society. It implies a 
continuous dialogue between the different parties involved, with feedback 
loops for the crosschecking of previous assumptions, insights, and 
demands. In table 4.1, the main characteristics of a transdisciplinary 
strategy, as described above, are summarized. 
 
 
Table 4.1  Main characteristics of a transdisciplinary strategy 
- holistic and integral approach 
- acknowledgement of complex context and set of actors (scientific and societal) 
- orientation on societal perspectives and problem-solving capability in the context of 
application 
- integration of explicit and implicit knowledge from various scientific and non-scientific 
sources 
- direct and personal involvement of relevant stakeholders in participatory processes 
- evaluation on the basis of different validation criteria, such as consistency, empirical 
adequacy, applicability, and contextual adequacy 
- dynamic, complex process with iterative feedback loops 
 
 
4.2 A transdisciplinary strategy for patient participation  
 
A successful transdisciplinary participation strategy covers different actions 
and conditions. First, a systematic process design needs to channel the 
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process. In addition, to ensure the effectiveness of such a procedure, the 
social setting, which determines the interactions between participants, has 
to meet certain conditions. Finally, members of the process management 
team who initiate and guide the transdisciplinary process have to possess 
or acquire some specific qualities and skills.  
Until now, general systematic guidelines for a transdisciplinary 
strategy have not yet been developed. However, within several scientific 
and societal contexts interactive or participatory strategies have been 
developed for involving end-users and other societal actors in decision-
making processes (e.g. Broerse and Bunders, 1999; 2000; Driessen et al., 
2001; Grin et al., 1997; Johnson et al., 2003; Kasemir, Jäger et al., 2003; 
Reuzel, 2004; Rip et al., 1995; Tress and Tress, 2003). Since these strategies 
focus on the interaction between both scientific (or professional) and non-
scientific (or lay) actors, as well as on the construction of an integral 
knowledge, they offer many procedural and conditional clues for a 
transdisciplinary strategy. In this section, we elaborate on the different 
components of a transdisciplinary strategy for the implementation of 
effective patient participation in decision-making on biomedical research. 
4.2.1 Process design 
Below, we propose a tentative transdisciplinary patient participation 
strategy based on the so-called Interactive Learning and Action (ILA) 
approach45, an interactive strategy that has been developed by members of 
the Athena Institute46 for the gearing of agricultural innovation projects 
towards the needs and interests of small-scale farmers in developing 
countries (see box 4.1) (Broerse, 1998; Broerse and Bunders, 1999; 2000). 
Reasons for choosing this approach are (1) it is a rather well elaborated 
and tested strategy that has proven to be successful in involving lay people 
in decision-making processes concerning science and technology, (2) we 
want to learn about the broader applicability of this strategy, and (3) we 
want to build on the rich experiences of members of our Institute with this 
participation strategy. 
The ILA methodology should not be regarded as a blueprint; it 
only provides guidelines and within the boundaries of the key 
characteristics it needs to be adapted and specified to the context of 
                                                 
45  formerly called the ‘Interactive Bottom-Up approach’ 
46  Athena Institute for Research on Innovation and Communication in Health and Life 
Sciences, Faculty of Earth and Life Sciences, Vrije Universiteit Amsterdam 
A TRANSDISCIPLINARY STRATEGY 
89 
application. In this study the ILA has been adapted to the context of 
patient participation in decision-making on biomedical research agendas.  
 
 
Box 4.1  The ILA approach 
 
Key characteristics of the ILA approach are the enhancement of trust 
relationships, mutual learning and knowledge integration between relevant 
stakeholders involved in a carefully guided process that is facilitated by a research 
team. Specific attention is paid to stakeholder groups that have previously been 
neglected in decision-making. To guide the process, the ILA approach is roughly 
structured along four phases (Broerse and Bunders, 2000).  
1. Initiation and preparation This phase consists of (a) the establishment, and if 
necessary training of, a research team that is to guide the overall project, (b) 
the gathering of preliminary, contextual information, and (c) the definition 
of objectives and roles. During this phase insight is obtained on the problem 
situation and the actor network, and the feasibility of the interactive exercise 
is assessed. At the end a ‘go/no-go’ decision is taken with respect to the 
project. 
2. Collection, exchange, and integration of information In this phase the team identifies 
and analyses perspectives, needs, and interests of the different stakeholders 
and assesses the status of current research. Subsequently, knowledge, 
perspectives, and needs of the stakeholders are mutually exchanged and 
integrated. This phase results in a thorough understanding of the problem 
and solutions from the perspective of the different stakeholders and an 
increased mutual understanding on the part of the various actors involved in 
the process. 
3. Public priority setting and planning The third phase allows all actors involved to 
review and reflect upon preliminary results from the previous phase, to 
identify priorities, and to establish a plan of action. Often this phase 
comprises an interactive priority setting and planning workshop.  
4. Project formulation and implementation The plan of action which resulted from 
the previous phase forms the input to the fourth phase, in which specific 
programmes or projects are formulated and implemented.  
Besides these general guidelines on how to structure activities, the ILA approach 
includes a rich tool kit of methods and techniques for knowledge generation and 
interaction from which the research team can draw as required. These methods 
and techniques range from literature study, various types of interviews and 
questionnaires, to a wide variety of group-based methods such as focus groups, 
and workshops designed for different purposes including brainstorming, 
dialogue, integration and consensus. Also various visualization, diagramming and 
prioritization techniques are included. 
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As has been argued above, in order to ensure the explicit 
integration of patients’ perspectives and knowledge in decision-making, 
consultation and collaboration methods should be combined in a 
structured process. In the original ILA approach knowledge integration 
between stakeholders involved alternates with the gathering of knowledge, 
both taking place in the second phase. Therefore in our transdisciplinary 
strategy we have divided the second phase into a separate consultation and 
a collaboration phase.  
A possibly appropriate design of a transdisciplinary strategy for 
implementing effective patient participation in decision-making on 
biomedical research thus could be as follows: 
1. Preparation and initiation phase  
In the first phase the biomedical field of interest is defined and the 
different stakeholders involved in that field, such as scientists, 
health care professionals, patients or patients’ organizations, and 
policy makers, are identified and contacted. Current patterns of 
thinking and decision-making are estimated and (possible) 
obstacles and opportunities for the implementation of patient 
participation are identified. For this purpose desk studies, literature 
surveys, and various exploratory and in-depth interviews can be 
conducted. Finally, a transdisciplinary team is established in order 
to facilitate and guide the next two phases of the transdisciplinary 
process. 
2. Consultation phase 
When the societal context has been assessed, in the consultation 
phase information and knowledge is gathered about the 
perspectives and views of the different stakeholders – including 
both central actors of the decision-making network and patients. 
This can be done via a variety of consultation techniques, such as 
exploratory and in-depth interviews, brainstorming sessions, 
discussion meetings, focus groups, and questionnaires. In order to 
investigate the separate perspectives of stakeholders and their 
mutual differences and overlaps, different stakeholder groups are 
not mixed at this stage. The preliminary findings – be they 
expressed research needs, relevant research topics, proposed 
research questions, criteria for priority setting, dilemmas 
encountered, or suggestions for further action – are laid down in 
an intermediary document.  
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3. Collaboration phase 
In the third phase the different stakeholders are brought together 
in interactive workshop or dialogue settings to review and discuss 
these intermediary findings, to exchange, combine, and negotiate 
views and perspectives, and to seek consensus concerning research 
needs, priorities, topics, etc. These workshops or dialogues need to 
be characterized by close and carefully guided interactions between 
the participants in order to facilitate mutual feedback, mutual 
learning and the development of shared constructions. This phase 
should ensure the explicit integration of patients’ perspectives and 
priorities in the outcomes. 
4. Prioritization phase 
Subsequently, in the prioritization phase participants are allowed to 
reflect on the results of the collaboration phase and to identify 
final priorities. In order to prevent that professionals or experts 
unintentionally overrule patients, this prioritization should be 
preferably done on an individual basis. Since the precise outcome 
of a priority setting strongly depends on which actors are involved, 
one should see that the participants in this phase adequately 
represent the different stakeholders involved, both in number and 
in characteristics.  
5. Specification phase  
The fifth phase comprises the translation and specification of 
priorities identified into a concrete plan of action, including e.g. 
research programmes, projects, or policy actions. Although this 
phase is often in hands of the ‘assigning body’ that has 
commissioned the patient participation initiative, the involvement 
of stakeholders can ensure that the resulting plan of action reflect 
their priorities.  
6. Implementation phase 
In the final phase, the plan of action established in the previous 
phase is implemented. This phase usually is in the hands of the 
‘assigning body’ as well. Ideally also in this phase stakeholder 
groups are involved. 
Each phase within such a transdisciplinary strategy consists of 
activities that can be undertaken several times, leading to an interactive, 
dynamic process. When ‘all’ information, knowledge, perspectives, ideas, 
demands, judgements, etc. are specified, analyzed, cross-checked, and 
integrated, the result is a shared construction of, and an integral vision of, 
the problem concerned or a possible course of action to be followed. The 
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procedure can be (successively) used to identify priorities and directions 
for research policy; to formulate research programmes; to identify, assess, 
and prioritize research topics; to formulate research questions and 
objectives; and to design research projects in a transdisciplinary manner. In 
table 4.2, the most important elements of the process design are listed. 
 
 
Table 4.2  Process design of a transdisciplinary strategy  
1. Preparation and  - definition of a field of interest 
initiation  phase - identification and contacting of all relevant actors 
 - establishment of a process management team 
2. Consultation phase - identification of stakeholders’ views, perspectives, needs, ideas, 
etc. 
 - literature research 
 - in-depth interviews, discussion meetings, focus groups, etc. 
3. Collaboration phase - development of shared constructions and an integral vision 
 - interactive workshops, dialogues, etc. 
 - repeated feedback on all kinds of results by all participants 
4. Prioritization phase - individual or collaborative prioritization of results 
5. Specification phase - translation and specification of priorities identified  
 - establishment of plan of action 
6. Implementation phase - implementation of plan of action 
 
4.2.2 Social Setting 
Central elements within transdisciplinary strategies are brainstorming 
sessions, discussion meetings, and interactive workshops that aim to 
enhance effective interaction between participants and integration of their 
knowledge. To make effective knowledge integration possible, however, 
the social setting of these meetings has to meet certain conditions. Within 
the context of the ILA approach, Broerse and Bunders (1999) have 
identified conditions for successful transdisciplinary social interactions. A 
first and indispensable condition is that the ‘central’ participants in the 
research process be committed to a shared vision with regard to the overall 
objective of the collaborative undertaking and on the importance of 
transdisciplinarity and knowledge integration in this process. Secondly, a 
kind of coalition building between the participants ensures optimal 
collaboration and the achievement of joint efforts and outcomes. The 
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atmosphere should be open and trustful and stimulate rational discourse, 
mutual learning, and feedback (in accordance with the theory of 
communicative action as described by Habermas, 1984; 1987). In addition, 
participants must have more or less equal access to information, support, 
funds, and other means. Central issues, such as overall research objectives 
and mutual expectations, have to be made explicit and formulated clearly 
for all participants. Finally, when established structures are to be changed 
during the process, the existence of some room for manoeuvring and 
negotiation is an additional condition. 
Because most of these conditions usually will not be met in a real-
world setting, a specific social setting conducive to the implementation of 
a transdisciplinary strategy often has to be created. For example, central 
participants can be selected based on whether they are open-minded 
towards other perspectives and willing to discuss their own. Although the 
deliberate selection of participants implies the initial establishment of a 
somewhat artificial situation, in many cases it is the only way to facilitate 
the development of a shared construction. Later in the process, a real-
world setting can be pursued. In addition, the social setting needs to be 
carefully managed in order to facilitate mutual respect, openness, and 
learning. In table 4.3, abovementioned conditions for the social setting of a 
transdisciplinary strategy are summarized. 
 
 
Table 4.3  Conditions for a transdisciplinary social setting  
- commitment to a shared vision 
- coalition building  
- equality in roles and means  
- openness   
- mutual respect  
- mutual learning 
- clarity in research objectives, strategies, expectations, and so on  
- room for manoeuvring and negotiation  
 
4.2.3 Team qualities and skills 
To be capable of creating and facilitating the necessary social setting and 
applying the proposed procedural steps, process managers who guide a 
transdisciplinary strategy need to possess or acquire some specific qualities 
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and skills. First and foremost, they need to be able to transcend 
disciplinary boundaries and to respect and value non-scientific knowledge. 
Furthermore, they should possess a number of basic ‘scientific’ skills. 
Because in transdisciplinary strategies knowledge from various sources is 
collected, analyzed, and integrated, more is needed than simply the 
scientific skills used in traditional monodisciplinary research. Julie 
Thompson Klein (1996) formulated scientific skills for interdisciplinary 
and transdisciplinary research, including the gathering, translating, 
analyzing, weighting and valuing, structuring, and synthesizing of scientific 
and experiential information and knowledge. In addition, various 
communication and organizational skills are indispensable for conducting 
specific transdisciplinary activities, such as interviewing actors with 
different backgrounds, facilitating collaboration between these actors, and 
organizing workshops and discussion meetings. 
To optimize the social interactions between the different 
participants, transdisciplinary process managers need to bridge 
communication and cultural gaps between the participants and play the 
role of intermediary. Bunders, Stolp, and Broerse (1991) identified several 
personal qualities and attitudes that are necessary for successfully 
mediating and guiding transdisciplinary processes, such as a broad interest, 
flexibility, creativity, openness, respectfulness towards people, perspectives, 
and cultures, and a tolerance to ambiguity. During the process, these 
intermediaries might slowly increase the awareness and receptiveness of 
the scientific world toward transdisciplinarity, thus acting as change agents 
as well. At the same time, they could play an important role in the 
 
 
Table 4.4  Qualities and skills for transdisciplinary process managers  
Qualities and Attitudes Skills 
- transcendence of disciplines - scientific skills for gathering,  
- broad interest translating, 
- flexibility analyzing, 
- reflexivity structuring, 
- creativity weighting and valuing, and 
- openness synthesizing knowledge and information 
- respectfulness - communication skills 
- tolerance to ambiguity  - organizational skills 
- willingness to act  
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empowerment of marginal actors (Anbar, 1986; Broerse and Bunders, 
1999; Schot and Rip, 1997). In table 4.4, the most important qualities and 
skills for transdisciplinary process managers are listed. 
 
4.3 Implementation within the biomedical sector 
 
Although various pleas are made for the inclusion of experiential 
knowledge of patients in decision-making on biomedical research, 
transdisciplinary decision-making on biomedical research is far from being 
common practice. Given the many conditions, qualities, and skills that are 
considered indispensable for a successful transdisciplinary strategy, as 
described in the previous section, one may even question the feasibility of 
a structural implementation of such a strategy. Is transdisciplinary 
decision-making on biomedical research simply a utopian dream, an ideal 
that cannot be realized? We have some indications that it might become a 
reality. 
In different cases of patient participation in decision-making on 
biomedical research, as described earlier, several of the identified 
procedural elements of, and conditions for, transdisciplinarity have been 
present to some extent. For example, patients of both Pro Retina (box 1.1) 
and the French Muscular Dystrophy Association (box 1.2) have actively 
and successfully sought intensive interaction with scientists in discussion 
meetings or conferences that were characterized by mutual openness, 
respect, and learning. In other examples, intermediaries have successfully 
transcended disciplinary boundaries and have integrated patients’ 
experiential knowledge in decision-making on scientific research topics or 
priorities. For this purpose they should have been open and respectful 
towards patients’ perspectives and views. However, since in all those cases 
only few conditions for transdisciplinarity were fulfilled in an ad hoc and 
implicit manner, they do not provide conclusive proof that the 
implementation of transdisciplinary decision-making on biomedical 
research is feasible. 
Another indication for the feasibility of successful implementation 
of our proposed transdisciplinary participation strategy can be derived 
from the different successful experiences with implementing the original 
ILA approach. In Ghana, Zimbabwe, and Bangladesh the ILA approach 
proved to be rather successful in involving end users and integrating their 
indigenous knowledge in agricultural priority setting and project design 
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(e.g. Broerse, 1998). Experiences in Bangladesh also showed the potential 
for institutionalization of this approach within established structures 
(Zweekhorst et al., 2003). Of course, further research still needs to 
investigate whether an ILA-based strategy is also applicable and effective 
in the context of biomedical research agenda setting. 
 
4.4 A view ahead 
 
The remaining part of this book describes a social experiment that aims to 
implement and evaluate the transdisciplinary strategy proposed above 
within the context of an interactive health research agenda-setting project, 
initiated and commissioned by the Netherlands Asthma Foundation 
(NAF) and co-financed by the Netherlands Organization for Health 
Research and Development (ZonMw). The project does not specifically 
focus on biomedical research but includes biomedical research in the 
agenda-setting process. Although this may somewhat complicate the 
further investigation of the feasibility of implementing transdisciplinary 
strategies within the biomedical sector, it does offer the additional 
possibility to investigate patients’ interest in, and demand for, biomedical 
research with respect to other types of health research. 
The context of asthma and COPD47 research agenda setting 
initiated by the NAF seems to be quite suitable for implementation of a 
transdisciplinary approach. Firstly, both asthma and COPD are chronic 
illnesses, which enables patients to obtain experiential knowledge. 
Secondly, although it is generally acknowledged that both diseases are 
caused by multiple genetic and environmental factors, precise details on 
these factors are unknown. In addition, adequate therapies without 
negative side effects do not yet exist. Therefore there might be some 
room, or even a need, for new and alternative inputs from patients 
concerning biomedical research topics or questions. Thirdly, the 
Netherlands Asthma Foundation is both a research fund and a patients’ 
organization – a rather unique combination in the Netherlands – which 
facilitates the gearing of research programmes and priorities towards 
patients’ needs and demands, and makes the NAF a possible facilitative, 
intermediary platform for interaction between scientists and patients. The 
                                                 
47  Chronic Obstructive Pulmonary Disease 
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next two chapters will describe and evaluate this social experiment in 
detail. 

 99 
5 
PATIENTS’ RESEARCH PRIORITIES48  
This chapter describes the consultation of Asthma and Chronic 
Obstructive Pulmonary Disease (COPD) patients on their priorities 
concerning health research. This consultation was an essential step 
within an interactive research agenda-setting project that was 
commissioned by the NAF and ZonMw. The overall project, which 
will be described and evaluated in the next chapter, aimed to apply 
and test the transdisciplinary participation strategy proposed in the 
previous chapter. An additional objective of the patient consultation 
step was to investigate the capability of patients to participate 
adequately in, and to contribute to, (biomedical) research agenda 
setting, which will validate the substantive argument in favour of this 
patient participation. For this purpose a consultation procedure was 
designed comprising seven focus groups, a feedback meeting, and a 
questionnaire. The focus groups and the feedback meeting aimed to 
explore the entire breadth of problems that patients experienced in 
relation to their diseases, while the questionnaire aimed to investigate 
patients’ prioritization of possible research targets that focus on solving 
these problems. The consultation procedure successfully elicited 
patients’ research priorities and their underlying arguments. Our 
results indicate that asthma and COPD patients are capable of 
research prioritization in a well-founded way and that they highly 
value biomedical research. Furthermore, since they prioritized some 
biomedical research topics that were not covered by current research 
programmes, we argue that patient participation will contribute to 
biomedical research agenda setting. 
 
                                                 
48  The text of this chapter is based on Caron-Flinterman, J.F., Broerse, J.E.W., and 
Bunders, J.F.G. (2005). Patients' priorities concerning health research: The case of 
asthma and COPD research in the Netherlands. Health Expectations 8(3): 253-263. 
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In order to apply and test the transdisciplinary participation strategy, 
proposed in the previous chapter, a social experiment was conducted, 
comprising an interactive research agenda-setting project, commissioned by the 
Netherlands Asthma Foundation (NAF) and co-financed by the 
Netherlands Organization for Health Research and Development 
(ZonMw). This project is described and evaluated in detail in the next 
chapter. 
This chapter only describes one, but essential, step within the 
project: the consultation of asthma/COPD patients on their health 
research priorities. Besides making patients’ research priorities explicit, 
which is an important input in the agenda-setting process, the patient 
consultation step offers a way to investigate patients’ capability of 
adequately identifying and prioritizing health research topics. Although the 
agenda-setting project does not specifically focus on biomedical research, 
biomedical research is part of it. Therefore, in an indirect way, we hope to 
be able to estimate patients’ capability of contributing to biomedical 
research agenda setting as well. This investigation will address a difference 
of opinions concerning the desirability and feasibility of patient 
participation in health or biomedical research agenda setting.  
As has been found in chapter 2, an important obstacle for effective 
patient participation in decision making on biomedical research is the 
opinion of many relevant actors (both researchers and patients) that 
patients should not contribute to decision-making on biomedical research 
agendas for various reasons. It was argued that patients: 
- lack essential knowledge about research issues and procedures,  
- do not speak nor understand scientific language,  
- are unable to put their own questions and demands into a scientific 
context,  
- have unrealistic expectations of scientific research,  
- are strongly influenced by the media,  
- are unable to abstract from their own individual situation,  
- have difficulty to think in long-term targets, and/or  
- are only interested in subjects concerning care or social issues.  
As a result, many concluded that patient involvement in biomedical 
research agenda setting would be useless and that their involvement in 
overall health research agenda setting would result in an undervaluing and 
subordination of biomedical research.  
Until now, available literature on the subject, such as systematically 
reviewed by Oliver et al. (2004), hardly provides evidence concerning the 
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tenability of above-mentioned presuppositions. Reports on patient 
consultations concerning research priorities often concern a restricted field 
of health research only, or do not distinguish patients’ priorities from the 
priorities of professionals. But even if many of the above-mentioned 
presuppositions can be substantiated, it may be unfair to conclude that 
patient participation in overall health research agenda setting is useless and 
undesirable. Scientific knowledge, for example, may not always be a 
necessary prerequisite for useful participation. Indeed, patients may 
possess other types of knowledge of value and relevance to research 
agenda setting, as is argued by several scholars (Entwistle et al., 1998; 
Goodare and Lockwood, 1999; Popay and Williams, 1996). According to 
these scholars, a distortion of research priorities due to the inclusion of 
patients’ knowledge can be positive, since this broadening of prioritization 
can counter potential biases of scientists and health care professionals.49 
We used the consultation of asthma/COPD patients on their 
research priorities to investigate the tenability of the different 
presuppositions described above. For this purpose, we had to design an 
adequate methodology that consults patients about their research priorities 
in an explicit and transparent way. Such a methodology would provide 
greater insight into whether patients can prioritize health (and biomedical) 
research topics in a well-argued way and can make relevant contributions 
to current health or biomedical research agendas. 
 
5.1 Methodology 
 
From September 2003 to February 2004 we consulted asthma and COPD 
patients about their priorities on asthma and COPD research using a 
triangulated strategy. Focus groups were conducted to explore the entire 
breadth of, and to gain insight in, patients’ problems concerning living 
with asthma or COPD. A subsequent questionnaire explicitly focused on 
possible research targets that aspire to solve those problems identified in 
the focus groups, while making final results more quantitative and 
representative for the entire patient community. Participants of both focus 
groups and questionnaire were all NAF members, selected on their 
willingness to participate. In many consultation studies, focus groups are 
                                                 
49  This view supports the substantive argument in favour of patient participation in 
decision making on biomedical research, see section 1.2.2.  
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only used as a preliminary tool to design a subsequent questionnaire (Berry 
et al., 2003; Chen et al., 2001; Steine et al., 2001). However, our focus 
groups had the additional objective of providing insight into perspectives 
and arguments that underlie patients’ priorities (see also Irwin, 2001).  
Focus groups 
In September 2003 we organized three workshops in three different 
regions, geographically spread across the country. Each workshop included 
a plenary introduction, two or three parallel focus groups, and a plenary 
discussion of preliminary focus group results. From the three regions, 61 
patients50 participated in seven focus groups of seven to eleven people.  
All focus groups involved a majority of women (42 in total) and 
the average age was 56 years. More asthma patients than COPD patients 
were involved. Table 5.1 shows the distribution of participants among age 
categories and diseases. Although we originally planned to form separate 
groups of asthma and COPD patients, this became infeasible in practice 
because in two of the three regions only a few COPD patients were able to 
participate. Other variables were considered irrelevant for segmentation.  
 
 
Table 5.1  The distribution of focus group participants along sexes, age 
categories, and diseases 
Sex** Age Disease*** Focus 
group* 
Number of 
participants M F 0-15 16-30 31-45 46-60 61-75 76+ A C A+C PR 
A1 7 2 5 0 1 1 4 1 0 3 2 0 2 
A2 7 1 6 0 0 2 3 1 1 3 1 2 1 
L1 8 2 6 0 1 3 2 2 0 4 2 1 1 
L2 8 4 4 0 0 0 3 4 1 3 2 3 0 
H1 11 3 8 0 1 3 4 2 1 6 2 2 1 
H2 10 3 7 0 1 2 2 1 4 7 2 1 0 
H3 10 4 6 0 0 1 1 5 3 2 7 1 0 
Total 61 19 42 0 4 12 19 16 10 28 18 10 5 
Total 
(%) 
100 31 69 0 6 20 31 26 16 46 30 16 8 
*   The letters refer to the locations of the different focus groups; A = Amsterdam, L = Leusden, H 
= Haren. 
**  M = male; F = female 
*** A = Asthma; C = COPD; A+C = Asthma and COPD; PR = patient relatives 
                                                 
50  Since we did not distinguish different kind of NAF members, in this article the term 
‘patients’ can refer to both actual asthma/COPD patients and relatives or carers of 
patients.  
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The focus group design was standardized and averagely structured 
(Morgan, 1996). Each focus group had a moderator to guide the discussion 
using 6 pre-established questions and exercises, and a monitor, who 
observed the group dynamics and recorded notes of the proceedings. 
Focus group discussions were recorded on video and cassette for further 
analysis. All participants consented to these recordings on conditions of 
anonymity and deletion after the project. 
Each focus group session focussed on the problems patients 
experience in relation to their diseases and not explicitly on their research 
priorities. Main reasons for this are (1) talking about problems better fits in 
with daily experiences than talking about research priorities and (2) many 
patients may be unfamiliar with the full range of research topics and fields 
(biomedicine, social sciences, policy sciences, etc.) that could be included 
in an overall research agenda on asthma and COPD. In order to prevent 
any unintentional underexposure of some research fields or topics we 
deliberately avoided direct requests for research priorities. Assuming that 
all disease-related research eventually aims to solve disease-related 
problems, we argue that problems mentioned by patients indirectly refer to 
potential research topics or directions.  
During the first part of each focus group session, patients were 
asked to discuss all disease-related problems they experience in daily life. 
In the second part of the session, patients were asked to collectively 
prioritize the listed problems by negotiation and distribution of urgency 
points. The main purpose of this prioritization exercise was to generate 
discussion and elicit explicit arguments that underlie each problem. Finally, 
each focus group identified specific research topics or questions. At the 
end of each plenary closing session, feedback forms were distributed that 
allowed participants to reflect on the workshops and to specify whether 
and in what ways they would like to be involved in decision-making 
processes in the future. Afterwards, reports of the discussions were sent to 
all participants for feedback. 
Focus group discussions were analysed by searching the tape-
recordings for mentioned causes of, and mutual relations between, 
identified problems. All problems, causes, and mutual relations mentioned 
were logically analysed in a so-called ‘causal tree’ (Klinkers, 2002). 
In November 2003 an additional feedback meeting was conducted 
in order to verify the focus group results. The group of participants (27) 
consisted of 17 women and 10 men of whom 11 were asthma patients, 12 
suffered from COPD, three from both diseases, and one was a parent of 
an asthma patient. The average age of these participants was 63. The main 
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focus of the feedback meeting was to check and complete the causal tree. 
For this purpose, participants were divided into three groups of eight to 
ten people, each of which focused on a different part of the overall causal 
tree. Based on the results of this meeting the causal tree was finalized.  
Since people below 30 and seriously ill patients were 
underrepresented in both the focus groups and the feedback meeting, we 
held some additional in-depth interviews with younger asthma patients and 
a seriously ill COPD patient. We discussed their main health problems and 
concerns in order to determine variance with problems of the other patient 
participants.  
Questionnaire 
In order to obtain a quantitative view of patients’ priorities on potential 
health research topics, the results of the focus groups were used to design 
a questionnaire. For this purpose, all problems identified in the focus 
groups were clustered and translated into seven categories of six potential 
research topics that imply the solution of the problems. An identified 
problem can be regarded as reflecting (1) a lack of effective solutions, or 
(2) a lack of adequate implementation strategies. Since health research 
could focus on the acquirement of knowledge for both the development 
and implementation of health interventions, we argue that each identified 
problem reflects a potential target for health research. The categories of 
research topics included: finances, emotions, social environment, primary 
care, specialist care, other forms of care, and knowledge on aetiology and 
drugs. These categories roughly reflect the variety of problem fields that 
emerged during the focus groups (see figure 5.1).  
The questionnaire consisted of three blocks of questions. The first 
block focused on demographic characteristics of respondents. The second 
and main block involved the prioritization exercises, requesting 
respondents to divide a maximum number of points among different 
wishes (a variant of the 'budget pie' method, see Mullen, 1999). The third 
block focused on the views of respondents concerning participation in 
decision-making on research. In the last block, respondents were 
encouraged to indicate any omission in the questionnaire and to give 
comments.  
A draft version of the questionnaire was tested by fifteen 
asthma/COPD patients and subsequently slightly adapted. For our 
analysis we needed at least 200 filled-in questionnaires. Since previous 
experience of the NAF indicated an average response of about 25%, we 
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sent the questionnaire to 1000 patients randomly selected from the entire 
pool of NAF members, and to 42 patients who had participated in the 
focus groups or the feedback meeting and had indicated a willingness to 
participate in a questionnaire. In addition, the questionnaire was placed on 
the Internet site of the NAF.  
In order to check possible differences in priorities between NAF 
members and asthma/COPD patients who are not NAF members, we 
also distributed questionnaires among non-members via various hospitals, 
physiotherapy practices, and a respiratory rehabilitation centre in 
Amsterdam. Questionnaire results were analysed in a stratified way in 
order to identify possible influences of disease-related or demographic 
characteristics on research priorities.  
 
5.2 Results 
 
Focus groups 
The results of the focus groups consisted of a causal tree of mutually 
related problems and causes, a list of prioritized problems, and a list of 
patients’ questions and suggestions for research.  
In figure 5.1 a simplified version of the overall causal tree of patient 
problems is depicted. At the highest level, there are four problem fields: 
psychological problems, social isolation, physical complaints, and financial 
problems. Problems with inadequacies of health care (both primary care 
and specialist care) contribute to a large cluster of problems that eventually 
result in physical and psychological problems. A small additional cluster is 
created by a lack of knowledge about the aetiology of the diseases and the 
lack of effective drugs, also eventually resulting in physical and 
psychological problems. The design of the questionnaire was based largely 
on these clusters of problems. 
During the prioritization sessions in the focus groups, two 
problems consistently received more than twice as many urgency points as 
other problems: side-effects of medication and hypersensitivity for all 
kinds of substances, such as smoke, perfumes, dust, and damp. Table 5.2 
lists all problems prioritized during the focus groups and their urgency 
scores. Problems that were added during the feedback meeting include the 
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Figure 5.1.  Highly simplified version of the causal tree reflecting problem (cluster)s and their mutual relations as experienced 
by asthma/COPD patients
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lack of (deployment of) asthma nurses as coaches and mediators in health 
care, the lack of attention of specialists for psychological aspects of the 
diseases, and the non-recognition of physical causes of some complaints 
by medical doctors. 
 
 
Table 5.2  Patients’ problems prioritized during the focus groups 
Rank Problem Score* 
1 side-effects of medication 27 
2 hypersensitivity for all kinds of substances, such as smoke, perfumes, dust, damp, etc. 23 
3 insufficiently coaching and follow-up with drug use by professionals 11 
4 (obscurity of) long term side-effects of medication 10 
5 obscurity of causes of disease or individual attacks 9 
6 interference with social life 9 
7 co-morbidity 7 
8 inadequate information and uncertainty on drug use 7 
9 fatigue 6 
10 lack of knowledge among general practitioners and pharmacists 6 
11 inadequate collaboration of health care professionals 4 
12 high costs for medication, aids and house adaptation 4 
13 non-understanding by social environment 3 
14 non-understanding at school and work 3 
15 feelings of grief and frustration about physical constraints and social isolation 3 
16 little attention for alternative therapies in health care 3 
17 lack of patients’ empowerment 2 
18 inadequate collaboration between regular and alternative medicine 2 
19 non-understanding by professionals 2 
20 inconvenience of drug use 2 
*   The score refers to the number of ‘urgency points’ (paperclips) the problem concerned was 
attached to by the focus group participants 
 
The interviews with young asthma patients indicated a common set 
of problems but a different rate of urgency in relation to older patients. 
For example, the interviewees gave higher priority to the fear of a sudden 
asthma attack during social activities and the insufficient knowledge of, 
and information from, general practitioners. The interview with the 
seriously ill COPD patient indicated no additional problems. 
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Patients’ input on specific research questions mainly concerned the 
causes of the diseases and the occurrence of co-morbidities. Other topics 
included options for the improvement of treatment and the improvement 
of the interaction between patients and their environment. Patients’ 
suggestions for action targeted the improvement of health care, 
prevention, and care organization. 
On the evaluation forms, a large majority of the participants 
indicated that the workshop had met their expectations and that they felt 
they had contributed something relevant to the discussion. Main 
suggestions for improvement included shortening the time-scheme, using a 
more convenient location, providing more information beforehand, 
inviting a research professional who could answer questions, and realizing 
a better representation of male and young patients. In addition, many 
participants suggested that the NAF should organize similar meetings on a 
regular basis. Finally, 44 of the 54 patients who filled in an evaluation form 
indicated a willingness to be involved in the ongoing process by means of 
additional workshops (35), interviews (22), questionnaires (29), or 
participation in a committee with professionals (18). 
Questionnaire 
From the 1042 questionnaires sent by mail, 244 patients responded (23.4% 
response of which 63% was female and 36% male). In addition, six 
patients filled in the questionnaire from the Internet. Figure 5.2 shows the 
distribution of respondents according to age, education level and disease. 
Equal numbers of respondents suffered from asthma and COPD. Of the 
asthma patients, 17% regarded the degree of their disease as serious, while 
this was 42% among COPD patients. The median age of respondents was 
between 46 and 60. However, the average ages within different types of 
patients varied; while many respondents with COPD were above 60, 
respondents with asthma were often younger. Finally, most respondents 
had received lower secondary education but middle and higher educated 
people were also amply represented. Although NAF’s membership 
includes twice as many asthma patients as COPD patients (Nederland et 
al., 2004), the other characteristics of our respondents roughly 
corresponded with the results of an earlier investigation on the 
demographic characteristics of NAF members (Kerklaan and Vermelis, 
2002). They also corresponded with characteristics of asthma and COPD 
patients in general, as investigated in a national study by the Netherlands 
Institute for Health Services Research (Heijmans and Rijken, 2003). 
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Table 5.3 shows the 15 highest priorities of patients. Patients 
prioritized research on the aetiology of asthma or COPD, co-morbidity, 
and effective medication above research on health care or social issues. 
One might assume that this is the result of calculating the means since not 
all patients will experience, for example, problems with their general 
practitioners, specialists, or social environment, while they will all 
experience the obscurity of the origin(s) of their diseases and the 
inadequacy of medication. Further investigation of questionnaire results, 
however, showed that about 50% of the respondents prioritized 
biomedical issues higher than other issues on an individual basis.  
A stratified analysis of questionnaire results indicated that neither 
sex nor age of patients significantly influenced their prioritization. Only the 
youngest group, the respondents below 15 years, had somewhat different 
priorities. This group prioritized ‘Reduction of fear for hypersensitivity or 
symptoms during activities outside’ as highest. Other high priorities of this 
group concerned topics that aim to improve the overall functioning of 
general practitioners.  
Differences between the priorities of asthma patients, COPD 
patients and patient relatives were limited as well. All types of patients and 
Figure 5.2   Distribution of questionnaire respondents along age categories,
diseases, and levels of education.
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their relatives prioritized research on the causes of the diseases and on new 
medication as most important. Besides these top priorities, many asthma 
patients also prioritized issues related to their social environment, while 
seriously ill COPD patients and patients with both asthma and COPD 
focused on the reduction of costs. 
 
 
Table 5.3  Patient priorities concerning potential research targets as resulting 
from the questionnaire 
Rank Potential research target (wish) Final score* 
1 more knowledge on the origins of asthma/COPD 11.6 
2 new and more effective drugs 11.3 
3 more knowledge on the relation between asthma/COPD and other diseases (co-morbidity) 9.8 
4 drugs that have less side-effects 9.4 
5 more knowledge on the mutual interaction of drugs 6.3 
6 the adaptation of governmental rules concerning public places and workplaces  5.6 
7 more compensation for medication and aids 4.9 
8 reduction of contributions for health insurances 4.4 
9 improvement of understanding and consideration by family and friends 4.0 
10 reduction of physical complaints that hamper daily life functioning 4.0 
11 reduction of fear for hypersensitivity or symptoms during activities outside 4.0 
12 compensation of costs for house adaptation 3.6 
13 knowledge on effects and efficacies of alternative therapies† 3.5 
14 compensation of costs for activities 3.4 
15 more time and understanding by general practitioners 3.4 
* Final scores refer to the average score attached to by all respondents 
†  Alternative therapies or complementary therapies comprise all kinds of non-traditional 
therapies, including homeopathy, orthomolecular medicine, yoga, breathing therapy, 
movement therapy, etc. 
 
 
Also the level of education hardly influenced the outcomes of the 
questionnaire, although people with only primary education deviated 
somewhat in their prioritization. This group prioritized research on causes 
and on co-morbidity somewhat lower and asked for more attention on 
‘improvement of understanding by the social environment’, ‘the adaptation 
of governmental rules concerning public places and workplaces’, and ‘the 
effects and efficacies of alternative medication’. 
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As became apparent from the results of the additional 
questionnaire among non-NAF members, the priorities of NAF members 
did not deviate from the priorities of non-members. Apparently, the 
membership of the NAF does provide a bias in patients’ priorities on 
health research. 
There was some overlap between priorities identified in the focus 
groups and priorities that surfaced from the questionnaire. In both 
exercises, the side effects of medication, the obscurity of causes of diseases 
and symptoms, and complaints related to hypersensitivity were prioritized 
highly. As a difference, in the focus groups problems concerning the 
quality of health care, including issues of coaching, information, and 
coordination, received much attention, while in the questionnaire patients 
gave knowledge on co-morbidity and reduction of costs a higher priority.  
Concerning patient participation in research in general, the 
majority of respondents considered patients’ contributions relevant to 
research agenda setting and were prepared to be involved in future 
consultations. Most of them preferred questionnaires, but about one 
fourth of the respondents was willing to be interviewed or to participate in 
workshops or committees as well. Because of the relatively low response, 
the overall percentage of NAF members that are prepared to be involved 
in future agenda-setting processes is likely to be lower.  
 
5.3 Discussion 
 
In this study we aimed to sample the entire range of patients’ problems 
concerning living with asthma/COPD. We, thus, had to be concerned 
whether all types of patients were represented in our focus groups – after 
all, different types of patients might experience different problems. Since 
younger patients and seriously ill patients were underrepresented, we held 
additional interviews. This, however, did not reveal new problems, but 
proved to indicate only slight differences in prioritization, as discussed 
above. We therefore think our focus group results adequately cover the 
entire range of patients’ problems. 
Although the response rate to our questionnaire was low, the 
respondents covered a representative variation in sex, disease, age, and 
educational level. We therefore consider our results as an adequate 
representation of research priorities of NAF members. In addition, since a 
smaller supplementary survey among non-NAF members resulted in the 
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same research priorities, our questionnaire results can be considered to 
reflect research priorities of asthma/COPD patients in general.  
Differences between priorities identified in the questionnaire and 
the preliminary priorities that were expressed during the focus groups are 
probably related to differences in objectives and ways of asking between 
the two methods used. Whereas, for example, lack of knowledge on 
aetiology may not be the most obvious answer when asking for 
experienced problems, the acquirement of this knowledge can be 
considered highly relevant when presented in a list of potential research 
targets. This argument is substantiated by the fact that patients’ research 
questions, as formulated during the last part of the focus groups, 
correspond very well with priorities resulting from the questionnaire. In 
addition, group dynamics within focus groups can hamper fair 
prioritization exercises. When discussing problems, patients will influence 
each other, easily resulting in potential (unintentional) over-emphasizing of 
a particular kind of problem and the under-exposing of other problems. 
When patients are confronted with a questionnaire, they can prioritize a 
complete series of potential research targets individually.  
The patient consultation resulted in a list of priorities that reflects 
solutions to problems identified during the focus groups. At first sight, 
some of these research targets, such as those focussing on the reduction of 
costs or the improvement of understanding of the social environment, 
may seem to have little relevance for scientific research. However, we 
argue that all these targets could be addressed directly or indirectly by 
different disciplines within the broad field of health research. For example, 
economic research could focus on the financial aspects of diseases, while 
social scientific research could elaborate societal patterns of interaction 
between patients and their social environment.  
Our results indicate that asthma and COPD patients (NAF 
members) prioritized biomedical research – research on the aetiology of 
the diseases and on new and better medication – above research on health 
care, social, or political issues. After comparison of the patients’ priorities 
identified with the research priorities as formulated in the current 
asthma/COPD research programmes of the NAF (see box 5.1, Astma 
Fonds, 2000a; b), we found that patients’ highest two priorities, concerning 
more knowledge about the causes of the diseases and more effective 
medication, correspond with priorities of the current NAF programme on 
Experimental and Descriptive Research. Priorities of the current Care and 
Prevention programme were addressed (and partly prioritized) by patients 
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when discussing problems during the focus groups, but were not 
prioritized as important research targets in the questionnaire.  
 
 
Box 5.1  Current research programmes of the NAF* 
 
Since 2000 the Netherlands Asthma Foundation has developed and implemented 
different policy programmes that together aim to realise their main policy targets. 
Two of those programmes include the funding of research projects: 
‘Experimental and Descriptive Research’ (EBO – ‘Experimenteel en 
Beschrijvend Onderzoek’) and ‘Care and Prevention’ (Z&P – ‘Zorg en 
Preventie’). 
While in the EBO programme the focus is on the development of 
knowledge on causes and mechanisms of asthma and COPD with the long term 
aim to contribute to optimal prevention and therapy in an innovative way, the 
focus of the Z&P programme is on the direct advancement of prevention and 
health care quality for asthma and COPD patients. 
For the policy period 2001-2004 the research agenda for the EBO programme 
in terms of research priorities is as follows: 
• Factors that influence the progression of COPD: 
- pulmonary and non-pulmonary disorders 
- heterogeneity of COPD 
- chronicity of COPD 
• Insight in genetic, (psycho)physiological, and behavioural scientific aspects 
of smoking addiction:  
- smoking addiction behaviour  
- “(non-)susceptible smokers”  
- stopping smoking 
• Extent and causes of increase in asthma:  
- chronicity of asthma 
- gene – environment interaction 
- heterogeneity of asthma 
- smoking and asthma 
• Possibilities for interventions focusing on a future cure for asthma: 
- phenotyping of asthma 
- immune modulation  
- endogenous inhibition mechanisms 
The agenda for the Z&P programme 2001-2004, in terms of targets for 
research, development, care innovation, and implementation projects, is as 
follows: 
• Breaching the progression of COPD and COPD as addiction disorder:  
- better prevention of COPD 
- less underdiagnosis of COPD 
        - structural embedding of quitting smoking in care and initiation of 
care continuum 
• Prevention and better control of asthma:  
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        - more possibilities for prevention, diagnosis and treatment of 
asthma among young children  
- more structural embedding of self management  
- better organization of care 
- more preventive ‘arbo’-care (concerning working conditions) 
• Advancement of integral quality care  
- implementation of quality framework 
- better preconditions for quality care 
- better quality care in regions 
- more involvement of patients’ perspective in care 
Both programmes have been formulated in close consultation with the 
respective programming committees, and were based on preliminary studies on 
the current state of affairs concerning care and research on asthma and COPD. 
In 2000, the EBO programming committee consisted of 15 researchers from the 
biomedical, social-scientific, clinical and epidemiological fields, including the 
programme manager. At that moment, the Z&P programming committee 
consisted of 14 professionals from a variety of medical and paramedical 
disciplines, one patient, and a programme manager. 
 
*  (Astma Fonds, 2000a; b) 
 
 
Topics that were prioritized by the patient community as third, 
fourth and fifth (co-morbidity, side effects of medication, and interaction 
between medications respectively) are not covered by the current research 
programmes. Possibly, research concerning the side effects of, and 
interaction between, medications is considered the territory of the 
pharmaceutical industry, and thus is not included in the NAF programmes. 
The fact that co-morbidity is not included in current research programmes 
could be explained by the strong differentiation of current medical practice 
and (bio)medical research; both the Dutch health care system and the 
biomedical research field are highly structured around individual diseases 
and professional disciplines. Research on co-morbidity, side effects of 
medication and drug interaction can thus are significant ‘alternative’ 
research priorities of patients. They originate from patients’ daily 
experiences with their diseases and their medication and thus can be 
considered manifestations of patients’ experiential knowledge.51 
The priorities of patients also deviate from the priorities within the 
current research programmes with respect to psycho-social aspects of 
asthma/COPD, such as fear of hypersensitivity and the (non-) 
understanding by the social environment. These topics were regarded as 
                                                 
51  In line with the typology of manifestations of experiential knowledge, as given in 
Chapter 3, these research priorities represent demands as well as judgements. 
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main problems by patients but are not explicitly addressed in any of the 
current research programmes. They also can be considered manifestations 
of patients’ experiential knowledge.  
 A third difference is that patients did not focus on targets 
addressing smoking addiction – a priority in both NAF programmes. A 
possible explanation for this absence among patients’ problems and 
priorities is that for some patients smoking addiction is a highly sensitive 
subject, while for others it might be irrelevant because they no longer, or 
never did, smoke. 
 
5.4 Concluding remarks 
 
The combination of focus groups and a questionnaire can be considered 
an appropriate methodology for investigating patients’ priorities on 
research. The questionnaire appeared a suitable tool for explicitly 
consulting a representative group of patients on their research priorities, 
without becoming obscured by group effects. The input from focus 
groups was indispensable for getting a proper design of the questionnaire 
as well as for gaining insight in underlying arguments and perspectives.  
The findings in this chapter contradict the presupposition of many 
people that patients are not capable of participating in broad health 
research agenda setting in a well-argued way. Firstly, NAF members in 
general seem to have sufficient knowledge to formulate and prioritize 
health research topics covering the entire health research field, including 
biomedical research. The focus group discussions have indicated that 
participants were able to substantiate their perspectives on priorities. 
Secondly, NAF members appeared to be able to think in biomedical, long-
term targets and in favour of future generations, and did not only focus on 
individual health care and social problems. Thirdly, based on their 
experiential knowledge they were capable of introducing some new 
(biomedical) research topics that were not covered by current research 
agendas: co-morbidity, side effects of medication, and drug interaction. 
One could reasonably assume that other patients will be able to do the 
same.  
Based on this study we thus conclude that patients are capable of 
participating in health research agenda setting in a well-argued way. 
Indeed, although just as medical professionals patients have their own 
biases, they have something new to contribute to research agendas, which 
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pleads for their participation in health research agenda setting. Since 
biomedical research was part of the agenda-setting process and since 
patients proved to be able to introduce and prioritize biomedical research 
topics, we argue that patients are capable of participating in biomedical 
research agenda setting as well. 
 
 
  
6 
A SOCIAL EXPERIMENT52 
 
This chapter reports on a social experiment that aimed to implement 
and evaluate a newly developed strategy for effective patient 
participation in research agenda setting, which has been described in 
chapter 4. The experiment involved an interactive agenda-setting 
project concerning research on asthma and COPD commissioned by 
the Netherlands Asthma Foundation (NAF) and the Netherlands 
Organization of Health and Medical Research (ZonMw). In this 
project, patients were, besides scientists and health care professionals, 
involved in decision-making on an overall asthma/COPD research 
agenda. The project design consisted of the first four phases of the 
developed strategy: preparation, consultation, collaboration, and 
prioritization. Whereas the consultation of patients has been described 
in detail in the previous chapter, this chapter describes the remaining 
part of the project. The project resulted in an integrated ‘societal’ 
research agenda that reflected the priorities of all stakeholders involved 
and was meant as an input for further research policy making by the 
NAF and ZonMw. The effectiveness of the participation exercise was 
assessed on the basis of an evaluation framework. The evaluation 
results suggest that the strategy used had realized rather effective 
patient participation, with respect to the legitimacy and rationality of 
the process, the quality of the outcomes, and the achievement of mutual 
learning. Patients had been involved in a fair and direct way and they 
had visibly influenced the resulting societal research agenda. In 
addition, mutual learning between the different stakeholders had been 
achieved to some extent. 
                                                 
52  The text of this chapter is partly based on Caron-Flinterman, J.F., Broerse, J.E.W., and 
Bunders, J.F.G. (submitted). Patient participation in health research agenda setting: 
The case of asthma and COPD research in the Netherlands. Science and Public Policy. 
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The main aim of this chapter is to describe the implementation and 
evaluation of the patient participation strategy developed in chapter 4 in a 
concrete practical situation. The implementation of the strategy took place 
within the framework of a recent project that concerned the participation 
of patients in agenda setting of asthma/COPD research in the 
Netherlands. This agenda setting concerned the entire breadth of health 
research and was not restricted to biomedical research. However, since 
biomedical research was explicitly part of the agenda-setting process, we 
considered the project an appropriate case for testing our strategy. We 
start this chapter with a description of the participation initiative and its 
outcomes. In order to be able to evaluate this initiative in terms of 
effectiveness, we formulate a framework based on the objectives of patient 
participation as defined in section 1.2.2. We subsequently present the 
evaluation results and close with some concluding and reflective remarks 
and some suggestions for the improvement of patient participation 
strategies. 
 
6.1 The interactive research agenda-setting project53 
 
As has been mentioned before, the interactive54 research agenda-setting 
project was commissioned by the Netherlands Asthma Foundation (NAF) 
and co-financed by the Netherlands Organization for Health Research and 
Development (ZonMw). The NAF is both a research-funding agency and 
a patients’ organization focusing on asthma and Chronic Obstructive 
Pulmonary Disease (COPD). At the moment, it funds different types of 
                                                 
53  The text of this section is based on: Teerling, J., Caron-Flinterman, J.F., and Broerse, 
J.E.W. (2004). Programmering wetenschappelijk onderzoek astma en COPD 2005-
2008: De maatschappelijke agenda. Amsterdam: Instituut voor Innovatie en 
Transdisciplinair Onderzoek, Vrije Universiteit Amsterdam. 
54  In literature one often uses the terms ‘participative’ or ‘participatory’ instead of 
‘interactive’ when describing comparable strategies or initiatives (e.g. Andersen and 
Jaeger, 1999; Black and Gergersen, 1997; Cornwall and Jewkes, 1995; Gray et al., 
2000). In this project, we use the term ‘interactive’ in order to stress that in our 
initiative patients not only participated in the process (which could imply different 
degrees of participation) but actually interacted with other participants in a sphere of 
true partnership and knowledge integration (cf. Tress et al., 2003).  
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health research within the context of two policy programmes (see box 5.1). 
The Experimental and Descriptive Research (EBO) programme focuses 
on knowledge production concerning the causes and mechanisms of 
asthma and COPD, with the long-term aim of innovatively contributing to 
optimal prevention and therapy (Astma Fonds, 2000a). The Care and 
Prevention (Z&P) programme commissions only applied research focusing 
on the direct advancement of prevention and health care quality for 
asthma/COPD patients (Astma Fonds, 2000b). ZonMw, the national 
medical research council in the Netherlands, also funds some applied 
research on asthma or COPD within their Health Promotion and Disease 
Prevention Programme.55 
Until recently, the NAF had used an expert-led approach to 
research programming, inviting leading scientists and health professionals 
to advice on research priorities through series of discussion and 
prioritization meetings. At the end of 2002, the NAF decided to involve 
patients in decision-making on overall health research agendas for the 
period 2005-2008. Since ZonMw also funds research on asthma/COPD, 
the NAF sought co-operation with ZonMw in order to assess possibilities 
for collaboration and mutual gearing of research policies and programmes.  
Because of our previous experiences in developing and 
implementing participatory strategies, the NAF consulted our Institute56 
for the purpose of realizing patient participation in research agenda setting. 
As a result, in February 2003 we started an interactive research agenda-
setting process. This process comprised the implementation of the first 
four phases of the phased transdisciplinary participation strategy that was 
developed in chapter 4. The strength of this strategy lies in the structured 
way in which consultation and collaboration methods are combined and in 
the explicit focus on the stimulation of knowledge integration. The design 
of the different phases and the (intermediary) results are described in more 
detail below. 
6.1.1  Preparation and initiation phase 
From February to July 2003, we conducted some preliminary research on 
the current situation of asthma/COPD research in the Netherlands. By 
means of fourteen semi-structured interviews with relevant actors in the 
                                                 
55  www.zonmw.nl 
56  the Athena Institute for Research on Innovation and Communication in Health and 
Life Sciences, Faculty of Earth and Life Sciences, Vrije Universiteit Amsterdam 
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field (researchers and representatives of funding agencies and industry) and 
additional desk studies, current decision-making patterns were investigated 
and visions of stakeholders concerning patient participation in decision-
making on research were explored. Results indicated that until then 
patients were hardly involved in decision-making processes concerning 
research on asthma or COPD. Most stakeholders interviewed considered 
patient participation in decision-making on asthma/COPD research in 
principle desirable, but at the same time identified some obstacles that 
hamper effective participation. Obstacles mentioned mainly concerned the 
incompetence and subjectivity of patients and the unwillingness of 
researchers to translate research topics and proposals into daily language. 
Identified conditions for effective patient participation in research agenda 
setting concerned the improvement of communication between patients 
and researchers, the education of patients on research items, and an 
important and facilitating role of the NAF (De Cooker and Koningstein, 
2003). 
Based on our previous findings and earlier experiences, we 
regarded none of the obstacles identified as insurmountable and 
considered an interactive stakeholder approach feasible. Subsequently, the 
NAF and ZonMw commissioned the Athena Institute to execute an 
interactive research agenda-setting project entitled ‘Interactive 
programming of asthma /COPD research: the societal agenda’. This 
project formally started July 2003 and ended June 2004. The formal part of 
the project consisted of the phases 2, 3, and 4 of the proposed strategy. 
The objectives of the project, the different stakeholders to be involved, the 
respective roles of the NAF, ZonMw, and the project team, the overall 
process structure, and the composition of the project team were defined 
and described in a project document and formal contract. The NAF and 
ZonMw jointly financed the project and a total budget of 56,000 Euros 
was made available. 
The main, substantive objective of the project was the construction 
of a ‘societal’ agenda for research on asthma or COPD that reflected the 
perspectives of the three main stakeholders of this research – patients, 
scientists, and health professionals. Another, more normative-based 
objective for the NAF and ZonMw was the enhancement of the legitimacy 
(and thus the social support) of the agenda-setting process and of 
subsequent research policy. An additional scientific objective for us was to 
realize and investigate mutual learning and knowledge building. This could 
result in an increased insight in knowledge integration processes, which 
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may contribute to knowledge production on, and the further optimization 
of, stakeholder participation processes.  
The design, management and execution of the agenda-setting 
project were predominantly the responsibility of the project team. This 
team consisted of (1) four staff members of the Athena Institute (including 
the author of this dissertation), who were responsible for the design, 
execution, and analysis of the interactive process, (2) three MSc students 
who assisted in the project as trainees, and (3) six MSc students who were 
involved in the organization and execution of the focus groups with 
patients (as part of a course on interactive research methodologies). The 
roles of the NAF involved the funding of the project, reflection on various 
aspects of the process design, and the facilitation of both the recruitment 
of adequate stakeholder representatives and the distribution of invitations, 
information, and the questionnaire. In addition, one of the NAF managers 
investigated the current status of scientific research concerning asthma or 
COPD. The roles of ZonMw remained restricted to funding and some 
reflection on process design.  
6.1.2  Consultation phase 
During the period September 2003 until March 2004, the three stakeholder 
groups (patients, scientists, and health professionals) to be involved in the 
interactive research agenda setting were explicitly and directly consulted on 
their priorities concerning research on asthma or COPD. Since the three 
stakeholders considerably differed with respect to their experience with 
research-agenda setting processes and their background knowledge on 
asthma/COPD research they were consulted by means of different 
consultation methods. The consultation included both inventory studies 
that aimed to explore views and perspectives of stakeholders on research 
priorities in a broad way and more in-depth studies that aimed to elaborate 
on the views and perspectives identified in order to get a more thorough 
understanding of the research priorities of the different stakeholders as 
well as of similarities and differences between these priorities.  
Throughout the process all participants received information about 
the process background, objectives, and structure, as well as on objectives 
and programmes of individual meetings or interviews. When patients were 
involved, scientific or professional terms were translated into daily 
language. All meetings were carefully chaired and facilitated by experienced 
project team members, who stimulated mutual respect and learning. In 
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addition, the meetings were recorded in minutes and on video or cassette 
for further analysis of underlying arguments, mutual interactions etc. All 
participants consented to these recordings on conditions of anonymity and 
deletion after the project. Interviews were conducted by both staff 
members and trainees. After each interview or meeting, interviewees or 
participants involved received a report with the request to provide 
comments if misinterpretation or omissions were found. In this way, 
interpretations and intermediary results could be verified. Below we 
describe the consultation of the different stakeholder groups. 
Patients 
For pragmatic reasons and in consideration with the NAF, patient 
consultation was restricted to NAF members. Since at that time the NAF 
did not have a pre-existing group of organized patients that could be 
consulted initially (during a reorganization operation in 2000 the Patient 
Advisory Board (PAR) was abolished), we turned to the broad group of 
NAF members. For the consultation of these patients57 we decided to start 
with a number of focus groups followed by a questionnaire.58 The patient 
consultation step and its results have been described in detail in chapter 5.  
Health care professionals 
Research priorities of the broad range of health care professionals 
concerned with asthma or COPD were initially explored in two discussion 
meetings with 11 members of the programme committee Care and 
Prevention (see box 5.1) of the NAF. This committee covers a wide range 
of disciplines and all members have good insight into the current state of 
affairs concerning care around asthma or COPD. The discussions had 
partly an exploratory character, focusing on identified problems 
(suboptimal situations) in health care and on priorities for improvement, 
and partly an in-depth character, focusing on mutual relationships between 
problems, causes, and arguments for priorities. All problems and causes 
were incorporated in a causal tree, which could be linked to the causal tree 
of patients’ problems (see figure 5.1). 
                                                 
57  In the remaining part of this chapter we use the term ‘patients’ to refer to the entire 
width of NAF-members, which includes partners, family members and carers of 
patients as well. 
58  This combination of the focus group and questionnaire methods has been previously 
used e.g. in consulting the public on their views and priorities concerning 
developments within the biosciences (Irwin, 2001). 
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In 13 subsequent semi-structured interviews, both with committee 
members and with additional health care professionals, this causal tree was 
further specified and supplemented. Interviewees were selected on the 
basis of their (expected) central position within a discipline, while all health 
care disciplines involved with asthma or COPD were covered. In addition, 
problems identified were translated into possible research objectives that 
were prioritized by all interviewees. From each interviewee the three 
highest priorities were included in a final list of priorities (see table 6.1).  
 
 
*   The order of the topics does not reflect any order of priorities. 
Scientists 
A preliminary inventory study by one of the research programme 
managers of the NAF had resulted in a list of knowledge gaps and research 
opportunities in scientific research on asthma or COPD. This list was used 
as an input for a discussion meeting with 16 scientists from different 
scientific disciplines, which had been selected by the programme manager 
on the basis of their central position within a discipline.59 It was attempted 
to cover all scientific disciplines involved with research on asthma or 
COPD. Although both (bio)medical and socio-cultural scientists had been 
invited, only (bio)medical scientists were able to attend the meeting. 
Several of them were members of the EBO programme committee (see 
                                                 
59  In the expectation that these scientists might be able of representing their disciplines in 
a quite adequate way since they may have good overview of current research directions 
and priorities within that disciplines. 
Table 6.1  Research priorities of health care professionals* 
- better coordination of health care 
- early diagnosis and prognosis of asthma 
- societal attention for COPD  
- better tuning between health care demand and supply 
- genetic predispositions of asthma and COPD  
- better treatment of COPD 
- patient empowerment 
- better diagnosis of COPD 
- prevention of smoking 
- introduction of case managers for asthma patients 
- roles and functions of asthma nurses 
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box 5.1) and thus were used to being involved in research agenda setting. 
During smaller group discussions these scientists were asked to mention 
and discuss priorities concerning scientific research on asthma or COPD. 
In subsequent exercises they were asked to find consensus on the highest 
priorities. They finally agreed on a list of eight (bio)medical research 
priorities, which is depicted in table 6.2. 
 
 
Table 6.2  Research priorities of (bio)medical scientists* 
- early disease markers for, and phenotyping of, asthma and COPD 
- aetiology of, and mechanisms for remission and persistence of asthma 
- longitudinal psychosocial, diagnostic, and mechanistic aspects of COPD 
- translation of in vitro results to disease-specific complex cell culture systems and in vivo 
models  
- individual treatment of asthma and COPD on the basis of phenotypes and proof of 
concept studies on long-term disease modifications 
*  The order of the topics does not reflect any order of priorities 
 
 
Since socio-cultural scientists were not present during this 
discussion meeting, this group of scientists was consulted by means of five 
semi-structured interviews. Interviewees were selected on their expected 
adequate representation (recommended by the NAF or by colleague 
scientists) of the few socio-cultural scientific research groups focusing on 
asthma or COPD. The highest research priorities of these interviewees 
were incorporated in a fourth list of research priorities (see table 6.3). 
 The consultation phase thus resulted in four lists of (possible) 
research priorities (tables 5.3, 6.1, 6.2, and 6.3), which partly overlapped. 
For example, all stakeholder groups mentioned additional research on the 
aetiology of asthma/COPD as a research priority, and also research on 
better medication for, and early diagnosis of, asthma/COPD scored high. 
Research priorities of patients that were not covered by the other 
stakeholder groups concerned research on co-morbidity, drug interaction 
and side effects, reduction of (medical) costs, and improvement of societal 
understanding and consideration.  
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Table 6.3  Research priorities of socio-cultural scientists* 
- better transitions between care and daily life 
- patient empowerment 
- aetiology of asthma and COPD (both genetic and environmental factors) 
- smoking behaviour 
- societal attention for COPD 
- early diagnosis of COPD 
- better diagnosis of asthma amongst young children 
- prevention of asthma 
- behavioural aspects of asthma and COPD 
- relations between labour circumstances and the onset, increase, or decrease of 
asthma/COPD 
- influence of psycho-social circumstances on children with asthma 
- more integral health care 
*  The order of the topics does not reflect any order of priorities 
 
6.1.3 Collaboration phase 
The aim of the collaboration phase (March and April 2004) was the 
explicit integration of the four priority lists into one shared research 
agenda by representatives of the different stakeholder groups.60 For this 
purpose it was decided to organize an integration meeting to discuss 
perspectives and priorities of different stakeholders, to accomplish mutual 
respect, understanding, and learning between the different stakeholders, to 
integrate the different research priorities into one research agenda, and to 
identify criteria for further prioritization of the research agenda.  
The integration meeting took place on 2 April 2004 in Utrecht. Of 
the 32 accepted invitations (we aimed for roughly 10 participants from 
each stakeholder group), one biomedical scientist, four health care 
professionals, and three patients were unexpectedly unable to attend the 
meeting. The 24 participants included six (bio)medical scientists, four 
                                                 
60  Since both professional stakeholder groups consulted included members of the formal 
NAF programme committees (whose advices on research programmes were usually 
taken up by the NAF management), this integration of priority lists can be considered 
as the integration of patients’ priorities with the priorities of central actors of the 
decision-making network, which corresponds to the term ‘collaboration’ as used in 
patient participation literature. 
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socio-cultural scientists, five medical specialists/clinical researchers, one 
other health care professional, and eight patients (three asthma and one 
COPD patients, two patients with both asthma and COPD, and two 
parents of young asthma patients). Scientists and health care professionals 
were selected based on the diversity of their background and on their 
indicated willingness to share decision-making with patients. Patients were 
selected from the focus group participants based on their indicated wish to 
attend an interactive meeting and on their capability to express themselves 
clearly and constructively as assessed during the focus groups. Before the 
meeting all participants received a summary of the consultation phase and 
its results by mail. Scientific or professional terms were translated into 
daily language. 
The meeting started with a plenary session in which the results of 
the consultation phase were presented and the aim of the meeting was 
specified. Then, the participants were split into three parallel, 
heterogeneous groups that discussed the four priority lists and tried to 
categorize and integrate the four lists into one integral research agenda. 
For this purpose all priorities were described on coloured post-its (the 
used colours depended on the stakeholders that had selected the priorities) 
that could be categorized and re-categorized on flip charts until consensus 
was achieved. After that the participants were individually asked to define 
criteria that could be used for further prioritization of this research agenda. 
Criteria were gathered on flipcharts and discussed and categorized as well. 
In a plenary session the integrated and categorized lists of research topics 
and the lists of criteria from the different groups were presented and 
discussed. Since the lists showed much similarity, they could be combined 
rather simply into one integrated ‘societal’ research agenda (see table 6.4), 
and one list of prioritization criteria (see table 6.5).  
 
 
Table 6.4  The ‘societal’ agenda concerning research on asthma or COPD. 
Themes and research targets Priority* 
Insight in causes and mechanisms of asthma and COPD 
- research on genetic factors causing asthma 
- research on genetic factors causing COPD 
- research on environmental factors and lifestyles that influence the onset of asthma 
- research on environmental factors and lifestyles that influence the onset of COPD 
- research on causes and mechanisms of increase or decrease of asthma symptoms 
 
P 
P 
P 
P 
P 
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- research on the course and mechanisms of COPD during life 
- research on possibilities for translating results of molecular and cellular research to 
disease related complex cell culture systems and animal models 
P 
 
Insight in causes and mechanisms of co-morbidities 
- research on relations between asthma and other diseases 
- research on relations between COPD and other diseases 
 
 
P 
Improvement of prevention of asthma/COPD 
- research on smoking behaviour and on interventions that influence starting and 
stopping with smoking 
- research on interventions that prevent the onset of asthma 
- research on interventions that prevent the onset of COPD 
 
P 
 
P 
P 
Improvement of diagnostics for asthma/COPD 
- research on the earliest stages of asthma and on methods to detect these stages 
- research on the earliest stages of COPD and on methods to detect these stages 
- research on improving the diagnosis of asthma based on individual disease 
characteristics 
- research on improving the diagnosis of COPD based on individual disease 
characteristics 
- research on diagnostic aspects of COPD during different stages of the disease 
 
P 
P 
 
 
Improvement of treatment of asthma/COPD 
- research on improving the treatment of asthma based on individual disease 
characteristics 
- research on improving the treatment of COPD based on individual disease 
characteristics 
- research on new, more effective therapies for asthma 
- research on new, more effective therapies for COPD 
- research on side-effects of asthma/COPD medication 
- research on the interaction between asthma/COPD drugs and other drugs 
 
P 
 
P 
 
Improvement of care organization  
- research on possibilities for better tuning of care processes to the daily life of the 
patient 
- research on possibilities for better streamlining of health care for the patient 
- research on possibilities for better gearing of care demand and supply 
- research on improving care for COPD patients during the latest stages of the 
disease 
 
 
 
Improvement of patient empowerment 
- research on factors that improve the empowerment of the patient towards 
emancipated care user 
 
 
Improvement of accessibility of care 
- research on the desirability of, and possibilities for, reducing health insurance 
contributions 
- research on the desirability of, and possibilities for, increasing financial 
compensation for medication and aids 
- research on cost-effectiveness of therapies and aids 
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Improvement of interaction between asthma/COPD patients and their 
environment 
- research on the influence of (psycho-)social circumstances on children with asthma 
- research on the interaction between asthma/COPD patients and their closest 
environment and on possibilities to improve this interaction 
- research on the relation between labour circumstances and the onset, increase, or 
decrease of asthma 
- research on the relation between labour circumstances and the onset, increase, or 
decrease of COPD 
- research on the desirability of, and possibilities for, adaptation of legislation 
concerning smoking, ventilation, etc. in public spaces and at working places 
- research on possibilities to improve the familiarity of, and attention for, COPD at 
the public and the government 
 
 
P 
 
 
 
 
 
 
 
 
 
 
Insight in personal impacts of asthma/COPD 
- research on psychosocial aspects of COPD related to the course of the disease 
during life 
- research on psychosocial aspects of asthma 
- research on (reduction of) fear for hypersensitivity or physical complaints among 
asthma/COPD patients 
 
 
 
 
 
 
*  P = belongs to the 15 highest prioritized research topics 
 
 
Table 6.5  Priority setting criteria 
 
Criteria with respect to the purposefulness of the research 
- the research addresses a relevant knowledge gap in health care or research 
- the research addresses an important problem for patients or care professionals 
- the research addresses a core problem that causes many other problems 
- the problem addressed is considered urgent and requires instantaneous action 
- the problem addressed concerns a big population 
- the research addresses a problem that costs a lot of money and attention 
- the research addresses a cost saving 
 
Criteria with respect to the efficiency of the research 
- the research could result in a large theoretical spin-off 
- the research results could have a direct impact on patient’s quality of life 
- the research seems to provide short term results 
- the research builds on existing knowledge 
- the expected results are favourable related to the expected investments 
- the research is feasible with current research methods and tools 
- the problem can be addressed by different types of research 
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6.1.4 Prioritization phase 
A final exercise in the project aimed to identify priority research topics 
within the agenda. In order to prevent bias (pseudo consensus) in the 
prioritization process, due to group dynamics and power or status 
differences, selected participants were asked to prioritize the research 
agenda individually. For this purpose we used a ‘prioritization matrix’. In 
the matrix, vertically the overall health research agenda with its research 
topics was listed while horizontally respondents were asked to rate the 
different research topics of the agenda by giving marks and to indicate in 
the matrix which criteria determined their priority setting. The 
prioritization matrix was sent to all earlier consulted scientists and 
professionals (39) and all patients who had indicated before to be willing 
to participate in dialogues with professionals (23). Eight (bio)medical 
scientists, six socio-cultural scientists, six medical specialists/researchers, 
six other health care professionals, and fifteen patients (eight asthma 
patients, three COPD patients, two patients with both asthma and COPD, 
and two parents of asthma patients) returned a filled in matrix (66% 
response).  
Final results were achieved by collecting the priorities of the 
different participants (the research topics that they had given the three 
highest marks). The frequencies with which research topics had been 
prioritized by individual participants determined the overall priorities of 
the topics. The total scores (added marks) of research topics were used to 
discriminate priorities of topics with similar frequencies of prioritization. 
The highest prioritized research topics were investigated in terms of the 
different criteria ascribed to. The fifteen highest prioritized research topics 
are indicated in the right hand column in table 6.4. These topics concern 
research that focuses on causes and mechanisms, prevention, diagnosis, 
and treatment of asthma or COPD, except one topic that comprises 
research on the influence of psycho-social circumstances on children with 
asthma. The three highest priorities of the different stakeholders during 
this priority setting exercise are presented in table 6.6. 
The three stakeholder groups used the selected criteria for further 
priority setting of research topics in a more or less similar way, although 
patients in general did ascribe fewer criteria to the different research topics 
than professionals. Nearly all research topics of the research agenda were 
indicated to meet the criteria ‘addresses a relevant knowledge gap’ and 
‘concerns a big population’. In addition, the twelve highest prioritized 
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Table 6.6  Priorities of different stakeholders during final priority setting 
Patients 
- research on environmental factors and lifestyles that influence the onset of asthma 
- research on the relation between labour circumstances and the onset, increase, or decrease 
of asthma 
- research on causes and mechanisms of increase or decrease of asthma symptoms 
(Bio)medical scientists 
- research on the earliest stages of COPD and on methods to detect these stages 
- research on smoking behaviour and on interventions that influence starting and stopping 
with smoking 
- research on interventions that prevent the onset of COPD 
Socio-cultural scientists 
- research on psychosocial aspects of COPD related to the course of the disease during life 
- research on psychosocial aspects of asthma 
- research on environmental factors and lifestyles that influence the onset of asthma 
Medical specialists/researchers 
- research on smoking behaviour and on interventions that influence starting and stopping 
with smoking 
- research on causes and mechanisms of increase or decrease of asthma symptoms 
- research on the earliest stages of COPD and on methods to detect these stages 
Other health care professionals 
- research on environmental factors and lifestyles that influence the onset of COPD 
- research on smoking behaviour and on interventions that influence starting and stopping 
with smoking 
- research on the earliest stages of COPD and on methods to detect these stages 
 
 
topics scored high on ‘might result in a large theoretical spin-off’, ‘builds 
on existing knowledge’, ‘addresses a core problem that causes many other 
problems’, and ‘can be addressed by different types of research’. Two 
criteria that patients ticked more frequently than the other stakeholders 
were ‘the results may have a direct impact on patient’s quality of life’ and 
‘addresses an important problem for patients or care professionals’. 
The project activities and results were published in a report 
(Teerling et al., 2004; in Dutch) and presented during two meetings of the 
NAF: the yearly general meeting in June 2004, attended by NAF-members 
and – staff members, and an invitational conference on NAF’s future 
policy in September 2004, attended by a range of different stakeholders 
that have a stake or interest in this policy. The resulting societal research 
agenda is currently used as guideline for the formulation of research 
policies and programmes of both the NAF and ZonMw, which will 
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eventually result in the actual funding of research projects as well as in 
possible lobbying activities towards pharmaceutical industry, government, 
or other actors. This specification and implementation (phases 5 and 6 of 
the proposed strategy) are in the hands of the management of both NAF 
and ZonMw and were not included in the project.  
 
6.2 An evaluation framework 
 
But to what extent has the participation strategy followed resulted in an 
effective participation process? Many scholars have formulated evaluation 
criteria for effective stakeholder or public participation in decision-making. 
They have based their frameworks on the views of participants (e.g. 
Bickerstaff and Walker, 2001; Carnes et al., 1998; Morrissey, 2000; Telford 
et al., 2004) or on implicitly or explicitly adopted definitions of effective 
participation. As has been argued in section 2.3, these definitions refer to 
objectives of participation, which can concern the participation process 
itself as well as its outcomes. As a consequence, evaluation frameworks 
focus on the participation process (e.g. Fiorino, 1990; Halvorsen, 2003; 
Laird, 1993), on its outcomes (e.g. Beierle and Konisky, 2000; Guston, 
1997; 1999; Irvin and Stansbury, 2004), or on both (e.g. Abelson et al., 
2003; Driessen et al., 2001; Rowe and Frewer, 2000; Webler, 1995; Webler 
and Tuler, 2000).  
 In line with the suggestions of Rowe and Frewer (2004), we 
formulate a suitable framework for the systematic evaluation of our 
participation strategy, starting with defining ‘effectiveness’ of patient 
participation on the basis of its objectives. In section 1.2.2 we elaborated 
on the different objectives of patient participation in decision-making on 
biomedical research. Within the context of patient participation in 
asthma/COPD research agenda-setting, important objectives are the 
legitimacy and rationality of the agenda-setting process and the quality of 
the resulting research agenda. These objectives had been more or less 
adopted by the NAF and ZonMw as well. The ‘quality’ of the research 
agenda was defined as its usefulness and adequate reflection of the 
perspectives of the three main stakeholders of asthma/COPD research. 
The social acceptance of the resulting agenda is not a very obvious 
objective of this specific agenda-setting process, because of its non-
controversial and non-public character. Besides, the acceptance of the 
agenda by NAF-members, NAF-supporters, researchers, and other 
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relevant stakeholders will mainly depend on both the legitimacy of the 
process and the quality of the outcomes. Therefore we left this aspect out 
of our evaluation framework. Increases in human and social capital were 
neither included in our framework since these both concern long-term 
outcomes that are very difficult to measure shortly after the exercise and 
depend on more factors than the participation strategy followed. Instead, 
we included the extent of mutual learning as an objective, since this is a 
precondition for increases in both human and social capital. In addition, a 
closer investigation of mutual learning could result in an increased insight 
in knowledge integration processes, which may contribute to knowledge 
production on, and the further optimization of, stakeholder participation 
processes.  
Based on these objectives, we thus consider patient participation in 
research agenda setting effective when procedures followed are legitimate 
and rational, when the resulting research agenda is useful and adequately 
reflects the perspectives of patients, and when mutual learning between 
patients and professionals has been accomplished. Consequently, our 
evaluation framework should consist of both process and outcome criteria 
that focus on the achievement of these objectives.  
Concerning the existing frameworks that focus on both the 
process and its outcomes, we found none of them sufficiently adequate for 
evaluating our participation strategy in a conclusive manner. Criteria 
mentioned are not sufficiently detailed (Driessen et al., 2001) or 
discriminating (Abelson et al., 2003), do not sufficiently reflect our 
definition and objectives of participation, and/or do not entirely apply to 
our context of patient participation in research agenda setting (Irvin and 
Stansbury, 2004; Rowe and Frewer, 2000; Webler and Tuler, 2000). We 
therefore borrow criteria from all these frameworks in order to formulate a 
new and more adequate evaluation framework below.  
6.2.1 Process criteria 
Process criteria for effective patient participation in research agenda setting 
need to reflect the agenda-setting legitimacy and rationality. Agenda-setting 
legitimacy can be achieved by involving patients in a representative and fair 
way, both in preliminary discussions on alternatives and criteria, and in 
final decision-making processes. In this way the process gives judgment to 
normative values underlying patient participation. Agenda-setting 
rationality can be achieved by ensuring that patients’ values, experiences, 
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and knowledge are included in discussions and decision-making processes. 
Key elements of the process to be evaluated are the stakeholder 
representation in the process, the process structure, and the process 
management.  
– Stakeholder representation: In order to achieve legitimacy, equal 
numbers of representatives from all key stakeholder groups should 
participate in decision-making steps of the process. Concerning 
patients, numbers of representatives should be higher rather than 
lower than the numbers of professional participants (Laird, 1993). 
In this way power imbalances due to unequal attendances are 
avoided. In addition, participants should adequately represent the 
different stakeholder communities (Abelson et al., 2003; Rowe and 
Frewer, 2000; Webler and Tuler, 2000). This implies the 
involvement of balanced representations of the demographic 
characteristics of the relevant patient community and of the 
spectrum of relevant professional disciplines. 
– Process structure: An effective participation process needs to be 
clearly and transparently structured (Rowe and Frewer, 2000). All 
participants need to know and understand which process 
objectives and roles of actors are involved, which steps the process 
consists of, how information is (or has been) gathered and 
processed, how decisions are (or have been) made, etc. (Rowe and 
Frewer, 2000; Webler and Tuler, 2000). In addition, both process 
structure and procedures used should ensure that patients are 
directly consulted for their views, priorities, needs, etc. as early as 
possible in the process (Abelson et al., 2003; Rowe and Frewer, 
2000; Webler and Tuler, 2000). Moreover, in order to ensure the 
rationality of the agenda-setting process, procedures used need to 
ensure that patients are directly involved in on-going discussions 
and decision-making steps, and that their input is explicitly 
incorporated in the outcome (Driessen et al., 2001; Fiorino, 1990; 
Laird, 1993; Webler and Tuler, 2000).  
– Process management: In order to ensure agenda-setting legitimacy, 
process managers and facilitators should be independent from 
parties involved and indifferent with respect to the outcomes of 
the process (Rowe and Frewer, 2000). Throughout the process, 
participants need to be and feel treated equally by the process 
management and have equal access to information and other 
resources such as payment of expenses (Abelson et al., 2003; 
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Fiorino, 1990; Laird, 1993; Rowe and Frewer, 2000; Webler and 
Tuler, 2000). In addition, during the various meetings, the process 
management should strive for an open, and respectful atmosphere 
that stimulates constructive interaction and mutual learning 
between participants (Abelson et al., 2003; Driessen et al., 2001; 
Fiorino, 1990; Halvorsen, 2003; Laird, 1993; Webler and Tuler, 
2000).  
6.2.2 Outcome criteria 
Criteria concerning the outcomes of the interactive health research agenda 
setting process need to evaluate both direct and indirect outcomes. Direct 
process outcomes concern resulting research agendas and other relevant 
decisions. The indirect outcome to be evaluated here concerns the 
achievement of mutual learning between participants. 
– Direct outcomes: The resulting research agenda should be based on 
consensus among participants (Abelson et al., 2003). In addition, it 
should reflect the inputs and perspectives of patients as well as of 
other stakeholders involved (Beierle and Konisky, 2000; Driessen 
et al., 2001; Irvin and Stansbury, 2004). All participants should 
recognize their own perspectives in the outcome. Furthermore, the 
research agenda needs to be reasonable and well translatable into 
future policy or actions. If necessary, participants should be able to 
explain and substantiate outcomes (Abelson et al., 2003). 
– Indirect outcomes: An indirect outcome that characterizes the 
effectiveness of our patient participation initiative is mutual 
learning resulting in changes in thinking of participants. This 
implies the learning of both patients and professionals in a 
substantive way (concerning substantial matters), in a procedural 
way (concerning participation procedures and methods), or in a 
reflexive way (concerning their own and each others knowledge, 
perspectives, roles, etc.) (Guston, 1999; Irvin and Stansbury, 2004). 
The occurrence of this kind of knowledge sharing between 
participants might facilitate future participation processes.  
In table 6.7 the evaluation criteria of our framework are summarized. 
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Table 6.7  Evaluation criteria for effective patient participation in health research 
agenda setting 
Process criteria Stakeholder representation adequate and equal representation of stakeholders  
 Process structure transparency of objectives, roles and structure 
  early & direct involvement of patients 
  explicit incorporation of patients’ inputs in discussions and decisions 
 Process management independent and unbiased management 
  equal treatment of participants 
  facilitation of mutual respect, openness, and constructive interaction 
Outcome criteria Direct process outcomes consensus on resulting research agenda  
  reflection of patients’ perspectives in research agenda 
  practicality of resulting research agenda 
 Indirect outcomes achieved (mutual) learning on substantive matters 
  achieved learning on procedural matters  
  achieved (mutual) learning on reflective matters 
 
6.3 Evaluation of the project 
 
The project was evaluated in terms of effectiveness based on the 
evaluation framework described above. Data concerning the evaluation of 
the effectiveness of patient participation within the project had been 
collected by means of a triangulated approach, involving documentary data 
analysis, video and cassette tape analysis, (direct) observation, and semi-
structured interviews, which were held within three months after the 
integration meeting. Meeting scenarios, minutes, and reports provided 
initial information on the adequacy of the overall process structure and the 
procedures used. Analysis of feedback reports and evaluation forms 
provided additional information on participants’ opinions concerning the 
adequacy of the procedures used, the analysis of results, etc. Comparison 
of the various reports provided insight in the actual influence of the 
different stakeholders on the resulting research agenda.  
Observation and tape analysis were used to investigate additional 
aspects of the process more thoroughly, such as the equality among, and 
interaction between, participants and their actual inputs in discussions. 
Although observation holds the danger of leading to subjective and biased 
results, it also offers important research opportunities that might be 
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missed when restricting to more objective and retrospective evaluation 
methods only. Semi-structured interviews with all participants who had 
been involved in the integration meeting (and thus in the entire agenda-
setting process) were used to investigate visions of participants on both the 
process and its outcomes more thoroughly. Interviews with two NAF 
managers, finally, provided amongst others information on the practicality 
of the outcomes. All interviews were held in the period April to June 2004. 
Interview reports were returned to the interviewees for feedback.  
Different members of our project team were involved in different 
parts of the evaluation process. Three project team members (including 
the author of this dissertation) were responsible for the design of the 
overall evaluation process, and were involved in both documentary data 
analysis and observation. The three MSc trainees, who had assisted in the 
execution of the participation project but had not been involved in process 
design and management, conducted the evaluative interviews. The 
triangulation of both methods and investigators enhanced the validity of 
the results. Below we describe the findings of the evaluation process. We 
start with evaluating the process itself, followed by an evaluation of the 
process outcomes. When possible and relevant we have illustrated our 
findings with citations from the interviews.61 
6.3.1 Evaluation of the process 
Adequate representation of stakeholders 
Three stakeholder groups participated in the agenda-setting process: 
patients, health care professionals, and scientists. During the consultation 
phase, respectively thirteen biomedical scientists, six socio-cultural 
scientists, eight medical specialists/researchers, and twelve health care 
professionals were involved, representing the main disciplines involved in 
asthma or COPD research or care. In addition, more than 300 patients, 
that together reflect the demographic and disease-related characteristics of 
the entire NAF member community as well as the Dutch population of 
asthma/COPD patients in general, were consulted. In this way we 
achieved an adequate representation of Dutch asthma/COPD patients. 
We thus can conclude that during the consultation phase an adequate 
representation of stakeholders had been achieved. 
                                                 
61 The original citations were in Dutch and have been translated by the author. 
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During the integration meeting we had intended to have equal 
numbers of patients, health care professionals and scientists. However, 
because of late excuses in particularly the group of patients and health 
professionals we did not succeed in this respect. This also implied that 
some professional disciplines were missing (a General Practitioner, a 
physiotherapist, a child psychologist, an asthma nurse, and a 
pharmacologist) and that the number of COPD patients was relatively low. 
Several interviewees specifically mentioned these shortcomings in 
representation: 
“My group mainly consisted of scientists and health care 
professionals/researchers. To my opinion more pure health care 
professionals could have been present. I think it was a fair process, but 
the balance in representation was somewhat distorted. More 
stakeholders should have been involved, such as asthma nurses, social 
workers, etc.” (a social scientist) 
“I think more people from the sociological field should have been 
present.” (a medical specialist/researcher) 
“I think there were more biomedical scientists present. However, I do 
not think outcomes would be different when stakeholder 
representation was more balanced because all perspectives and views 
have been discussed.” (a biomedical scientist) 
In addition, interviewees mentioned that the number of patient 
participants was rather low in comparison with the total number of ‘expert’ 
participants. Another comment with reference to the patient participants 
in the collaboration phase concerned their rather high levels of education 
and professionalism, which were not considered representative for the 
average asthma or COPD patient. However, at the same time many 
interviewees indicated that these higher levels are necessary when patients 
are to be ‘worthy’ discussion partners of professionals.  
“I think you need good patient representatives. They need to be 
capable of holding their own during a discussion [with professionals].” 
(a COPD patient) 
“Patients who participate should have some knowledge of asthma, for 
example by reading information provided by the Asthma Foundation 
and by being member of the Asthma Foundation. They should have 
been ill for a number of years so that they can look beyond their own 
problems. In that case patient participation [in research agenda setting] 
could be useful for the Asthma Foundation.” (a biomedical scientist) 
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During the final prioritization of this agenda the numbers of 
representatives from the three stakeholder groups differed as well, because 
of the non-response by several people approached.  
Transparency of objectives, roles and structure 
The objectives of the project as well as the respective roles of the NAF, 
the project team, and the different stakeholders to be involved, had been 
defined at the start of the process and were laid down in the initial project 
document and contract. Throughout the process all participants received 
information concerning the background, objectives, and structure of both 
the process and individual meetings or interviews. In addition, a summary 
of the consultation phase and its results was presented at the start of the 
integration meeting. When patients were involved, scientific or 
professional terms were translated into daily language.  
Most interviewees mentioned that for them the process structure 
had been transparent. They indicated that the information provided was 
adequate and understandable and that objectives and roles were clear. 
Some points of criticism concerned the start of the consultation phase 
(especially for scientists and health care professionals) and the follow up of 
the project, i.e. the further specification and implementation of the 
research agenda: 
“I think at the start of the process many things were unclear. Probably 
the [NAF] office could not communicate very well what was going to 
happen. As from February 4 [the scientist consultation meeting], this 
improved and the process became transparent.” (a biomedical scientist) 
“I knew that the meetings were part of the decision-making process. It 
was explained that there would be an important consultation round. 
However, I did not read the information from the Asthma Foundation 
on this in detail. Therefore it was very useful that the process structure 
was summarized again on April 2 [the integration meeting].” (a medical 
specialist/researcher) 
“For me the entire process was quite clear and transparent. […] I only 
do not know which steps are going to be taken now.” (an asthma 
patient) 
Early and direct involvement of patients 
The consultation phase at the start of the project ensured the early and 
direct involvement of all relevant stakeholders. Also in the collaboration 
phase stakeholders were involved in a direct manner. Any interpretations 
and intermediary results were verified by sending participants reports after 
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all interviews and meetings with the request to comment on these reports. 
If necessary, results were amended. 
Explicit incorporation of patients’ inputs in discussions and decisions 
Concerning their input into discussions and decision-making processes, 
patients stated on feedback forms and during evaluation interviews that 
they felt they had contributed to discussions and agenda-setting exercises.  
“I got good opportunities during the [integration] meeting. I definitely 
did not let me be pushed aside during the exercises. But I neither got 
the impression that people wanted to do that. We could consult each 
other and express whether we did or did not agree freely.” (a COPD 
patient) 
“I could indicate what is important for me as a patient. In addition, I 
am glad that through my participation ‘the patient’ has had an input in 
the agenda setting.” (an asthma patient) 
This finding was confirmed by results from observation and tape analysis.  
A remark by a few interviewees was that in principle there had not 
been a functional need to perform the integration of the priority lists in an 
interactive manner. However, they all acknowledged the surplus value of 
an interactive process with respect to the legitimacy of outcomes. 
“It was good to do it together, but the [integration] probably would 
have resulted in the same outcome without me, or when three other 
people had been absent. However, in this way it was much fairer and 
more broadly supported. Otherwise the feeling may have arisen that 
results could have been manipulated.” (a biomedical scientist) 
In general, the adequacy of the various procedures and the process 
structure was agreed upon by most participants and interviewees. Two 
patients indicated they had preferred the organization of an additional 
patient meeting just before the integration meeting in order to get 
acquainted with each other and to be able to discuss patients’ priorities in 
preparation to the integration meeting.  
Independent and unbiased management 
The process management was in the hands of project team members who 
all were independent from both assigning bodies and the different 
stakeholders as well as unbiased with reference to asthma/COPD 
research.  
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Equality of participants 
All participants interviewed had experienced to be treated equally in both 
the consultation meetings and the integration meeting. Procedures and 
discussions were generally regarded as fair, both within the consultation 
meetings and the integration meeting.  
“Fairness was ensured by the open discussions in the subgroups. […] 
In the subgroups everybody got a chance. To my opinion there was no 
top-down steering in a certain direction. In addition, the chairman 
ensured that people did not fall back in riding their hobbyhorses. 
Besides, there was a kind of social control within the group that was on 
the alert for these things. What was plenary discussed by the chairman 
later on was broadly supported by the group.” (a biomedical scientist 
about the consultation meeting with scientists) 
“I experienced that I could freely speak and that discussions were fair. I 
felt that participants on April 2 were not opponents but partners what 
also was caused by the adequate classification in groups.” (a COPD 
patient) 
Concerning access to resources, all participants of each meeting were 
provided the same information beforehand and afterwards, as well as 
travelling expenses if requested. 
Facilitation of mutual respect, openness, and constructive interaction 
During the different meetings, atmospheres were open, respectful and 
collaborative. Participants indicated to have felt stimulated and free to 
express and explain themselves and to question each other.  
“The collaboration between participants was good and agreeable. There 
was mutual sympathy and people increasingly understood each other. 
There were different visions, but that is how it should be. I could 
express my thoughts without problems and they were listened to as 
well.” (a medical specialist/researcher about the consultation meeting) 
 “There was mutual respect and everybody listened to each others 
opinions. This certainly had a surplus value. This surplus value occurs 
because you are informed about the reasons why people have certain 
views on what is important and what is not.” (a biomedical scientist 
about the integration meeting) 
“I did not have the feeling that everybody was talking from his or her 
own interest. I have experienced the integration meeting as a very 
pleasant meeting, also due to the skilful chairing. […] I experienced 
much interest and understanding towards the patient.” (a COPD 
patient) 
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In this way constructive interaction between different stakeholders was 
facilitated. In general, the interviewees were quite satisfied about the 
management of the different meetings. 
 
Regarding the fulfilment of process criteria we thus can conclude that the 
participation implemented can be considered quite effective in terms of 
legitimacy and rationality of the process. The overall process structure 
appeared to be quite adequate for accomplishing direct, early, and fair 
involvement of patients and their inputs in discussions and decision-
making processes, while the process management seems to have been 
adequate in terms of ensuring equal treatment of participants, creating an 
open and respectful atmosphere, and facilitating constructive interaction. 
A less optimal aspect concerned the inadequacy of stakeholder 
representation during the integration meeting.  
6.3.2 Evaluation of the outcomes 
Consensus on resulting research agenda 
The main (direct) outcome of the interactive research agenda-setting 
process consists of a shared ‘societal’ agenda for asthma/COPD research, 
comprising a wide range of concrete research topics, including biomedical, 
socio-cultural, health care, and policy research topics. This agenda resulted 
from the integration of the different research priority lists of the different 
stakeholder groups. During the integration meeting consensus between the 
stakeholders on integration and categorization of research topics was easily 
achieved. Also between the three subgroups during this meeting there was 
considerable consensus.  
“The process was enjoyable because everybody was taking part in it. 
Each group had more or less the same outcomes, indicating that these 
were broadly supported.” (a biomedical scientist) 
Afterwards, all participants interviewed indicated to agree with the results 
and to recognize their own views and priorities within the research agenda.  
A second direct outcome of the project is the prioritized research 
agenda. This outcome was not based on consensus but was a combined 
result of 41 individual prioritizations. The 15 highest prioritized research 
topics concerned mainly biomedical and epidemiological research topics.  
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Reflection of patients’ perspectives in research agenda 
The societal research agenda adequately reflects the perspectives of all 
stakeholders involved. The specific contribution of patients, consisting of 
research priorities that were not mentioned by the other stakeholder 
groups during the consultation phase, is clearly traceable in the agenda.  
In the prioritized research agenda, however, patients’ actual 
influence is more difficult to trace. Although patients’ highest priority 
during the consultation phase – research on the aetiology of asthma and 
COPD – was also prioritized during the final priority setting exercise, this 
does not prove patients’ influence on the process outcomes since the same 
topic had been identified as a priority by most stakeholder groups during 
the consultation phase. Research on co-morbidity related to COPD was 
the only ‘patient-specific’ priority that was prioritized during the final 
prioritization.  
Practicality of resulting research agenda 
In general, the overall research agenda seems to be well substantiated and 
well translatable into further policy or action. All research topics included 
in the agenda had been founded on arguments provided during the 
consultation phase. In addition, both NAF managers interviewed indicated 
that they considered research agendas useful for further specification and 
implementation within their research policy, although they had expected 
different outcomes.  
“The expectation was that patients would prioritize a concrete need, 
such as improvement of health care. Instead the focus of patients was 
on biomedical research. [...] The results from the meetings with the 
different stakeholders, together with the integration of these results, are 
usable for further policy making.” (one of the programme managers of 
the NAF) 
Achieved learning on substantive, procedural and reflective matters 
Concerning the indirect outcomes, both interviews and final prioritization 
results indicated that knowledge sharing had occurred. Several interviewees 
indicated to have learned something throughout the process. At a 
substantive level, some scientists and health care professionals stated to 
have learned about each others disciplines, both during the consultation 
phase and the collaboration phase.  
“I learned that hereditary aspects can be influenced from generation to 
generation. For example, the behaviour of the mother during 
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pregnancy can influence the course of the disease. Most other research 
topics were rather familiar to me.” (a health care professional) 
“I think the integration meeting was very informative and special. Prior 
to the meeting my perspective on biomedical science was rather 
limited. During the meeting I learned more about the types of research 
that are funded by the NAF.” (a social scientist) 
Patients indicated to have learned about disease and health care related 
matters from fellow patients as well as about professional matters from 
scientists and health care professionals.  
“Because within the meeting there was room to hear from other 
participants, I learned from the other patients. I have gained more 
insight in patients’ perceptions of their environment as well as more in-
depth knowledge about the disease.” (a young asthma patient) 
“I noticed that scientists have strong views concerning research priority 
setting. This has strengthened my view on the importance of basic 
research.” (a parent of an asthma patient)  
At a procedural level, several participants (both patients and 
professionals) indicated to have learned something about interactive 
methods and processes, and their possible value. 
“A procedure as has taken place is interesting and I certainly have 
learned from it. The process of funnelling to a whole with different 
stakeholders with as much objectivity and as less directivity as possible 
is also a learning experience.” (a medical specialist/researcher)  
“I learned a lot from the process. In particular that there was coherence 
between all activities that facilitates the alignment of all opinions and 
the eventual formulation of one list with priorities.” (a COPD patient) 
At a reflexive level, finally, almost half of the participants stated to 
have learned about their own and each others perspectives and priorities.  
“I learned that we [the scientists] do not always speak the same 
language. What is clear to me is not necessarily at the same time clear to 
someone else. How I think the world works is not necessarily the 
truth.” (a biomedical scientist about the consultation meeting for 
scientists) 
“One mainly learns to speak each others language and to know each 
others motives. In addition, one learns to know each others 
hobbyhorses, as well as one’s own.” (a biomedical scientist about the 
integration meeting)  
For example, some experts mentioned to have learned that patients are 
capable of thinking beyond individual problems and in (biomedical) long-
term targets.  
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“I learned about the visions of the patient group, namely that patients 
think about long-term solutions and not only about solutions for the 
short term.” (a social scientist) 
“It was remarkable and good that patients had the insight that 
fundamental research is important as well. However, it was 
disappointing to me that aspects of health care were less present in 
both the patients’ list and the list of health care professionals.” (a health 
care professional) 
“The priority lists comprised several surprising aspects. An important 
aspect within the list of patient priorities was [the focus on] research on 
mechanisms of asthma and COPD. Although this was surprising, it is 
logical that patients regard this topic as important; the clarification of 
mechanisms of asthma and COPD could lead to better therapies and 
interventions. I also learned that patients judged co-morbidity an 
important topic. I have never before considered doing research on co-
morbidity.” (a biomedical scientist)   
Other participants stated to be surprised about the consensus on 
various priorities between the different stakeholders. Also the NAF 
managers involved indicated to be surprised about patients’ focus on 
biomedical research and about the consensus on priorities between the 
different stakeholders. 
“It was instructive to see that there was so much overlap between the 
priorities of the different groups. It was good to see this overlap and to 
notice that the components of the different lists mutually corresponded 
and that only the angles of the different groups differed.” (a social 
scientist) 
The occurrence of changes in thinking became also evident by the 
fact that there were some shifts in priority setting by stakeholders after the 
integration meeting. For example, while research on co-morbidity was not 
prioritized by health care professionals in the consultation phase, some 
professionals did prioritize this topic during the final priority setting in the 
collaboration phase (data not shown). As another example, research on 
smoking behaviour was not mentioned by biomedical scientists in the 
consultation phase but was prioritized as second highest by this 
stakeholder group in the collaboration phase (compare tables 6.2 and 6.6). 
Within this framework one biomedical scientist interviewed remarked that 
he noticed opinions about priorities growing closer to each other during 
the process: 
“I think the achieved outcome is a synthesis of all interests. During the 
process opinions have converged and have been adjusted along the 
way. I think this is indicative for the adequacy of the process outcome.” 
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Also one of the patients involved explicitly mentioned his change of view: 
“I think I have filled in the matrix in a different way than I would have 
done without having attended the integration meeting. Through the 
meeting I underwent a learning process that also has changed my way 
of filling in the matrix.” (a parent of an asthma patient) 
There thus had been some implicit and explicit mutual learning between 
the several participants involved.  
 
With respect to the process outcome and the extent of knowledge sharing 
we thus can conclude that our participation exercise seems rather effective 
as well. Patients, just as the professional participants, have clearly 
contributed to the main process outcome: the societal asthma/COPD 
health research agenda. However, with respect to the further prioritization 
of this agenda, patients’ influence on the outcome was less clearly 
traceable. Finally, the achievement of some knowledge sharing suggests 
that objectives of increase in social capital and human capital may be 
achieved as well. 
  
6.4 Discussion 
 
The results of our evaluation indicate that the proposed strategy for 
patient participation in research agenda setting realizing can be regarded as 
appropriate for realizing effective participation in terms of achieving its 
main objectives. However, the participation exercise realized showed some 
suboptimal aspects as well. One suboptimal aspect was the under-
representation of some stakeholder groups during the last two phases, as a 
result of late excuses and non-response. However, we can state that this 
suboptimal stakeholder representation did not affect the legitimacy of the 
overall process nor the quality of the outcome. The overall representation 
of the different stakeholders during the consultation phase was adequate 
and all consultation results were incorporated unchanged into the end 
result.  
Another suboptimal aspect of the participation exercise concerns 
the limited reflection of patients’ original perspectives in the final 
prioritized research agenda. This aspect reflects a more serious problem. 
Patients’ highest priorities during the final priority setting exercise (see 
table 6.6) deviated from the priorities of patients as indicated in the 
questionnaire (table 5.3). In the final prioritization patients hardly 
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prioritized research on co-morbidity or on drug interaction (polypharmacy) 
or side effects, which were high priorities of patients during the 
consultation phase. Only co-morbidity related to COPD was prioritized by 
some patients and finally included in the prioritized agenda.  
Several explanations can be given for this change in patients’ 
priorities. Firstly, the 15 patients participating in the final priority setting 
may not be representative for the entire patient community that had been 
consulted before, although the stratified analysis of the questionnaire 
indicated that neither demographic nor disease characteristics significantly 
influenced research priorities. Possibly, a higher level of proto-
professionalism has resulted in different research priorities, for example 
through the loss of original perspectives. Secondly, research on the 
aetiology of asthma and COPD involved one topic within patients’ 
questionnaire but covered five topics that patients could prioritize in the 
final priority setting exercise. Patients’ prioritization of aetiological research 
topics may have pushed aside other priorities. Thirdly, patients’ priorities 
may have changed after ‘learning’ from the professional participants. 
Patients (implicitly) might have adopted research priorities from 
professionals or changed their own views concerning research priorities. 
For example, during the integration meeting some professionals stressed 
(although not agreed by all professionals!) that research on medication is 
the territory of the pharmaceutical industry and should not be included in 
a research agenda for the NAF and ZonMw. Likewise, topics related to the 
reduction of costs were considered policy topics rather than research 
topics by most professionals. Possibly patients have internalized opinions 
like these and have changed their own priorities. One of the patients 
involved explicitly mentioned this change of view: 
“I think I have filled in the matrix in a different way than I would have 
done without having attended the integration meeting. Through the 
meeting I underwent a learning process that also has changed my way 
of filling in the matrix.” (a parent of an asthma patient) 
 It is here that we face two additional complications. Firstly, 
changes of thinking among patients could be caused by mutual learning as 
well as by the overruling of patients by professionals. Distinguishing 
mutual learning from overruling in this kind of processes is very difficult, 
if possible. Moreover, even careful guiding of interactive processes by 
experienced process managers may not prevent some overruling of ‘lay 
people’ by experts. Secondly, mutual learning may facilitate (future) 
participation and integration processes but may also result in a loss of 
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original perspectives. As we have argued previously, the loss of original 
perspectives implies the loss of possibly valuable patients’ experiential 
knowledge (Caron-Flinterman et al., 2005) that could contribute to the 
quality of decision-making. At the same time it seriously complicates the 
assessment of the integration of patients’ perspectives in final decisions, 
which is one of our criteria for effective participation. This dilemma calls 
for further research. 
Finally, we want to reflect on an additional criterion that was 
excluded from our evaluation framework: the actual impact of the 
participatory results on further policy and action. This criterion is 
considered very important by several scholars dealing with public or 
stakeholder participation (e.g. Guston, 1999; Rowe and Frewer, 2000). In 
addition, several participants that were interviewed in our evaluation study 
indicated that they wanted to postpone their overall opinion on the 
effectiveness of the agenda-setting process until the actual impact of the 
agenda on eventual research programmes would be clear. Indeed, if the 
resulting research agenda is actually translated into concrete research 
programmes by the NAF, ZonMw, or other research financiers, and 
eventually leads to the execution of alternative research projects, patients 
can be said to have contributed to the quality and relevance of research. In 
that case, the interactive research agenda-setting project can be considered 
effective with respect to the long term as well.  
However, the long-term impact of the agenda is only indirectly 
influenced by the participation methodology used. It strongly depends on 
the commitment of the NAF and ZonMw management to both the 
agenda-setting process and its outcomes. In turn, this commitment 
depends on the rationality and legitimacy of the agenda-setting process, the 
roles of the NAF and ZonMw management in the design and execution of 
the process, the congruency of the resulting agenda with expectations and 
existing policy lines, and their (felt) dependency on the support of 
stakeholder groups. Other factors that contribute to the eventual adoption 
of the agenda are the translation and specification procedures followed, 
the room for manoeuvring within existing policy lines, the success of 
lobbying activities, the receptiveness and influence of other relevant actors 
in the field, the willingness of individual researchers to submit alternative 
research proposals, etc. We therefore abstained from evaluating the longer-
term impact of the project results on further policy and action. However, 
the fact that the NAF management is currently using the ‘societal agenda’ 
concerning asthma/COPD research as a guideline for the next research 
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programming implies a promise towards some long-term impact of the 
participation exercise. 
 
6.5 Concluding remarks 
 
Our patient participation strategy, including an elaborated consultation 
phase and a collaboration phase, and focussing on the facilitation of 
mutual learning and constructive interaction, can be considered an 
adequate strategy for implementing effective patient participation in the 
agenda setting of asthma/COPD research. By making patients priorities 
explicit and subsequently integrating these priorities in the resulting 
research agenda in a deliberative way, it overcomes the main inadequacies 
of current strategies for patient participation that only involve consultation 
or collaboration. It realized the main objectives of patient participation in 
research agenda setting as had been identified before: it provided a 
legitimate and rational process that resulted in the actual influence of 
patients on the main process outcome: a ‘societal research agenda’, which 
was generally considered quite substantial and useful and which serves as a 
guideline for research programming by the NAF management. In addition, 
as an indirect outcome, some knowledge sharing between participants had 
taken place, resulting in changes of thinking that might facilitate possible 
future interactive research agenda-setting processes.  
One could reasonably assume that a similar strategy may be 
appropriate for the implementation of effective patient participation in 
other research agenda-setting contexts as well. For example, although the 
agenda-setting process concerned the entire breadth of health research on 
asthma and COPD, we argue that the strategy is quite well applicable 
within the specific context of biomedical research as well. After all, a 
substantial part of the research agenda concerned biomedical research and 
patients proved to be capable of reflecting on, and prioritizing biomedical 
research topics (see chapter 5).  
Further research should focus on the actual longer term impact of 
the participation exercise as well as on finding a balance between striving 
for mutual learning and requiring the adequate reflection of patients’ 
inputs in final results. 
 
  
7 
CONCLUSIONS  
This study aimed to analyse the current situation concerning patient 
participation in decision-making on biomedical research and to contribute 
to the development and implementation of a strategy that could realize 
patient participation in a more structural and effective way. The main 
research question addressed in this dissertation is: 
“To what extent is effective patient participation in biomedical 
research decision-making possible?” 
In order to answer this question, I formulated three sub-questions that 
determined the outline of the study: 
I. What causes the apparent limited participation of patients in 
decision-making on biomedical research agendas? 
II. What strategy could be devised to include them more actively and 
effectively in biomedical research decision-making processes? 
III. What can we learn from the practical implementation of this 
strategy, in particular in terms of effectiveness?  
The study thus consisted of three different research parts: a more 
descriptive-analytical part, a more conceptual part, and a social-
experimental part that followed each other in a more or less chronological 
way. 
In order to answer the main research question, twelve detailed 
research questions were formulated during the course of the study (see 
section 1.3.2) and subsequently addressed in the chapters 2 to 6. In the 
sections below the main findings and conclusions of the study are 
summarized and discussed. Based on these findings and conclusions the 
three sub-questions will be answered. Subsequently, the main conclusions 
and their contribution to the scientific and societal objectives of the study 
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will be discussed. In the last section, I will give some suggestions for 
further research. 
 
7.1 The current situation  
 
The first sub-question focused on the current situation concerning 
initiatives of, strategies for, as well as obstacles to, patient participation in 
decision-making on biomedical research (research questions 1 to 4). Data 
had been collected by means of interviews and desk studies.  
Firstly, the findings presented in chapters 2 and 3 indicate that 
patients are still rarely involved in decision-making on biomedical research 
and that if they are involved, it is on an ad hoc basis. Subsequently, it was 
found that in the examples identified in the Netherlands, patient 
participation in decision-making on biomedical research was mainly 
achieved by following one out of three strategies: (1) the successful lobbying 
of patient organizations for certain types of research, (2) the ad hoc use of 
patients’ ideas and demands as research questions, topics, or priorities via 
intermediaries, and (3) the membership of patient representatives in 
existing decision-making research committees or councils. Although this 
part of the study focused on the situation in the Netherlands, literature 
research and informal communication with informants involved with 
patient participation in other countries have indicated that these findings 
apply broadly. 
The three strategies identified were analysed in terms of ‘levels’ of 
participation. For this purpose, Sherry Arnstein’s participation ladder 
(1969) (see figures 1.1 and table 1.1) was used as a framework. The first 
two strategies identified were labelled as forms of ‘consultation’, a minimal 
level of participation in Arnstein’s participation ladder. Within these 
strategies patients or patients’ organizations either push forward their 
views or are consulted on their views by intermediaries, but professionals 
eventually decide about the use of these views. Patients thus are not 
directly involved in the decision-making process itself. In addition, there is 
no guarantee that patients actually influence decision-making on research 
policy or projects. The fact that these forms of consultation usually occur 
in a rather ad hoc and non-structural manner further limits patients’ 
potential influence.  
The third strategy identified reflects a higher participation level of 
‘placation’ or ‘partnership’, depending on the actual power sharing 
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between patients and professionals.62 However, interviewees stressed that 
in practice this kind of participation seldom reflects real ‘partnership’. 
Usually only one or two patient members have to face a majority of 
(different) professional members, which easily results in placation instead 
of partnership. In addition, since the actual influence of patients on 
outcomes strongly depends on their proto-professionalism and 
empowerment, their representativeness is limited. Moreover, decision-
making processes within committees or councils are far from transparent 
since they comprise lobbying, private negotiation, and strategic behaviour. 
As a result, even patient members of committees who felt taken seriously 
and heard could not mention any concrete example of their actual 
influence on overall decision-making.  
Subsequently the appropriateness of the three strategies for 
realizing effective participation was estimated, in terms of ensuring the 
achievement of generally acknowledged objectives of stakeholder 
participation. As a definition it was stated that effective patient 
participation should accomplish a form of partnership, involving the direct 
and early involvement of patients in fair decision-making processes that 
include negotiation, deliberation and power-sharing as well as the 
structural integration of participants’ knowledge in, and thus their actual 
influence on, process outcomes. Concerning the three identified strategies, 
it was concluded that, although individual implementations may have 
resulted in changed research agendas, none of them can be considered as 
realizing effective participation. The first two strategies end in some actual 
influence of patients on biomedical research agendas but only in an ad hoc 
manner without realizing any partnership, while the third strategy 
structurally involves patients in decision-making but cannot warrant their 
actual influence on the outcomes. 
Since in other research fields effective participation has been 
successfully implemented, it was suggested that some obstacles might 
hamper effective patient participation in decision-making on biomedical 
research. Interviews with relevant actors indicated that obstacles for 
effective patient participation are related to limited resources, such as time 
and money, to structural and cultural characteristics of the current 
biomedical research decision-making network, and to characteristics of the 
patient community that is to be involved in this network. These obstacles 
together reflect a kind of resistance of the biomedical research decision-
                                                 
62  In the literature on patient participation this kind of strategy is usually termed 
‘collaboration’, which can refer to either placation or partnership. 
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making network and its stabilized ways of thinking and acting (its ‘regime’) 
towards change in terms of structurally involving patients in decision-
making. Obstacles attributed to the characteristics of patients mainly refer 
to patients’ limited capability to contribute anything relevant to decision-
making on biomedical research, because of their limited knowledge, 
interests, and competencies. Since this category of obstacles implicitly 
refers to the incongruence of patients’ characteristics with the current 
regime of the biomedical decision-making network, it could be regarded as 
reflecting network characteristics as well.  
 
7.2 Patients’ capabilities 
 
One of the obstacles for effective patient participation identified was the 
general adhered presupposition that patients are incapable of adequately 
participating in decision-making on biomedical research, because of their 
lack of relevant knowledge, their lack of objectivity, and their lack of 
interest in long term, biomedical research targets. Since this presupposition 
contradicts the important substantive argument for patient participation 
which builds on the potential expert-role of patients, it justifies more in-
depth study. Therefore the tenability of this presupposition – and thus 
simultaneously the tenability of the substantive argument for patient 
participation – was assessed by investigating the capability of patients to 
contribute something relevant to decision-making on biomedical research 
in practice. 
Firstly, research questions 5 and 6 addressed the potential 
contribution patients could make to decision-making processes regarding 
biomedical research. In answer to these questions, in chapter 3 it was 
suggested that patients’ potential contribution is primarily related to their 
‘experiential knowledge’. However, it appeared to be difficult to make a 
conclusive judgement on whether patients’ experiential knowledge can be 
considered valid, since this judgement depends on the (epistemological) 
paradigm adhered to. Therefore, a pragmatist approach was followed by 
estimating the validity of patients’ experiential knowledge in terms of its 
practical value by investigating concrete examples of the application of this 
knowledge – expressed in ideas, demands, or judgements – in biomedical 
research decision-making.  
Although extensive literature research and interviews resulted in 
the identification of only few concrete examples, these examples indeed 
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suggest that patients’ experiential knowledge has potential value for 
decision-making regarding biomedical research. In these examples patients’ 
experiential knowledge had been translated into explicit demands or ideas 
that formed a direct input to biomedical research processes as new 
research priorities, topics, or hypotheses.  
Secondly, research questions 9 to 11 addressed patients’ actual 
capability of participating adequately in (biomedical) research agenda-setting 
processes. These research questions were addressed in chapter 5, which 
described the consultation of asthma or COPD patients (members of the 
NAF; the Netherlands Asthma Foundation) on their health research 
priorities within the context of an interactive asthma/COPD health 
research agenda-setting process (see next section). The patients were 
successively consulted by means of exploratory focus groups, a feedback 
meeting, and a questionnaire. 
The results of the questionnaire indicated that NAF members 
prioritized biomedical and epidemiological research topics higher than 
topics concerning health services research or socio-cultural research. In 
addition, the focus group discussions indicated that NAF members were 
able to substantiate their perspectives on priorities. Although this study 
was restricted to the consultation of NAF members only, an additional 
questionnaire among asthma/COPD patients who were not member of 
the NAF demonstrated that there was no difference in research priorities 
between members and non-members. 
The results of this consultation contradict the presupposition of 
many people (both experts and patients) that patients are not capable of 
participating adequately in biomedical research agenda setting. Firstly, 
asthma/COPD patients seemed to obtain enough knowledge and 
information to formulate and prioritize health research topics covering the 
entire health research field, including biomedical research. Secondly, they 
appeared to be able to think in biomedical, long-term targets and in favour 
of future generations and did not only focus on personal health care and 
social problems. Thirdly, asthma/COPD patients were capable of 
introducing some new biomedical research topics that were neither 
covered by current NAF research agendas nor by the research priorities of 
other stakeholder groups: co-morbidity, side effects of medication, and 
mutual interaction of medication. Although obtained in the framework of 
health research agenda setting, these findings indicate that asthma/COPD 
patients are very well capable of participation in biomedical research 
agenda setting as well, since they appeared to be able to suggest, reflect on, 
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and prioritize biomedical research topics. One could reasonably assume 
that other patient groups will be able to do the same. 
These findings thus refute the notions that participating in 
decision-making on biomedical research requires highly specialized 
knowledge and that patients could not contribute to this decision-making. 
Instead, it could be concluded that patients, based on their experiential 
knowledge, have something new to contribute, which substantiates the 
substantive argument for patient participation in biomedical agenda 
setting. 
 
7.3 A transdisciplinary strategy  
 
Although the existence of different participation initiatives indicates that 
actors already experiment with patient participation in decision-making on 
biomedical research, its structural and effective implementation requires a 
change of the current decision-making network and its regime, which 
could be considered a ‘transition’. Transition management may offer a way 
to breach the resistance of the biomedical research decision-making 
network and to realize a change of the network towards effective patient 
participation.  
In chapter 2 it was argued that such a transition could be induced 
by the portrayal of successful examples of effective patient participation in 
decision-making on biomedical research. Therefore, the research questions 
7 and 8 focused on what the design of a suitable strategy for effective 
patient participation could look like. Based on the findings of the previous 
chapters, on literature research, and on earlier experiences of the Athena 
Institute, a new patient participation strategy (or methodology; see note 
40) was formulated in chapter 4.  
The participation strategy proposed was based on the Interactive 
Learning and Action (ILA) approach, which was developed by members 
of the Athena Institute (department of Biology and Society) for the gearing 
of agricultural innovation processes towards the needs and interests of 
small-scale farmers in developing countries (Broerse and Bunders, 2000). 
This approach has proven to be successful in realizing stakeholder 
participation in decision-making on science and technology. Since effective 
patient participation in decision-making on biomedical research implies, 
among others, involving patients in an early, direct, and fair way while 
ensuring their influence on process outcomes, the participation strategy 
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included separate consultation and collaboration63 phases. In order to utilize the 
full potential of patients’ knowledge, the strategy had a transdisciplinary64 
character, explicitly and deliberately integrating patients’ experiential 
knowledge with the knowledge of biomedical researchers and other 
professionals.  
The new patient participation strategy is a phased, transdisciplinary 
strategy that aims to facilitate equality, constructive interaction, mutual 
learning, and knowledge integration between patients, biomedical 
researchers, and other relevant actors. It consists of six phases:  
1. Preparation and initiation This phase comprises preliminary research 
that aims to identify relevant actors and to assess current patterns 
of thinking and acting within the biomedical field of interest, by 
means of desk studies and interviews. In addition, the objectives of 
the process, the methods to be used, and the roles of the 
participants are specified, while a process management team is 
established in order to guide the process. 
2. Consultation This phase aims to gather information about the 
perspectives and views of actors involved. For this purpose a 
variety of techniques can be used, such as interviews, 
brainstorming sessions, discussion meetings, focus groups, and 
questionnaires. Different stakeholder groups may demand different 
consultation techniques.  
3. Collaboration Subsequently, in the third phase the different actors 
are brought together in interactive settings in order to discuss these 
perspectives and views and to integrate them into one shared 
construction. Interactive settings should be carefully guided in 
order to facilitate and stimulate mutual openness and respect, 
constructive interaction, and mutual learning. 
4. Prioritization In this phase participants identify priorities. In order to 
prevent undue mutual influencing such as the overruling of 
                                                 
63  The term ‘collaboration’ is usually used to indicate a way of participation that implies 
the structural involvement of patients in formal decision-making structures such as 
committees or boards. ‘Collaboration’ can thus refer to both Arnstein’s participation 
levels of ‘placation’ and ‘partnership’. In practice it is often very difficult to distinguish 
placation from true partnership because the actual influence of patients in decision-
making within mixed committees or boards is hard to assess. 
64  The term ‘transdisciplinary’ refers to the integration of both scientific and non-
scientific knowledge in problem-solving or decision-making processes in search for a 
more integral and ‘socially robust’ knowledge. 
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patients by the views and priorities of experts and professionals, 
prioritization should preferably occur on an individual basis. 
5. Specification The fifth phase comprises the translation and 
specification of priorities identified into a concrete plan of action, 
comprising for example research programmes, projects, or policy 
actions. Although this phase is often in hands of the ‘assigning 
body’ that has commissioned the patient participation initiative, the 
involvement of stakeholders can ensure that the resulting plan of 
action reflect their priorities.  
6. Implementation The final phase comprises the implementation of the 
established plan of action. This phase usually is in the hands of the 
‘assigning body’ as well. Ideally also in this phase stakeholder 
groups are actively involved. 
Additional conditions identified for the successful implementation 
of such a transdisciplinary strategy comprise conditions for the social 
setting as well as for the members of the process management team. For 
example, the social setting should be characterized by mutual equality and 
coalition building between participants in an open and trustful atmosphere 
that stimulates rational discourse, feedback, mutual learning, and the 
achievement of shared constructions. In addition there should be clarity 
about process objectives and mutual expectations as well as some room 
for manoeuvring and negotiation. The process management team should 
possess both scientific and communication/organizational skills and 
should be able to generate the appropriate social setting and to guide 
constructive and transdisciplinary interaction between participants in an 
open, respectful, and creative way. 
 
7.4 Implementation and evaluation of the strategy 
 
In a social experiment, described in chapters 5 and 6, the proposed 
transdisciplinary strategy for effective patient participation in decision-
making on biomedical research agendas was implemented in a concrete 
setting and evaluated in terms of accomplishing effective participation. This 
part of the study addresses research question 12. The implementation took 
place in the context of a broader participative health research agenda-
setting project that was commissioned by the Netherlands Asthma 
Foundation (NAF) and co-financed by the Netherlands Organization for 
Health Research and Development (ZonMw).  
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The overall participative research agenda-setting project consisted 
of the first four phases of the transdisciplinary strategy described above. In 
a preparation and initiation phase the asthma/COPD research field and its 
decision-making patterns were assessed. In addition, the project team and 
process design were established and the process objectives were defined.  
In a consultation phase the three main stakeholders of 
asthma/COPD research – researchers, health care professionals, and 
patients – were consulted on their views concerning asthma/COPD 
research priorities from the perspective of their specific background and 
expertise. To this end different consultation methods were used. As had 
been argued in chapter 5, the combination of focus groups and a 
questionnaire constituted an appropriate methodology for investigating 
patients’ priorities on research. The questionnaire was a suitable tool for 
explicitly consulting a representative group of patients on their research 
priorities, without becoming obscured by group effects; the input from 
focus groups was indispensable for getting a proper design of the 
questionnaire as well as for gaining insight in underlying arguments and 
perspectives. The other stakeholder groups were consulted by means of 
discussion meetings and interviews. 
Subsequently, in a collaboration phase all research priorities of the 
different stakeholders – including many (expert) members of current 
research committees – were discussed and integrated into one ‘societal’ 
research agenda during an integration meeting. In a final prioritization 
phase participants were individually asked to prioritize this agenda using a 
prioritization matrix.  
In chapter 6 the appropriateness of the implemented participation 
strategy was evaluated in terms of accomplishing effective patient 
participation. This evaluation took place with respect to various process 
and outcome criteria, which were formulated on the basis of participation 
objectives considered relevant within the context of the interactive 
asthma/COPD research agenda setting process: (1) the legitimacy and 
rationality of the agenda-setting process, (2) the quality of the resulting 
agenda in terms of usefulness and adequate reflection of stakeholders’ 
perspectives, and (3) the occurrence of mutual learning between 
stakeholders involved. 
The evaluation results indicated that the transdisciplinary strategy 
used for the implementation of patient participation in research agenda 
setting was appropriate for realizing effective participation. The strategy 
gave rise to a legitimate and rational process that resulted in the actual 
influence of patients on a societal research agenda, which was generally 
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considered useful and which serves as a guideline for further research 
programming. Patients introduced three new biomedical research topics 
into the research agenda that were not mentioned by the other 
stakeholders: research on co-morbidity, on side effects of medication, and 
on drug interaction. These topics can be considered as originating from 
patients’ experiential knowledge. In addition, as an indirect outcome, 
mutual learning between participants had taken place, resulting in changes 
of thinking that might facilitate possible future interactive research agenda-
setting processes.  Although the agenda-setting process focused on health 
research, it can be assumed that patient participation in biomedical 
research agenda setting can be successfully designed in a similar way.  
Sub-optimal aspects of the participation exercise were (1) the 
somewhat low and unequal representation of the different stakeholder 
groups during the last two phases, as a result of late excuses and non-
response among all stakeholder groups, and (2) the relatively poor 
reflection of patients’ influence in the final prioritized research agenda. 
Probably, the most obvious explanation for the latter issue is that patients 
participating in the final priority setting were not (or no longer after 
mutual learning) representative for the patient community that had been 
consulted before and did not (or no longer) consider the earlier identified 
highest priorities of patients as most urgent.  
 
7.5 Overall conclusion 
 
Based on all the findings summarized in this chapter, the three sub-
questions can be answered as follows. 
The results of the descriptive-analytical part of the study lead to the 
conclusion that the ‘apparent limited participation of patients’, which was 
assumed in the introduction, is not the result of inadequate documentation 
of patient participation initiatives but corresponds with the actual practice 
of decision-making concerning biomedical research agendas. The study 
showed that patients are currently involved in decision-making concerning 
biomedical research only on a limited scale and often in an ineffective way 
(in terms of involving patients early and directly in fair decision-making 
processes that ensure their influence on the decision outcome). Secondly, 
this limited patient participation can be considered as being caused by the 
resistance of the current biomedical research decision-making network, 
and its regime, towards change.  
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The findings of the designing part of the study suggest that a 
transdisciplinary strategy, including both an explicit consultation and a 
collaboration phase, and enhancing constructive interaction and 
knowledge integration, could be an appropriate patient participation 
strategy. The results of the social-experimental part of the study confirm 
that the proposed strategy indeed provides a suitable strategy for realizing 
effective patient participation in decision-making on biomedical research. 
In addition, both the analysis of earlier cases of patient participation and 
the social experiment indicate that patients are potentially capable of 
identifying, valuing, and prioritizing biomedical research topics, and that 
they have something new to contribute to biomedical agenda setting. 
Concerning the main research question, I thus can conclude that 
although effective patient participation in biomedical research decision-
making is not common practice, its implementation is possible when 
following a carefully developed transdisciplinary strategy that includes 
explicit phases of consultation and collaboration (in terms of partnership) 
and that stimulates constructive interaction and knowledge integration 
between actors involved. 
The study described in this dissertation contributed to scientific 
knowledge production on strategies for effective patient participation 
within the biomedical sector. It has resulted in increased insight in the 
value of patients’ experiential knowledge for biomedical research, in 
obstacles that hamper effective patient participation in decision-making on 
biomedical research, and in conditions and procedural elements that 
stimulate and facilitate constructive interaction and knowledge integration 
between patients and professionals. Since in other scientific fields 
comparable obstacles and opportunities are faced, many of the insights 
obtained probably could be generalized to other contexts of stakeholder 
participation. 
On a societal level, the implementation of the developed strategy 
for effective patient participation within the context of an asthma/COPD 
health research agenda-setting process has contributed to the construction 
of a useful and broadly supported research agenda for asthma and COPD 
research. The developed strategy proved to be appropriate for the 
implementation of effective patient participation in decision-making on 
health research as well as on biomedical research. When further optimized 
and adapted it may form the basis for a broader applicable stakeholder 
participation strategy as well.  
Finally, by providing both scientific insights on, and a successful 
societal application of, patient participation in biomedical research 
CHAPTER 7 
160 
decision-making, the study described in this dissertation might contribute 
to the induction of a transition of the biomedical decision-making network 
towards the structural inclusion of patients. It may dispel the largely held 
presupposition that patients are not capable of participating in decision-
making on biomedical research in an adequate way and convince an 
increasing number of actors from the network about the feasibility and the 
added value of patient participation in decision-making. Similar changes in 
thinking were already observed in the social experiment concerning patient 
participation in asthma/COPD health agenda setting. Most participants of 
the agenda-setting process were quite enthusiastic about the interactive 
strategy followed and its outcomes. In addition, knowledge production on 
strategies for effective participation and their (pre)conditions will smooth 
future participation initiatives, also within other contexts. 
Further signs of a transition towards a more structural involvement 
of patients in decision-making on research may soon become visible. Since 
the publication and distribution of the research report on the interactive 
research agenda-setting project by the NAF, other charity funds and 
patients’ organizations are exploring possibilities for initiating similar 
processes.  
 
7.6 Discussion 
 
Concerning the first part of the study a point of discussion concerns the 
tenability of the conclusion that patient participation in decision-making 
on biomedical research occurs rarely and usually in an ineffective way. This 
conclusion was based on the facts that only a limited amount of examples 
could be identified and that these examples hardly reflected effective 
participation. Consulting additional patients’ organizations or funding 
agencies might have resulted in some additional examples that might 
comprise other participation strategies. Nevertheless, the quite large 
number and variety of interviews held and the extensiveness of the 
literature research conducted to some extent ensured the validity of the 
outcomes. In addition, the many obstacles for effective patient 
participation identified further strengthen these findings. 
Of all the obstacles identified, only the one concerning patients’ 
apparent limited capability to participate adequately in, and to contribute 
to, biomedical research decision-making was explicitly addressed in this 
study. On the one hand, this obstacle was considered essential since it 
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questions one of the central arguments in favour of patient participation, 
which is based on the potential substantive contribution patients could 
make to biomedical research decision-making. Thereby, it strongly 
determines people’s belief or disbelief in the potential success and value of 
patient participation efforts, which in turn determines whether people are 
willing to experiment with it. On the other hand, this obstacle could be 
refuted rather easily when it can be demonstrated that patients are capable 
of participating adequately in biomedical research agenda setting processes 
in practice. For example, the evaluation results of the participative research 
agenda setting process conducted and described in this study showed that 
several expert participants admitted to have adjusted their opinion on 
patients’ capabilities based on the results of the patient consultation step. 
Concerning the last part of the study,  a critical remark should be 
made. The design and management as well as the evaluation of the 
participation initiative were in the hands of the project team involved. The 
evaluation thus can be considered a kind of self-evaluation, which strongly 
bears the danger of bias. This bias was minimized by: (1) ensuring that 
those who conducted the evaluation study were not the same as those who 
designed and managed the process, (2) involving all participants in the 
evaluation process in an open way, (3) applying triangulation of evaluation 
methods and member checks, and (4) presenting rich data. 
Another discussion point concerns the sub-optimal elements of the 
designed transdisciplinary patient participation strategy that need 
improvement. Firstly, the representation of stakeholder groups in the 
collaboration and prioritization phases could be improved, for example by 
inviting more and equal numbers of stakeholder representatives. In this 
respect, it should be discussed whether equal numbers of all stakeholders 
need to be involved in the integration meeting or equal numbers of 
patients and experts. However, since it cannot be prevented that people 
call off attending a meeting at the last moment, the adequate 
representation of stakeholder groups can never be guaranteed in advance.  
A second aspect that demands optimization is the explicit and 
traceable inclusion of patients’ priorities in the prioritized research agenda. 
However, as has already been discussed in chapter 6, this optimization 
faces a dilemma. Involving a more representative group of patients in the 
final priority setting exercise might result in a better and more visible 
inclusion of patients’ original research priorities in the final prioritization, 
but at the same time reduce the effects of mutual learning, something that 
has been considered an important condition for adequate participation 
processes. This dilemma refers to a more general dilemma in effective 
CHAPTER 7 
162 
participation processes: the two evaluation criteria mutual learning and 
representativeness seem to exclude each other to some extent. Mutual 
learning may result in a loss of original perspectives (and thus of 
potentially valuable patients’ experiential knowledge) and complicates the 
assessment of patients’ influence on final outcomes. When designing 
and/or evaluating a patient participation initiative, one should seek a 
balance in meeting both criteria. 
Another optimization of the strategy could involve the insertion of 
additional meetings, such as a second patient meeting to discuss the 
questionnaire outcomes, (extra) meetings with socio-cultural scientists and 
health care professionals in order to discuss research priorities of these 
stakeholder groups more thoroughly, and an additional feedback meeting 
after the integration meeting or the prioritization exercise, which could 
optimize the substantiation of stakeholder priorities, the mutual learning in 
and between stakeholder groups, as well as the social support of the 
prioritized agenda even more. However, since these extra meetings will 
considerably increase the total costs, it is questionable whether this can be 
regarded as cost-effective. 
A criterion that was excluded from our evaluation framework, but 
what is considered important by scholars in the field of stakeholder 
participation as well as by participants in the social experiment, concerned 
the actual impact of participatory results on further policy and action. 
Indeed, when the resulting asthma/COPD health research agenda is 
actually translated into concrete research programmes by the NAF, 
ZonMw, or other research financiers, and eventually leads to the execution 
of research projects that reflect the societal research agenda, patients can 
be said to have contributed to the quality and relevance of research. 
However, since this final impact of the developed societal agenda depends 
on a number of factors that lie beyond the scope of this study, the 
evaluation of the participation exercise has been restricted to the short-
term outcomes of the project. It would therefore certainly be very 
interesting to assess the final impact of the societal asthma/COPD 
research agenda on the concrete research practice two or three years from 
now. The fact that the societal research agenda currently serves as a 
guideline for research programming by the NAF indicates that this impact 
may become visible. 
 A final remark concerns some stakeholder groups that have not 
been involved in the interactive agenda-setting project. One of those is the 
group of supporters of the NAF. Since they provide the major part of the 
funds that can be spend on research, and thus are relevant stakeholders, 
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they could be ascribed the right to participate in decision-making on 
research agendas as well. In addition, since ZonMw is also a sponsor and 
user of the agenda-setting project, it could be argued that the government 
and even the public at large should have participated in the agenda-setting 
process. In the framework of this study these stakeholder groups are 
excluded from participation since the NAF decided to involve only the 
three ‘core’ (expert) stakeholder groups in the agenda-setting process and 
possibly to involve other relevant stakeholders at a later stage. 
 
7.7 Further research 
  
I would like to close this dissertation by presenting some ideas for further 
research. Firstly, further research should comprise a follow-up study after 
three years or so in order to measure the impact of this social experiment 
on the research policy and decision culture of the NAF and ZonMw as 
well as on eventual asthma/COPD research projects executed. This 
research thus would involve the evaluation of the implementation phase of 
the participation strategy. It may lead to the identification and analysis of 
variables that could stimulate successful implementation of participation 
outcomes and thus could increase the effectiveness of the participation 
initiative in terms of actual impact. 
At the same time, additional research could comprise the more 
thoroughly investigation of the social experiment described in this 
dissertation and its outcomes. For example the mutual interaction between 
the different stakeholder groups during the integration meeting could be 
investigated in more detail by conducting tape-analysis. Likewise it would 
be interesting to inquire the more specific role of patients’ experiential 
knowledge on criteria they use for priority setting. These aspects may 
enrich insights in knowledge integration processes and conditions for their 
optimization. 
In addition, further research could address the optimization of the 
participation strategy proposed and implemented in this study. As 
described above, this optimization may concern the representativeness of 
stakeholders involved in the collaboration and prioritization phases, the 
more explicit traceability of patients’ influence on final outcomes, and the 
efficiency of the strategy. It would be interesting to investigate whether it 
is possible to obtain similar levels of effectiveness with less time and 
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reduced costs. For this purpose slightly adapted versions of the strategy 
should be repeatedly applied. 
Other research could focus on the applicability of the formulated 
participation strategy within alternative contexts, concerning other patient 
communities or even other scientific fields. In comparison with other 
patient communities, the community of asthma/COPD patients is quite 
mobile, while the community of NAF members in particular is rather 
active and well-organized, as well as relatively well informed about 
developments within the research field (amongst others by the patient 
magazine ‘Contrastma’). Other patient communities may demand 
additional efforts and facilities, for instance when being invited to attend 
group meetings. The application of the participation strategy in other 
scientific fields may require further adaptations. 
Finally, additional research could address a more structural 
implementation, and eventually the sustainable institutionalization, of 
patient participation in established biomedical decision-making structures. 
For this purpose several steps could be undertaken. For example, 
managers of research funding agencies and other central actors in decision-
making on biomedical research agendas could be made aware of and 
trained in the execution of participatory agenda setting processes. In 
addition, research could focus on making the strategy more efficient, in 
particular for follow-up agenda-setting processes. Furthermore, the 
training of biomedical students in transdisciplinary and participatory 
approaches could gradually change the strong disciplinary biomedical 
culture towards more openness and flexibility with respect to the 
participation of patients and their knowledge in decision-making 
processes. 
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De laatste decennia vindt er binnen de wetenschap een toenemende 
democratisering van besluitvorming plaats. Enerzijds wordt op nationaal 
en internationaal niveau het grote publiek steeds vaker betrokken bij 
besluitvorming over controversiële wetenschappelijke ontwikkelingen, 
zoals binnen de biotechnologie en de genetische geneeskunde. Door het 
organiseren van publieke debatten of consensusconferenties probeert men 
draagvlak te creëren voor beleid en eventuele maatschappelijke weerstand 
te voorkomen. Anderzijds worden binnen bepaalde (meestal toegepaste) 
wetenschapsgebieden in toenemende mate relevante maatschappelijke 
actoren – zoals eindgebruikers, financiers of beleidsmakers –  betrokken 
bij besluitvorming over de inhoud van onderzoeksprogramma’s, -projecten 
of zelfs over oplossingsrichtingen. Behalve dat deze maatschappelijke 
actoren belangrijke stakeholders van dergelijk wetenschappelijk onderzoek 
zijn, zijn ze ook experts omdat ze een bepaalde vorm van contextuele 
kennis hebben die onmisbaar is voor het succesvol vormgeven van 
wetenschappelijke processen. Deze kennis wordt wel locale kennis, 
lekenkennis of ervaringskennis genoemd. 
Binnen wetenschapsgebieden als milieuwetenschappen, planologie, 
agrarische wetenschappen, ontwikkelingsstudies en vele vormen van 
gezondheidsonderzoek wordt in de literatuur steeds vaker gerefereerd naar 
dergelijke vormen van ‘stakeholderparticipatie’ in besluitvorming over 
onderzoek. Echter, de biomedische wetenschap lijkt op het eerste gezicht 
gevrijwaard van stakeholderparticipatie in besluitvorming. Dit is op zijn 
minst opmerkelijk aangezien de biomedische wetenschap grote 
maatschappelijke belangen herbergt. Immers, het stelt zich ten doel bij te 
dragen aan de gezondheid van de mens, en daarmee aan de kwaliteit van 
leven. Bovendien wordt er, internationaal gezien, zeer veel geld in 
geïnvesteerd. Het doel van dit proefschrift is dit fenomeen nader te 
onderzoeken. 
Biomedisch onderzoek is een ‘technische’ vorm van 
gezondheidsonderzoek die zich richt op het verkrijgen van inzicht in de 
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fysische mechanismen en processen die ten grondslag liggen aan 
gezondheid en ziekte. Daarmee vormt biomedisch onderzoek een 
belangrijke wetenschappelijke basis van onze westerse geneeskunde. 
Subdisciplines binnen het biomedisch onderzoek zijn immunologie, 
pathologie, neurologie, genetica, etc. Een belangrijke stakeholdergroep 
wordt gevormd door de patiënten, die de belangrijkste doelgroep en tevens 
eindgebruikersgroep van biomedisch onderzoek vormen. Bovendien zijn 
patiënten te beschouwen als (niet-gecertificeerde) experts omdat zij op 
basis van hun ervaringen met hun ziekte een vorm van ervaringskennis 
opbouwen die complementair is aan professionele, biomedische kennis en 
mogelijk een belangrijke bijdrage biedt aan de sturing van biomedisch 
onderzoek. Op grond van dit stakeholder- en expert-zijn van patiënten 
pleiten verschillende normatieve (ethische en politieke) en inhoudelijke 
argumenten ervoor hen actief te betrekken bij besluitvorming rondom 
biomedische onderzoeksagenda’s. Patiëntenparticipatie in besluitvorming 
rondom biomedisch onderzoek kan bijvoorbeeld bijdragen aan de 
legitimiteit en de rationaliteit van besluitvormingsprocessen, aan de 
kwaliteit van genomen besluiten (bijvoorbeeld in termen van 
maatschappelijke relevantie van onderzoeksprojecten of –programma’s) en 
aan een verhoogde maatschappelijke acceptatie van besluiten. Indirect kan 
het bovendien bijdragen aan een vergroting van het maatschappelijke 
sociaal en menselijk kapitaal, respectievelijk door netwerkvorming en door 
het delen van kennis. Hoewel op overheidsniveau het grote publiek en 
patiëntenorganisaties af en toe betrokken worden bij besluitvorming over 
bepaalde beleidsontwikkelingen binnen de biomedische wetenschap, zoals 
rondom kloneren, xenotransplantatie en onderzoek aan menselijke 
embryo’s, lijkt een eerste literatuurscan erop te wijzen dat patiënten zelden 
betrokken worden bij besluitvorming over concrete onderzoeksagenda’s 
van instituten of individuele onderzoekers.  
In het licht van deze discussie is de centrale onderzoeksvraag in 
dit proefschrift: 
“In welke mate is effectieve patiëntenparticipatie in besluitvorming over 
biomedische onderzoeksagenda’s mogelijk?” 
Om deze vraag te kunnen beantwoorden zijn de volgende drie deelvragen 
geformuleerd:  
I. Wat veroorzaakt de schijnbare beperkte participatie van 
patiënten in besluitvorming rondom biomedische onderzoeks-
agenda’s? 
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II. Welke strategie kan ontwikkeld worden om patiënten actiever en 
effectiever te betrekken bij deze besluitvorming? 
III. Wat kunnen we leren van de praktische implementatie van deze 
strategie, in het bijzonder wat betreft haar effectiviteit? 
 
Deze drie deelvragen bepalen min of meer de structuur van het aan 
dit proefschrift ten grondslag liggende kwalitatieve onderzoek. Het eerste 
deel van het onderzoek bestaat uit beschrijvend-analytisch onderzoek dat 
focust op de huidige situatie wat betreft patiëntenparticipatie in 
besluitvorming over biomedisch onderzoek. Klopt de aanname dat 
patiënten slechts beperkt participeren in deze besluitvorming met de 
werkelijke situatie? En als dat zo is, wie of wat zijn daar dan de oorzaken 
van? Het tweede deel van het onderzoek is meer conceptueel van aard en 
omvat het ontwerpen van een participatiestrategie die effectieve 
patiëntenparticipatie in besluitvorming rondom biomedisch onderzoek 
mogelijk zou moeten maken. Hierbij wordt uitgegaan van de analyse en 
interpretatie van eerdere bevindingen zowel binnen als buiten het kader 
van dit onderzoek, aangevuld met literatuuronderzoek. Het derde deel van 
het onderzoek bestaat uit een ‘maatschappelijk experiment’ waarin de 
geformuleerde strategie wordt toegepast en geëvalueerd in een concrete 
situatie. Het primaire doel van het hele onderzoek is het reflecteren op, en 
experimenteren met, participatiestrategieën om daarmee bij te dragen aan 
een groter inzicht in hoe een geschikte strategie voor effectieve 
patiëntenparticipatie vormgegeven zou kunnen worden. 
In hoofdstuk 2 wordt de eerste deelvraag geadresseerd. Door 
middel van een workshop, interviews met allerlei betrokkenen en 
aanvullend literatuuronderzoek is het huidige Nederlandse ‘biomedische 
besluitvormingsnetwerk’ in kaart gebracht en is gezocht naar voorbeelden van 
patiëntenparticipatie in besluitvorming over biomedisch onderzoek. Uit de 
resultaten blijkt inderdaad dat patiënten op dit moment niet structureel 
deel uitmaken van het biomedische besluitvormingsnetwerk maar dat er 
wel enkele initiatieven genomen worden om patiënten wat meer te 
betrekken bij deze besluitvorming. De enkele gevonden initiatieven zijn 
echter geen effectieve participatie te vertegenwoordigen in de zin van dat 
patiënten op een directe en gelijkwaardige wijze al in een vroeg stadium in 
besluitvormingsprocessen participeren en dat hun daadwerkelijke invloed 
op de uiteindelijke besluitvorming gewaarborgd wordt. Op dit moment 
worden patiëntenparticipatieinitiatieven veelal vormgegeven als een ad hoc 
consultatie van patiënten of patiëntenorganisaties – al of niet door hen 
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afgedwongen – of als een zitting nemen van patiëntleden in gemengde 
adviescommissies. Bij de consultatie van patiënten blijft het meestal onzeker 
of de inbreng van patiënten ook daadwerkelijk onderzoeksagenda’s zal 
beïnvloeden. Maar ook bij de zitting van patiënten in commissies is de 
beïnvloeding door patiënten marginaal of op z’n best onduidelijk. Ten 
eerste wordt de precieze inbreng van patiënten zelden expliciet gemaakt, 
wat het moeilijk maakt deze bewust te integreren in een eindbeslissing of  
–advies. Ten tweede zijn de posities van patiënten en professionals in 
dergelijke commissies volgens insiders vaak niet gelijkwaardig en raakt een 
eventuele patiënteninbreng gemakkelijk ondergesneeuwd door de inbreng 
van professionals. Hoewel dit deel van het onderzoek zich beperkt heeft 
tot de Nederlandse situatie, hebben informele gesprekken met relevante 
actoren uit andere landen en aanvullend literatuuronderzoek laten zien dat 
de resultaten breder toepasbaar zijn. 
Vervolgens zijn, tevens door middel van interviews, de obstakels die 
effectieve patiëntenparticipatie tegengaan, geïnventariseerd en in kaart 
gebracht. Een groot deel van de beschreven obstakels lijken deel uit te 
maken van een algemene ‘weerbarstigheid’ van het huidige biomedische 
besluitvormingsnetwerk. Bestaande onderzoeksstructuren, gangbare 
praktijken en heersende denkwijzen bieden weinig ruimte voor 
verandering, noch voor andersoortige programma’s of projecten noch 
voor inbreng van patiënten.  
Een sterk belemmerende heersende denkwijze, zowel binnen het 
biomedische onderzoeksveld als binnen de patiëntenwereld, is 
bijvoorbeeld dat patiënten zich niet met biomedisch onderzoek moeten 
bemoeien. Ten eerste wordt de biomedische wetenschap door velen 
beschouwd als een ‘esoterische’ wetenschap die door de maatschappij met 
rust gelaten moet worden. Daarbij wijst men op het gevaar dat als het 
biomedische onderzoek zich teveel gaat richten op maatschappelijke 
behoeften, dit ten koste gaat van essentieel fundamenteel onderzoek, 
waardoor de biomedische kennisbasis te smal zou worden. Bovendien 
wordt benadrukt dat veel grote biomedische doorbraken ontstaan zijn 
door toeval of vanuit puur wetenschappelijke interesses. Ten tweede 
worden patiënten niet in staat geacht om mee te beslissen over 
biomedische onderzoeksagenda’s. Besluitvorming over biomedisch 
onderzoek zou specialistische kennis vereisen die patiënten niet hebben; de 
ervaringskennis van patiënten wordt zelden als mogelijke waardevolle 
inbreng voor biomedisch onderzoek erkend. Bovendien zouden patiënten 
niet in staat zijn over hun eigen subjectieve problemen heen te kijken en 
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alleen behoefte hebben aan korte termijn sociaal-wetenschappelijk of 
zorggerelateerd onderzoek.  
Betreffende het eerste tegenargument – het niet mogen inter-
fereren in een esoterische wetenschap – is veel geschreven in de literatuur 
over publieks- en stakeholderparticipatie in besluitvorming aangaande 
wetenschappelijk(e) onderzoek(sagenda’s). Het volstaat hier te 
benadrukken dat eerder genoemde argumenten die pleiten voor een 
maatschappelijke beïnvloeding van biomedische onderzoeksagenda’s niet 
inhouden dat al het bestaande biomedische onderzoek maatschappelijk 
gestuurd moet worden. Er zal een balans gevonden moeten worden zodat 
er altijd ruimte zal blijven voor fundamenteel, puur wetenschappelijk 
geïnspireerd onderzoek.  
Het tweede tegenargument, dat focust op het (on)vermogen van 
patiënten om effectief mee te beslissen over biomedisch onderzoek, vraagt 
om nader onderzoek. In hoofdstuk 3 wordt daarom de ervaringskennis van 
patiënten en haar mogelijke nut voor biomedisch onderzoek nader 
onderzocht. Door middel van literatuuronderzoek en aanvullende 
interviews is de in het vorige hoofdstuk al gestarte inventarisatie van 
voorbeelden van patiëntenbetrokkenheid bij besluitvorming over 
biomedisch onderzoek voortgezet. Uit de 22 gevonden voorbeelden blijkt 
dat de inbreng van patiënten in deze besluitvorming vooral bestaat uit het 
uiten van behoeften aan onderzoeksrichtingen, ideeën voor onderzoeksvragen 
en hypotheses en oordelen over de relevantie van onderzoeksprioriteiten of -
projecten. Deze behoeften, ideeën en oordelen zijn mogelijke 
uitingsvormen van de ervaringskennis van patiënten binnen de context van 
biomedisch onderzoek. Binnen de gevonden voorbeelden is vervolgens 
gezocht naar casussen die meer inzicht bieden in de concrete, inhoudelijke 
inbreng van patiënten en dus in hun gebruikte kennis. Slechts enkele 
voorbeelden bleken dit inzicht te bieden. Al zijn deze casussen mogelijk 
niet overtuigend genoeg om twijfelende onderzoekers over de streep te 
trekken, ze zijn in ieder geval een aanwijzing voor het nut van 
ervaringskennis voor biomedisch onderzoek.  
Het doorbreken van de eerder genoemde weerbarstigheid van het 
biomedische besluitvormingsnetwerk met haar gangbare wijzen van 
denken en handelen, vergt meer dan een discussie over het mogelijke nut 
van de ervaringskennis van patiënten. Er is een cultuur- en 
structuuromslag nodig; met andere woorden: er moet een transitie op gang 
komen. Volgens de transitieliteratuur kan een dergelijke omslag het beste 
geïnitieerd worden door maatschappelijke druk, die ‘top-down’ wordt 
uitgeoefend, te combineren met succesvolle voorbeeldinitiatieven die het 
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netwerk ‘bottom-up’ beïnvloeden. Top-down prikkels voor een transitie 
van het biomedische besluitvormingsnetwerk richting het structureel 
betrekken van patiënten worden gevormd door de steeds sterker worden 
maatschappelijke pleidooien (zowel binnen de overheid als in de literatuur) 
voor patiëntenparticipatie in besluitvorming over biomedisch onderzoek. 
Nu zijn er nog bottom-up initiatieven nodig, het liefst van invloedrijke en 
centrale actoren.  
Hoe zou een dergelijk initiatief eruit kunnen zien? In hoofdstuk 4 
wordt een voorstel gedaan voor een nieuwe strategie die effectieve 
patiëntenparticipatie zou kunnen realiseren. Omdat een dergelijke strategie 
moet garanderen dat patiënten in een vroeg stadium en op een directe 
wijze in het besluitvormingsproces betrokken worden en dat hun inbreng 
de uiteindelijke besluitvorming expliciet beïnvloedt, is gekozen voor een 
aanpak die een expliciete consultatiefase combineert met een samenwerkingsfase. 
In de consultatiefase kunnen de patiëntenperspectieven en –prioriteiten 
expliciet gemaakt worden terwijl in de samenwerkingsfase deze 
perspectieven en –priorititeiten (en dus indirect de ervaringskennis van 
patiënten) doelbewust geïntegreerd kunnen worden in de uiteindelijke 
besluitvorming. Zo kunnen de tekortkomingen die de eerder beschreven, 
hedendaagse strategieën voor patiëntenparticipatie hebben, worden 
voorkomen. Omdat de integratie in de samenwerkingsfase zowel 
wetenschappelijke (biomedische) kennis als niet-wetenschappelijke 
(patiënten-) kennis betreft, kunnen we haar ‘transdisciplinair’ noemen. Het 
begrip transdisciplinariteit verwijst naar een vorm van probleemoplossen 
of kennisproductie waarin wetenschappelijke kennis en maatschappelijke 
kennis met elkaar geïntegreerd worden. Omdat kennisintegratie tussen 
zulke verschillende vormen van kennis een complex en delicaat proces is, 
vergt het een voorzichtige, goed uitgedachte aanpak. Vanuit de literatuur 
zijn verschillende condities voor een succesvolle transdisciplinaire aanpak 
gedestilleerd en met elkaar gecombineerd.  
Een eerste conditie is de beschikbaarheid van een systematische 
aanpak. Gekozen is voor een gefaseerde strategie, gebaseerd op de 
‘Interactive Learning and Action’ benadering; een benadering die door de 
afdeling Biologie en Samenleving is ontwikkeld om kleinschalige boeren te 
betrekken bij besluitvorming over de ontwikkeling en implementatie van 
landbouwtechnologieën. De participatiestrategie omvat na een eerste 
vooronderzoeksfase, een expliciete consultatiefase en een samenwerkings-
fase die resulteren in geïntegreerde perspectieven ten aanzien van 
onderzoeksagenda’s. In daaropvolgende prioriterings- en implementatie-
fasen kan een definitief programma of plan van actie opgesteld, 
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respectievelijk geïmplementeerd worden. Andere condities voor een 
succesvol transdisciplinair participatieproces betreffen de sociale setting en 
de kwaliteiten van de procesmanagers die optimale kennisintegratie 
moeten faciliteren en stimuleren. 
In de hoofdstukken 5 en 6, tenslotte, wordt de voorgestelde 
strategie in de praktijk getoetst. De beschreven casus betreft een initiatief 
tot patiëntenparticipatie in onderzoeksagendering in opdracht van het 
Nederlands Astma Fonds (NAF) en mede gefinancierd door ZonMw. In 
dit initiatief werden patiënten, naast wetenschappers en zorgverleners, 
betrokken bij het opstellen van een ‘maatschappelijke onderzoeksagenda’ 
rondom astma en COPD die als basis moest dienen voor te formuleren 
onderzoeksbeleid en onderzoeksprogramma’s.  
In hoofdstuk 5 wordt de consultatie van astma- en COPD-
patiënten (NAF-leden) apart beschreven. Behalve dat deze deelfase een 
essentieel onderdeel van het hele onderzoeksagenderingsproces is, biedt 
het ook de mogelijkheid om in de praktijk te onderzoeken of patiënten 
inderdaad op basis van hun ervaringskennis in staat zijn om adequaat te 
participeren in een onderzoeksagendering waar biomedisch onderzoek deel 
van uit maakt. Daarmee kan de houdbaarheid van het eerder genoemde 
‘tweede’ argument tegen patiëntenparticipatie – namelijk dat patiënten daar 
niet toe in staat zijn – nader onderzocht worden.  
De consultatieprocedure bestond uit twee stappen. Door middel 
van focusgroepen werden astma/COPD-patiënten in eerste instantie 
gevraagd naar de ervaren problemen met hun ziekte en naar oorzaken van 
en argumenten rondom die problemen. Daarmee werd aangesloten bij de 
directe ervaringen van patiënten en tevens een aanzet gegeven voor het 
formuleren van te prioriteren onderzoeksdoelen. Vervolgens werd een 
brede enquête gebruikt om patiënten die onderzoeksdoelen op een 
expliciete en kwantitatieve wijze te laten prioriteren.  
Uit de resultaten blijkt dat de betrokken astma/COPD-patiënten 
goed in staat zijn om te participeren in een brede onderzoeksagendering en 
naar alle waarschijnlijkheid ook in een specifiek biomedische 
onderzoeksagendering. Ten eerste waren ze in staat om een breed scala aan 
(waaronder biomedische) onderzoeksonderwerpen te prioriteren op een 
onderbouwde manier. Deze onderbouwing is terug te vinden in de 
resultaten van de focusgroepen. Ten tweede prioriteerden ze biomedische 
onderwerpen als hoogste en hadden ze dus niet alleen aandacht voor korte 
termijn sociaal-wetenschappelijk of zorggerelateerd onderzoek. Ten derde 
hadden de betrokken patiënten enkele biomedische onderzoeks-
onderwerpen geformuleerd en geprioriteerd die in huidige onderzoeks-
SAMENVATTING 
172 
programma’s niet voorkomen, namelijk onderzoek aan co-morbiditeit en 
onderzoek aan de bijwerkingen van, en onderlinge wisselwerking tussen, 
medicijnen. De betrokken astma/COPD-patiënten zijn dus niet alleen in 
staat om te prioriteren, ze hebben, op basis van hun ervaringskennis, ook 
iets bij te dragen aan huidige biomedische onderzoeksagenda’s.  
Aangenomen dat andere patiënten hiertoe ook in staat zullen zijn, 
is met dit onderzoek het hierboven genoemde tweede argument tegen 
patiëntenparticipatie ontkracht. Bovendien wordt met de resultaten van 
hoofdstuk 3 en 5 het inhoudelijke argument vóór patiëntenparticipatie, 
welke verwijst naar de mogelijke bijdrage van patiënten aan de kwaliteit 
van de besluitvorming, versterkt. 
Hoofdstuk 6 beschrijft het overkoepelende participatieve 
agenderingsproces, zoals dat conform de in hoofdstuk 4 geformuleerde 
strategie heeft plaatsgevonden. Het proces heeft geresulteerd in een 
‘maatschappelijke onderzoeksagenda’ van 40 onderzoeksonderwerpen die 
in 10 verschillende thema’s waren ondergebracht en in een globale 
prioritering van deze onderzoeksagenda.  
Vervolgens is de effectiviteit van de bewerkstelligde participatie, in 
termen van het bereiken van vooraf gedefinieerde en normatief en 
inhoudelijk geïnspireerde doelen, geëvalueerd aan de hand van een van te 
voren opgesteld evaluatiekader. Evaluatie van zowel de legitimiteit en de 
rationaliteit van het proces, als de kwaliteit van directe en indirecte 
uitkomsten wees uit dat de gevolgde strategie geschikt is voor het effectief 
betrekken van patiënten in besluitvorming rondom onderzoeksagenda’s. 
Enkele nog suboptimale aspecten betroffen de niet helemaal evenwichtige 
vertegenwoordiging van stakeholders in de samenwerkings- en 
prioriteringsfasen en de minimale zichtbaarheid van de patiëntenbijdragen 
in de uiteindelijke geprioriteerde agenda. Hoewel de gevolgde strategie 
binnen het beschreven initiatief gebruikt werd voor de agendering van aan 
astma/COPD gerelateerd gezondheidsonderzoek op zijn breedst, zou 
dezelfde strategie waarschijnlijk ook goed gebruikt kunnen worden voor 
het vormgeven van effectieve patiëntenparticipatie in biomedische 
onderzoeksagendering, aangezien dit laatste op impliciete wijze al deel van 
het initiatief uitmaakte. 
De effectiviteit in termen van daadwerkelijke impact van de 
patiëntenparticipatie op het uiteindelijke onderzoeksbeleid en de 
uiteindelijk uitgevoerde onderzoeksprojecten is (nog) niet geëvalueerd. 
Echter, het feit dat het NAF de geformuleerde onderzoeksagenda 
momenteel gebruikt als leidraad voor haar verdere onderzoeks-
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programmering kan beschouwd worden als een eerste indicatie voor een 
dergelijk langere termijn effect.  
Uit het promotieonderzoek zijn verschillende conclusies te 
trekken. Een eerste conclusie is dat patiëntenparticipatie in biomedische 
besluitvorming inderdaad nog niet zo veel voorkomt en als het voorkomt 
het meestal op een ineffectieve en niet-structurele wijze plaatsvindt. 
Effectieve patiëntenparticipatie wordt tegengehouden door vele obstakels 
die vooral te maken hebben met de weerbarstigheid van het huidige 
biomedische besluitvormingsnetwerk. Een tweede conclusie is dat veel 
patiënten in staat zijn om adequaat te participeren in besluitvorming over 
biomedische onderzoeksagenda’s. Zij zijn zich bewust van het belang van 
biomedisch onderzoek, zijn in staat om over hun eigen individuele korte 
termijn problemen heen te kijken, zijn in staat om op een onderbouwde 
manier onderzoeksonderwerpen te prioriteren en kunnen alternatieve 
biomedische onderzoeksprioriteiten of –onderwerpen formuleren. Dit 
laatste versterkt het inhoudelijke argument om patiënten bij besluitvorming 
over biomedische onderzoeksagenda’s te betrekken. Een derde conclusie 
uit dit onderzoek is dat de voorgestelde, gefaseerde transdisciplinaire 
strategie, met expliciete consultatie- en samenwerkingsfases, een geschikte 
strategie is voor het effectief vormgeven van patiëntenparticipatie in 
besluitvorming rondom biomedisch onderzoek. Het waarborgt zowel een 
legitiem en rationeel proces als de daadwerkelijke invloed van patiënten op 
het eindproduct.  
Om een dergelijke strategie structureel te kunnen implementeren 
binnen het huidige besluitvormingsnetwerk zijn nog veel obstakels te 
overwinnen. Het realiseren van meerdere succesvolle voorbeelden van 
effectieve patiëntenparticipatie, kan bijdragen aan een verdere transitie van 
het netwerk. Enkele recente initiatieven tot het toepassen van vergelijkbare 
strategieën voor participatieve onderzoeksagendering binnen andere 
contexten zijn daarom erg hoopvol. Verder onderzoek zou zich kunnen 
richten op het efficiënter maken van de strategie ten behoeve van een 
succesvolle institutionalisering.  
 Het onderzoek als geheel heeft bijgedragen aan zowel 
wetenschappelijke als maatschappelijke doelen. Wetenschappelijk gezien 
heeft het onderzoek nieuwe inzichten opgeleverd aangaande obstakels en 
strategieën voor effectieve patiëntenparticipatie in biomedische 
besluitvorming. Op een indirecte wijze heeft het daarmee bijgedragen aan 
kennisvorming rondom effectieve stakeholderparticipatiestrategieën 
binnen de wetenschap in het algemeen. Maatschappelijk gezien heeft het 
onderzoek bijgedragen aan het opstellen van een maatschappelijke 
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onderzoeksagenda voor astma/COPD onderzoek, aan het formuleren van 
een strategie voor effectieve patiëntenparticipatie in biomedische 
besluitvorming en aan het een stapje dichterbij brengen van een transitie 
van het biomedische besluitvormingsnetwerk richting een structurele 
participatie van patiënten. 
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